



## (51) International Patent Classification:

A61K 39/02 (2006.01) A61P 31/04 (2006.01)  
C07K 16/12 (2006.01)

## (21) International Application Number:

PCT/US2013/050058

## (22) International Filing Date:

11 July 2013 (11.07.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/676,668 27 July 2012 (27.07.2012) US

(71) Applicants: **BAXTER INTERNATIONAL, INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE SA** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opifkon) (CH).

(72) Inventors: **BARRETT, Noel, P.**; Steinwandgasse 6A, A-3400 Klosterneuburg/ Weidling (AT). **AICHINGER, Gerald**; Frimmelgasse 6, A-1190 Vienna (AT). **CROWE, Brian, A.**; Nussallee 4, A-2100 Leobendorf (AT). **LIVEY, Ian**; Husarenweg 71, A-1220 Vienna (AT). **WRESSNIGG, Nina**; Weintraubengasse 11/W11, A-1020 Vienna (AT).

(74) Agents: **JANULIS, Lynn, L.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


## Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: COMPOSITIONS COMPRISING CHIMERIC OSP A MOLECULES AND METHODS OF USE THEREOF

Fig. 1



(57) Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.



---

— *with sequence listing part of description (Rule 5.2(a))*

# COMPOSITIONS COMPRISING CHIMERIC OSPA MOLECULES AND METHODS OF USE THEREOF

## CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No. 61/676,668, filed July 27, 2012 which is incorporated herein by reference in its entirety.

## FIELD OF THE INVENTION

[0002] The invention generally relates to chimeric OspA polypeptides, nucleic acids encoding the polypeptides, compositions comprising these molecules, and methods of use thereof.

## BACKGROUND OF THE INVENTION

[0003] Lyme disease is a tick-borne disease caused by *Borrelia burgdorferi sensu lato* (s.l.). The disease is typically characterized by the development of an expanding red rash at the site of the tick bite that may be followed by systemic complications including meningitis, carditis or arthritis. Almost all cases of Lyme disease are caused by one of three genospecies, *Borrelia afzelii*, *Borrelia garinii* and *Borrelia burgdorferi sensu stricto* (s.s.). In Europe, all three species which infect humans are found. However, in North America only a single species, *Borrelia burgdorferi sensu stricto*, is found. *Borrelia burgdorferi* is a species of Gram negative bacteria of the spirochete class of the genus *Borrelia*. Antibiotic treatment of Lyme disease is usually effective but some patients develop a chronic disabling form of the disease involving joints or nervous system, which does not substantially improve even after parenteral antibiotic therapy, thus highlighting the need for a vaccine for high-risk populations.

[0004] Outer surface protein A (OspA) is a 31 kDa antigen, expressed by *Borrelia burgdorferi* s.l. species present in the midgut of Ixodes ticks. OspA has proven to be efficacious in preventing Lyme disease in North America (Steere et al., *N. Engl. J. Med.* 339: 209-15, 1998; Sigal et al., *N. Engl. J. Med.* 339:216-22, 1998; erratum in: *N. Engl. J. Med.* 339:571, 1998). The amino terminus of fully processed OspA is a

cysteine residue that is post-translationally modified with three fatty-acyl chains that anchor the protein to the outer surface of the bacterial membrane (Bouchon et al., *Anal. Biochem.* 246: 52-61, 1997). Lipidation of OspA is reported to stabilize the molecule (Luft, personal communication) and is essential for protection in the absence of a strong adjuvant (Erdile et al., *Infect. Immun.* 61: 81-90, 1993). A soluble, recombinant form of the protein lacking the amino-terminal lipid membrane anchor was co-crystallized with the Fab fragment of an agglutinating mouse monoclonal antibody to determine the structure of OspA, which was shown to comprise 21 anti-parallel  $\beta$ -strands followed by a single  $\alpha$ -helix (Li et al., *Proc. Natl. Acad. Sci. U.S.A.* 94:3584-9, 1997).

**[0005]** A monovalent OspA-based vaccine (LYMERix®) was marketed in the USA for the prevention of Lyme disease. However, in Europe heterogeneity in OspA sequences across the three genospecies precludes broad protection with a vaccine based on OspA from a single strain (Gern et al., *Vaccine* 15:1551-7, 1997). Seven principal OspA serotypes have been recognized among European isolates (designated serotypes 1 to 7, Wilske et al., *J. Clin. Microbiol.* 31:340-50, 1993). OspA serotypes correlate with species; serotype 1 corresponds to *B. burgdorferi s.s.*, serotype 2 corresponds to *B. afzelii* and serotypes 3 to 7 correspond to *B. garinii*.

**[0006]** Protective immunity acquired through immunization with OspA is unusual since the interaction between the host's immune response and the pathogen does not take place in the host, but in the mid-gut of the tick vector. In the case of Lyme disease, a tick acts as a vector or carrier for the transmission of Lyme disease from animals to humans. OspA specific antibody acquired during feeding by an infected tick prevents transmission of *B. burgdorferi s.l.* to the immunized mammalian host (de Silva et al., *J. Exp. Med.* 183: 271-5, 1996). Protection is antibody-mediated and is mainly affected through bactericidal antibody although an antibody that blocks attachment of the spirochete to a receptor on the lining of the tick gut epithelium may also be efficacious (Pal et al., *J. Immunol.* 166: 7398-403, 2001).

**[0007]** Rational development of effective OspA vaccines requires identification of the protective epitopes such as that defined by the protective monoclonal antibody LA-2 (Golde et al., *Infect. Immun.* 65: 882-9, 1997). X-ray crystallography and NMR analysis have been used to identify immunologically important hypervariable domains in OspA and have mapped the LA-2 epitope to amino acids 203–257 (Ding



et al., *J. Mol. Biol.* 302: 1153-64, 2000; Luft et al. *J Infect Dis.* 185 (Suppl. 1): S46-51, 2002).

**[0008]** There is a need in the art for the development of an OspA vaccine that can provide broad protection against a variety of species of *Borrelia* that are present in the United States, Europe, and elsewhere. The following disclosure describes the specifics of such a vaccine.

### **SUMMARY OF THE INVENTION**

**[0009]** The invention addresses one or more needs in the art relating to the prevention and treatment of Lyme disease or Lyme borreliosis.

**[0010]** The invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 1, 3, and 5. In some aspects, the invention includes an isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 1, 3, and 5. In other aspects, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity with a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5; and (b) a nucleotide sequence complementary to (a). In further aspects, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity with a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6; and (b) a nucleotide sequence complementary to (a). In even further aspects, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, the polypeptide having a substitution of one to 25 conservative amino acids; (b) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, the polypeptide having an insertion of one to 25 conservative amino

acids; (c) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, the polypeptide having an internal deletion of one to 25 conservative amino acids; (d) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, the polypeptide having a C- and/or N-terminal truncation of one to 25 amino acids; (e) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, the polypeptide having a modification of one to 25 amino acids selected from amino acid substitutions, amino acid insertions, amino acid deletions, a C-terminal truncation, or an N-terminal truncation; and (f) a nucleotide sequence complementary to any of (a)-(e).

**[0011]** The invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 7, 9, and 11. In some aspects, the invention includes an isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 7, 9, and 11. In additional aspects, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity with a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11; and (b) a nucleotide sequence complementary to (a). In further aspects, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity with a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12; and (b) a nucleotide sequence complementary to (a). In even further aspects, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, the polypeptide having a substitution of one to 25 conservative amino acids; (b) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or

SEQ ID NO: 12, the polypeptide having an insertion of one to 25 conservative amino acids; (c) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, the polypeptide having an internal deletion of one to 25 conservative amino acids; (d) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, the polypeptide having a C- and/or N-terminal truncation of one to 25 amino acids; (e) a nucleotide sequence encoding a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, the polypeptide having a modification of one to 25 amino acids selected from amino acid substitutions, amino acid insertions, amino acid deletions, a C-terminal truncation, or an N-terminal truncation; and (f) a nucleotide sequence complementary to any of (a)-(e).

**[0012]** The invention includes vectors, host cells, and processes of producing polypeptides by culturing the host cells discussed herein. In some aspects, the invention includes a vector comprising any of the nucleic acid molecules described herein. In other aspects, the invention includes a host cell that comprises such vectors. In some aspects, the host cell is a eukaryotic cell. In other aspects, the host cell is a prokaryotic cell. In various aspects, the process of producing a polypeptide comprises culturing the host cells described herein under conditions suitable to express the polypeptide, and optionally isolating the polypeptide from the culture. In various aspects, the invention includes compositions comprising any of these chimeric nucleic acid molecules or any vectors comprising such nucleic acid molecules and a pharmaceutically acceptable carrier or carriers.

**[0013]** The invention includes compositions comprising any of the nucleic acid molecules discussed herein, or any of the vectors discussed herein, and a pharmaceutically acceptable carrier. In some aspects, the invention includes compositions comprising at least two of the nucleic acid molecules discussed herein and a pharmaceutically acceptable carrier, wherein the nucleic acid molecules have different nucleotide sequences. In specific aspects, the invention includes compositions comprising a combination of the nucleotide sequences set forth in SEQ ID NOS: 1, 3, and 5.

**[0014]** The invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of the sequence set forth in SEQ ID

NOS: 2, 4, and 6. In some aspects, the invention includes an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 2, 4, and 6. In additional aspects, the invention includes an isolated polypeptide comprising an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6. In further aspects, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 8, 10, and 12. In even further aspects, the invention includes an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of the sequence set forth in SEQ ID NOS: 8, 10, and 12. In some aspects, the invention includes an isolated polypeptide comprising an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12.

**[0015]** The invention includes compositions comprising any of the polypeptides discussed herein and a pharmaceutically acceptable carrier. In some aspects, the invention includes compositions comprising at least two of the polypeptides discussed herein and a pharmaceutically acceptable carrier, wherein the polypeptides have different amino acid sequences. In specific aspects, the invention includes compositions comprising a combination of the polypeptides comprising the amino acid sequences set forth in SEQ ID NOS: 2, 4, and 6.

**[0016]** The invention includes immunogenic compositions. In some aspects, an immunogenic composition of the invention comprises any of the compositions discussed herein and a pharmaceutically acceptable carrier. In various aspects, the immunogenic composition has the property of inducing production of an antibody that specifically binds an outer surface protein A (OspA) protein. In certain aspects, the immunogenic composition has the property of inducing production of an antibody that specifically binds *Borrelia*. In particular aspects, the immunogenic composition has the property of inducing production of an antibody that neutralizes *Borrelia*. In certain aspects, the *Borrelia* is *Borrelia burgdorferi sensu lato*. In particular aspects, the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, or *Borrelia*

*burgdorferi sensu stricto*. In further aspects, the *Borrelia* is *Borrelia japonica*, *Borrelia andersonii*, *Borrelia bissettii*, *Borrelia sinica*, *Borrelia turdi*, *Borrelia tanukii*, *Borrelia valaisiana*, *Borrelia lusitaniae*, *Borrelia spielmanii*, *Borrelia miyamotoi* or *Borrelia lonestar*. In some aspects, the antibody is produced by an animal. In further aspects, the animal is a mammal. In even further aspects, the mammal is human.

**[0017]** The invention includes vaccine compositions. In some aspects, a vaccine composition of the invention comprises any immunogenic composition discussed herein and a pharmaceutically acceptable carrier. In various aspects, the invention includes a combination vaccine. In certain aspects, a combination vaccine of the invention comprises any vaccine composition discussed herein in combination with at least a second vaccine composition. In some aspects, the second vaccine composition protects against a tick-borne disease. In various aspects, the tick-borne disease is Rocky Mountain Spotted Fever, Babesiosis, Relapsing Fever, Colorado tick fever, Human monocytic ehrlichiosis (HME), Human granulocytic ehrlichiosis (HGE), Southern Tick-Associated Rash Illness (STARI), Tularemia, Tick paralysis, Powassan encephalitis, Q fever, Crimean-Congo hemorrhagic fever, Cytauxzoonosis, boutonneuse fever, or tick-borne encephalitis. In other aspects, the second vaccine composition is a vaccine selected from the group consisting of: a tick-borne encephalitis vaccine, a Japanese encephalitis vaccine, and a Rocky Mountain Spotted Fever vaccine. In various aspects, the second vaccine composition has a seasonal immunization schedule compatible with immunization against *Borrelia* infection or Lyme disease.

**[0018]** The invention includes methods for inducing an immunological response in a subject. In various aspects, such methods comprise the step of administering any of the immunogenic compositions or vaccine compositions discussed herein to the subject in an amount effective to induce an immunological response. In certain aspects, the immunological response comprises production of an anti-OspA antibody. The invention includes antibodies or fragments thereof that specifically bind to any of the polypeptides described herein.

**[0019]** The invention includes methods for preventing or treating a *Borrelia* infection or Lyme disease in a subject. In various aspects, such methods comprise the step of administering any of the vaccine compositions discussed herein or any of

the combination vaccines discussed herein to the subject in an amount effective to prevent or treat the *Borrelia* infection or Lyme disease. In other aspects, such methods comprise the step of administering any of the antibodies discussed herein to the subject in an amount effective to prevent or treat the *Borrelia* infection or Lyme disease. In certain aspects, such methods comprise the step of administering an antibody or fragment thereof produced by immunizing a mammal with the vaccine composition of any one of claims 28-34 to the subject in an amount effective to prevent or treat the *Borrelia* infection or Lyme disease. In some aspects, the antibody or fragment thereof is a hyperimmune serum, a hyperimmune plasma, or a purified immunoglobulin fraction thereof.

**[0020]** The invention includes methods for passively preventing a *Borrelia* infection or Lyme disease in a subject, the methods comprising the step of administering an anti-OspA antibody or fragment thereof produced by immunizing a mammal with any of the vaccine compositions discussed herein to the subject in an amount effective to prevent the *Borrelia* infection or Lyme disease, wherein the antibody or fragment thereof is a purified immunoglobulin preparation or an immunoglobulin fragment preparation.

**[0021]** The invention includes methods for preventing a *Borrelia* infection or Lyme disease in a subject, the methods comprising the step of administering to the subject an anti-OspA monoclonal antibody or fragment thereof generated after immunizing a subject with any of the vaccine compositions discussed herein in an amount effective to prevent the *Borrelia* infection or Lyme disease. In some aspects, the monoclonal antibody or fragment thereof is humanized. In a particular aspect, the monoclonal antibody is F237/BK2.

**[0022]** The invention includes a composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0023]** The invention includes a composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0024]** The invention includes a composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0025]** The invention includes a composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0026]** The invention includes a composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0027]** The invention includes a composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said

composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0028]** The invention includes a composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0029]** The invention includes a composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0030]** The invention includes methods of inducing a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising administering to the subject an immunologically effective amount of any of the compositions described herein. In some aspects, the immunologically effective amount of the composition is administered in a single unit dose. In some aspects, the immunologically effective amount of the composition is administered in multiple unit doses. In some aspects, the multiple unit doses are administered at about monthly intervals. In further aspects, a booster of the composition is administered at about 6 months to about 18 months after the initial unit dose of the composition. In other aspects, the booster is further administered at about 9 months to about 12 months after the initial unit dose. In more particular aspects, the composition is administered at monthly intervals, for example, at about Day 1, at about Day 29, and at about Day 57. In some of these particular aspects, the booster is administered at about 9 months to about 12 months after the first unit dose. In some aspects, the unit dose



is about 10 µg to about 90 µg. In particular aspects, the unit dose is about 30 µg or about 60 µg.

**[0031]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0032]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0033]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0034]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

**[0035]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an

amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0036]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0037]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0038]** The invention includes uses of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

**[0039]** In various aspects, the compositions of the invention further comprise an adjuvant. In some aspects, the adjuvant is aluminum hydroxide.

**[0040]** In particular aspects of the invention, the combination of polypeptides in the composition comprises an equal amount of each polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6. In aspects of the invention, the composition is an immunogenic composition or a vaccine composition.

**[0041]** In some aspects of the invention, the *Borrelia* is *Borrelia sensu lato* or *Borrelia sensu stricto*. In more particular aspects, the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, *Borrelia burgdorferi sensu stricto*, *Borrelia japonica*, *Borrelia andersonii*, *Borrelia bissettii*, *Borrelia sinica*, *Borrelia turdi*, *Borrelia tanukii*, *Borrelia valaisiana*, *Borrelia lusitaniae*, *Borrelia spielmanii*, *Borrelia miyamotoi* or *Borrelia lonestar*. In even more particular aspects, the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, or *Borrelia burgdorferi sensu stricto*.

**[0042]** In various aspects, the composition of the invention is formulated in a unit dose effective to increase *Borrelia* antibody production in a subject to a geometric mean titer (GMT) level of about 1,000 to 10,000 at about 60 days after initial dosing. In some aspects, the composition is formulated in a unit dose effective to increase *Borrelia* antibody production in a subject to a geometric mean titer (GMT) level of about 2,000 to 30,000 at about 90 days after initial dosing. In some aspects, the composition is formulated in a unit dose effective to increase *Borrelia* antibody production in a subject to a geometric mean titer (GMT) level of about 15,000 to 50,000 after booster administration.

In some aspects, a composition of the invention is formulated in a unit dose effective for administration in a single dose. In some aspects, the composition is formulated in a unit dose effective for administration in multiple doses. In some aspects, the composition is formulated in a unit dose effective for administration in multiple doses at monthly intervals. In some aspects, the composition is formulated for administration as a booster at about 6 months to about 18 months after the initial unit dose. In some aspects, the composition is formulated for administration as a booster at about 9 months to about 12 months after the initial unit dose. In some aspects, the composition is formulated for administration in multiple unit doses at about monthly intervals, for example, about Day 1, at about Day 29, and at about Day 57. In some aspects, the composition is formulated for administration in multiple doses followed by a booster at about 9 months to about 12 months after the first unit

dose. In some aspects, the unit dose is about 10 µg to about 90 µg. In particular aspects, the unit dose is about 30 µg or about 60 µg. In even more particular aspects, the unit dose is about 30 µg. In some aspects, the unit dose is about 10 µg to about 90 µg. In some aspects, the unit dose is about 30 µg or about 60 µg.

**[0043]** The invention includes uses of compositions of the invention for the preparation of medicaments. Other related aspects are also provided in the instant invention.

**[0044]** The foregoing summary is not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the following detailed description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein are contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. Other features and advantages of the invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

**[0045]** Figure 1 is a schematic overview for preparation of lipidated OspA chimera constructs.

**[0046]** Figure 2 is the amino acid sequence of lipB sOspA 1/2<sup>251</sup> (SEQ ID NO: 2).

**[0047]** Figure 3 shows nucleotide (SEQ ID NO: 1) and deduced amino acid sequences (SEQ ID NO: 2) of lipB sOspA 1/2<sup>251</sup>.

**[0048]** Figure 4 is the amino acid sequence of lipB sOspA 6/4 (SEQ ID NO: 4).

**[0049]** Figure 5 shows nucleotide (SEQ ID NO: 3) and deduced amino acid sequences (SEQ ID NO: 4) of lipB sOspA 6/4.

**[0050]** Figure 6 is the amino acid sequence of lipB sOspA 5/3 (SEQ ID NO: 6).

- [0051]** Figure 7 shows nucleotide (SEQ ID NO: 5) and deduced amino acid sequences (SEQ ID NO: 6) of lipB sOspA 5/3.
- [0052]** Figure 8 depicts optimization of codon usage for high level expression.
- [0053]** Figure 9 shows sequence differences between lipidated and non-lipidated constructs.
- [0054]** Figure 10 is a description of the T7 expression system.
- [0055]** Figure 11 is an SDS-PAGE showing expression of the novel recombinant OspA proteins from induced and un-induced cultures.
- [0056]** Figure 12 is a map of plasmid pUC18.
- [0057]** Figure 13 is a map of plasmid pET30a.
- [0058]** Figure 14 shows the strategy for creation of the lipB sOspA 5/3 Kpn I - Bam HI fragment.
- [0059]** Figure 15 is an alignment highlighting the amino acid change (SEQ ID NO: 39) in lipB sOspA 1/2<sup>251</sup> and the PCR primer sequences (SEQ ID NOS: 21 and 41) used to introduce the change (lipB OspA 1/2 mod (SEQ ID NO: 38); consensus sequence (SEQ ID NO: 40)).
- [0060]** Figure 16 is an alignment of OspA sequence of Blip OspA BPBP/A1 with the modified molecule lipB sOspA 1/2<sup>251</sup>. The top strand is the original sequence (SEQ ID NO: 42) and the bottom strand is the optimized sequence (SEQ ID NO: 43). Note: Three bases (CAT) at the start of the sequence are not shown; they form part of the *Nde* I site CATATG.
- [0061]** Figure 17 is an alignment of OspA sequence of Blip OspA KT with the modified molecule lipB sOspA 6/4. The top strand is the original sequence (SEQ ID NO: 44) and the bottom strand is the optimized sequence (SEQ ID NO: 45). Note: A single base (C) at the start of the sequence is not shown; they form part of the *Nde* I site CATATG.
- [0062]** Figure 18 is an alignment of OspA sequence of Blip OspA 5/3 with the modified molecule lipB sOspA 5/3. The top strand is the original sequence (SEQ ID NO: 46) and the bottom strand is the optimized sequence (SEQ ID NO: 47).

**[0063]** Figure 19 shows the distribution of functional anti-OspA responses in antibody surface binding and growth inhibition assays among protected and infected animals immunized with 3 ng of OspA 1/2 before challenge with *B. burgdorferi* s.s. B31 strain. Mann-Whitney p values demonstrated a highly significant difference in functional antibody content between protected and infected animals.

**[0064]** Figure 20 shows the distribution of functional anti-OspA responses in antibody surface binding and growth inhibition assays among protected and infected animals immunized with 3 ng of OspA 1/2 before challenge with feral ticks. Mann-Whitney p values demonstrated a highly significant difference in functional antibody content between protected and infected animals.

**[0065]** Figure 21 shows surface binding (mean fluorescence intensities (MFI)) and growth inhibition (GI-50 titers) in pooled mouse sera after immunization with three doses of the 3-component chimeric OspA vaccine. Efficient surface binding and growth inhibition were detected against all six *Borrelia* strains expressing OspA types homologous to the OspA types in the vaccine (types 1-6).

**[0066]** Figure 22 shows mean fluorescence intensity (MFI) titers that were obtained using day 42 sera from individual mice immunized with combinations of rOspA vaccines in a surface binding assay (SBA). Results showed that all three rOspA components (1/2, 6/4, and 5/3) are required in a multivalent vaccine to induce high titers of surface binding IgG antibodies against all 6 strains in C3H mice. Two-component vaccines did not fully cover the 2 missing strains.

**[0067]** Figure 23 shows the growth inhibition of *Borreliae* using day 42 sera from individual mice (in groups of 10) immunized with combinations of rOspA vaccines. Only the multivalent vaccine (the vaccine comprising all three strains) gave >50% growth inhibition in >90% of the animals (n=10). Bars in black (solid bars) indicate the strains homologous to the vaccine used.

**[0068]** Figure 24 shows the coverage of *Borreliae* expressing intra-type variants of OspA. Surface binding was categorized into strong (fluorescence increased >10-fold) or weaker (fluorescence increased 2-10-fold).

## **DETAILED DESCRIPTION OF THE INVENTION**

**[0069]** The invention provides chimeric OspA molecules that are useful as antigens that can be delivered as an immunogenic composition or vaccine composition for Lyme disease or a *Borrelia* infection. Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the figures and examples. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All references cited in this application are expressly incorporated by reference herein.

**[0070]** The invention embraces other embodiments and is practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The terms "including," "comprising," or "having" and variations thereof are meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

**[0071]** Embodiments of the invention are exemplified in the design and synthesis of three chimeric OspA coding sequences that encode three distinct lipidated OspA molecules, all of which share some common features. Each chimeric coding sequence represents two OspA serotypes and the chimeric coding sequences were designed to encode stable chimeric OspA molecules that are safe and highly immunogenic, and afford a subject protection against infection with *B. burgdorferi sensu lato* (*s.l.*).

**[0072]** In one aspect, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype while retaining the protective properties of both of the parent polypeptides. The chimeric OspA nucleic acid molecules were expressed in *Escherichia coli* (*E. coli*) to provide antigens which could be formulated as a combination vaccine to provide protection against all six prevalent serotypes (serotypes 1-6) associated with Lyme disease or *Borrelia* infection in Europe and against the single OspA serotype associated with Lyme disease or *Borrelia* infection in North America. Because a

vaccine comprising serotypes 1-6 provides protection against *B. afzelii*, *B. garinii*, *B. bavariensis*, and *B. burgdorferi*, the vaccine is designed for global use.

**[0073]** The invention also includes the preparation of a second set of chimeric OspA coding sequences which is, in one aspect, derived from the first set of three genes, by removing nucleic acid sequences encoding a leader sequence needed to produce a lipidated OspA molecule. The two sets of constructs (giving rise to lipidated and non-lipidated polypeptides) were needed to evaluate their ease of production in the fermentor (biomass, stability, product yields etc.), to assess how readily different types of antigen can be purified and to compare their biological characteristics (safety profile and protective potency).

**[0074]** The invention includes immunogenic compositions comprising the chimeric OspA molecules of the invention. The invention likewise includes vaccines and vaccine kits comprising such OspA molecules, processes for making the immunogenic compositions and vaccines and the use of the immunogenic compositions and vaccines in human and veterinary medical therapy and prevention. The invention further includes methods of immunizing against Lyme disease or *Borrelia* infection using the OspA compositions described herein and the use of the OspA compositions in the manufacture of a medicament for the prevention of Lyme disease or *Borrelia* infection.

## **Definitions**

**[0075]** Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The following references provide one of skill with a general definition of many of the terms used in this invention: Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY (2d ed. 1994); THE CAMBRIDGE DICTIONARY OF SCIENCE AND TECHNOLOGY (Walker ed., 1988); THE GLOSSARY OF GENETICS, 5TH ED., R. Rieger, et al. (eds.), Springer Verlag (1991); and Hale and Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY (1991).



**[0076]** The following abbreviations are used throughout.

AA	Amino acid
Amp	Ampicillin
bp	Base pairs
<i>B. afzelii</i>	<i>Borrelia afzelii</i>
<i>B. bavariensis</i>	<i>Borrelia bavariensis</i>
<i>B. burgdorferi</i>	<i>Borrelia burgdorferi</i>
<i>B. garinii</i>	<i>Borrelia garinii</i>
DNA	Deoxyribonucleic acid
dNTPs	Deoxynucleotide triphosphate
<i>E. coli</i>	<i>Escherichia coli</i>
GC content	Percentage of a sequence containing bases Guanine and Cytosine
hLFA-1	Human leukocyte function-associated antigen-1
HPLC	High Performance Liquid Chromatography
IP	Intellectual property
IPTG	Isopropyl-beta-D-thiogalactopyranoside
Kan	Kanamycin
kDa	KiloDaltons
LB	Luria Broth
Lip B	Leader sequence from Outer surface protein B
Mab	Monoclonal antibody
OD	Optical density
OspA	Outer surface protein A
OspB	Outer surface protein B
PCR	Polymerase chain reaction

RNA	Ribonucleic acid
s.l.	<i>Sensu lato</i>
s.s.	<i>Sensu stricto</i>
SDS	Sodium dodecyl sulfate
SMK	Growth media for <i>E. coli</i> (ketoglutarate sorbitol media)
tRNA	Transfer ribonucleic acid
WCB	Working cell bank

**[0077]** It is noted here that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise.

**[0078]** As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

**[0079]** The term “gene” refers to a DNA sequence that encodes a sequence of amino acids which comprise all or part of one or more polypeptides, proteins or enzymes, and may or may not include introns, and regulatory DNA sequences, such as promoter or enhancer sequences, 5'-untranslated region, or 3'-untranslated region which affect, for example, the conditions under which the gene is expressed. In the present disclosure, the *OspA* gene is bacterial and, therefore, there are no introns. The term “coding sequence” refers to a DNA sequence that encodes a sequence of amino acids, but does not contain introns or regulatory sequences. Likewise, in the present disclosure the *OspA* coding sequence does not contain regulatory sequences.

**[0080]** “Nucleic acid” or “nucleic acid sequence” or “nucleic acid molecule” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

The terms encompass molecules formed from any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenine, aziridinyl-cytosine, pseudoisocytosine, 5-(carboxyhydroxymethyl)uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylaminomethyluracil, dihydrouracil, inosine, N6-iso-pentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyamino-methyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.

**[0081]** Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions, in some aspects, are achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka et al., *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini et al., *Mol. Cell. Probes* 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.

**[0082]** The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues linked via peptide bonds. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. The term "protein" typically refers to large polypeptides. The term "peptide" typically refers to short polypeptides. Synthetic polypeptides can be synthesized, for example, using an automated polypeptide synthesizer.

**[0083]** The term “Osp A molecule” or “chimeric OspA molecule” refers, in one aspect, to an “OspA nucleic acid” comprising the nucleotide sequence of SEQ ID NO: 1 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 3 (lipB sOspA 6/4), SEQ ID NO: 5 (lipB sOspA 5/3), SEQ ID NO: 7 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 9 (sOspA 6/4), SEQ ID NO: 11 (sOspA 5/3), SEQ ID NO: 168 (orig sOspA 1/2), SEQ ID NO: 170 (orig sOspA 6/4), or SEQ ID NO: 172 (orig sOspA 5/3), or, in another aspect to an “OspA polypeptide” comprising the amino acid sequence of SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3).

**[0084]** The term “lipB sOspA molecule” refers, in one aspect, to an “OspA nucleic acid” comprising the nucleotide sequence of SEQ ID NO: 1 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 3 (lipB sOspA 6/4), or SEQ ID NO: 5 (lipB sOspA 5/3) or, in another aspect to an “OspA polypeptide” comprising the amino acid sequence of SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), or SEQ ID NO: 6 (lipB sOspA 5/3). The nucleic acid sequences of SEQ ID NOS: 7, 9, and 11 lack the nucleic acid sequence encoding the lipB leader sequence (MRLIGFALALALIG (SEQ ID NO: 13)). In addition, the nucleic acid sequences of SEQ ID NOS: 7, 9, and 11 encode a methionine residue at the amino terminus of SEQ ID NOS: 8, 10, and 12 in place of the cysteine residue present at the carboxy terminus of the lipB leader sequence in SEQ ID NOS: 2, 4, and 6.

**[0085]** The term “orig sOspA molecule” or “original sOspA molecule” refers, in one aspect, to an “OspA nucleic acid” comprising the nucleotide sequence of SEQ ID NO: 168 (orig sOspA 1/2), SEQ ID NO: 170 (orig sOspA 6/4), or SEQ ID NO: 172 (orig sOspA 5/3) or, in another aspect to an “OspA polypeptide” comprising the amino acid sequence of SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3). These “original” molecules are chimeric constructs without mutations and without codon optimization.

**[0086]** The invention includes “lipidated OspA” and “non-lipidated OspA” chimeric molecules. In various aspects, lipidation confers adjuvant properties on OspA. In some aspects of the invention, the lipidated OspA molecules comprise an OspB leader sequence. In some aspects of the invention, the OspB leader sequence

comprises amino acids MRLIGFALALALIG (SEQ ID NO: 13). In other aspects, the OspB leader sequence comprises other amino acids.

**[0087]** The terms “identical” or percent “identity” as known in the art refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by comparing the sequences. In the art, “identity” also means the degree of sequence relatedness between nucleic acid molecules or polypeptides, as the case may be, as determined by the match between strings of two or more nucleotide or two or more amino acid sequences. “Identity” measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., “algorithms”). “Substantial identity” refers to sequences with at least about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% sequence identity over a specified sequence. In some aspects, the identity exists over a region that is at least about 50-100 amino acids or nucleotides in length. In other aspects, the identity exists over a region that is at least about 100-200 amino acids or nucleotides in length. In other aspects, the identity exists over a region that is at least about 200-500 amino acids or nucleotides in length. In certain aspects, percent sequence identity is determined using a computer program selected from the group consisting of GAP, BLASTP, BLASTN, FASTA, BLASTA, BLASTX, BestFit and the Smith-Waterman algorithm

**[0088]** It also is specifically understood that any numerical value recited herein includes all values from the lower value to the upper value, i.e., all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application. For example, if a concentration range is stated as about 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. The values listed above are only examples of what is specifically intended.

**[0089]** Ranges, in various aspects, are expressed herein as from "about" or "approximately" one particular value and/or to "about" or "approximately" another particular value. When values are expressed as approximations, by use of the antecedent "about," it will be understood that some amount of variation is included in the range.

**[0090]** The term "similarity" is a related concept but, in contrast to "identity", refers to a measure of similarity which includes both identical matches and conservative substitution matches. If two polypeptide sequences have, for example, 10/20 identical amino acids, and the remainder are all non-conservative substitutions, then the percent identity and similarity would both be 50%. If, in the same example, there are five more positions where there are conservative substitutions, then the percent identity remains 50%, but the percent similarity would be 75% (15/20). Therefore, in cases where there are conservative substitutions, the degree of percent similarity between two polypeptides will be higher than the percent identity between those two polypeptides.

**[0091]** The term "isolated nucleic acid molecule" refers to a nucleic acid molecule of the invention that (1) has been separated to any degree from proteins, lipids, carbohydrates or other materials with which it is naturally found when total DNA is isolated from the source cells, (2) is not linked to all or a portion of a polynucleotide to which the "isolated nucleic acid molecule" is linked in nature, (3) is operably linked to a polynucleotide which it is not linked to in nature, or (4) does not occur in nature as part of a larger polynucleotide sequence. Substantially free as used herein indicates that the nucleic acid molecule is free from any other contaminating nucleic acid molecule(s) or other contaminants that are found in its natural environment that would interfere with its use in polypeptide production or its therapeutic, diagnostic, prophylactic or research use.

**[0092]** The term "isolated polypeptide" refers to a polypeptide of the present invention that (1) has been separated to any degree from polynucleotides, lipids, carbohydrates or other materials with which it is naturally found when isolated from the source cell, (2) is not linked (by covalent or noncovalent interaction) to all or a portion of a polypeptide to which the "isolated polypeptide" is linked in nature, (3) is operably linked (by covalent or noncovalent interaction) to a polypeptide with which it is not linked in nature, or (4) does not occur in nature. In one aspect, the isolated

polypeptide is substantially free from any other contaminating polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic or research use.

**[0093]** As used herein a “fragment” of a polypeptide refers to any portion of the polypeptide smaller than the full-length polypeptide or protein expression product. Fragments are typically deletion analogs of the full-length polypeptide wherein one or more amino acid residues have been removed from the amino terminus and/or the carboxy terminus of the full-length polypeptide. Accordingly, “fragments” are a subset of deletion analogs described below.

**[0094]** As used herein an “analog” refers to a polypeptide substantially similar in structure and having the same biological activity, albeit in certain instances to a differing degree, to a naturally-occurring molecule. Analogues differ in the composition of their amino acid sequences compared to the naturally-occurring polypeptide from which the analog is derived, based on one or more mutations involving (i) deletion of one or more amino acid residues at one or more termini of the polypeptide (including fragments as described above) and/or one or more internal regions of the naturally-occurring polypeptide sequence, (ii) insertion or addition of one or more amino acids at one or more termini (typically an “addition” analog) of the polypeptide and/or one or more internal regions (typically an “insertion” analog) of the naturally-occurring polypeptide sequence or (iii) substitution of one or more amino acids for other amino acids in the naturally-occurring polypeptide sequence. Substitutions are conservative or non-conservative based on the physico-chemical or functional relatedness of the amino acid that is being replaced and the amino acid replacing it.

**[0095]** “Conservatively modified analogs” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified nucleic acids refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent

variations,” which are one species of conservatively modified analogs. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

**[0096]** As to amino acid sequences, one of skill will recognize that individual substitutions, insertions, deletions, additions, or truncations to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified analog” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

**[0097]** The following eight groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
- 7) Serine (S), Threonine (T); and
- 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

**[0098]** As used herein a “variant” refers to a polypeptide, protein or analog thereof that comprises at least one amino acid substitution, deletion, insertion, or modification, provided that the variant retains the biological activity of the native polypeptide.



**[0099]** As used herein an “allelic variant” refers to any of two or more polymorphic forms of a gene occupying the same genetic locus. Allelic variations arise naturally through mutation and, in some aspects, result in phenotypic polymorphism within populations. In certain aspects, gene mutations are silent (no change in the encoded polypeptide) or, in other aspects, encode polypeptides having altered amino acid sequences. “Allelic variants” also refer to cDNAs derived from mRNA transcripts of genetic allelic variants, as well as the proteins encoded by them.

**[00100]** The term “derivative” refers to polypeptides that are covalently modified by conjugation to therapeutic or diagnostic agents, labeling (e.g., with radionuclides or various enzymes), covalent polymer attachment such as pegylation (derivatization with polyethylene glycol) and insertion or substitution by chemical synthesis of non-natural amino acids. In some aspects, derivatives are modified to comprise additional chemical moieties not normally a part of the molecule. Such moieties, in various aspects, modulate the molecule's solubility, absorption, and/or biological half-life. The moieties, in various other aspects, alternatively decrease the toxicity of the molecule and eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed in Remington's Pharmaceutical Sciences (1980). Procedure for coupling such moieties to a molecule are well known in the art. For example, in some aspects, an OspA derivative is an OspA molecule having a chemical modification which confers a longer half-life *in vivo* to the protein. In one embodiment, the polypeptides are modified by addition of a water soluble polymer known in the art. In a related embodiment, polypeptides are modified by glycosylation, PEGylation, and/or polysialylation.

**[00101]** The term “recombinant” when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, underexpressed or not expressed at all.

**[00102]** As used herein “selectable marker” refers to a gene encoding an enzyme or other protein that confers upon the cell or organism in which it is expressed an

identifiable phenotypic change such as resistance to a drug, antibiotic or other agent, such that expression or activity of the marker is selected for (for example, but without limitation, a positive marker, such as the neo gene) or against (for example, and without limitation, a negative marker, such as the diphtheria gene). A “heterologous selectable marker” refers to a selectable marker gene that has been inserted into the genome of an animal in which it would not normally be found.

**[00103]** Examples of selectable markers include, but are not limited to, an antibiotic resistance gene such as neomycin (neo), puromycin (Puro), diphtheria toxin, phosphotransferase, hygromycin phosphotransferase, xanthineguanine phosphoribosyl transferase, the Herpes simplex virus type 1 thymidine kinase, adenine phosphoribosyltransferase and hypoxanthine phosphonbosyltransferase. The worker of ordinary skill in the art will understand any selectable marker known in the art is useful in the methods described herein.

**[00104]** The term “heterologous” when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

**[00105]** As used herein, the term “homologous” refers to the relationship between proteins that possess a “common evolutionary origin,” including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins from different species (e.g., myosin light chain, etc.) (Reeck et al., *Cell* 50:667, 1987). Such proteins (and their encoding genes) have sequence homology, as reflected by their sequence similarity, whether in terms of percent similarity or the presence of specific residues or motifs at conserved positions.

**[00106]** Optimal alignment of sequences for comparison is conducted, for example and without limitation, by the local homology algorithm of Smith et al., *Adv. Appl. Math.* 2:482, 1981; by the homology alignment algorithm of Needleman et al., *J. Mol. Biol.* 48:443, 1970; by the search for similarity method of Pearson et al., *Proc.*

*Natl. Acad. Sci. USA* 85:2444, 1988; by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel et al., *supra*). Another example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., *J. Mol. Biol.* 215:403-410, 1990. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin et al., *Proc. Natl. Acad. Sci. USA* 90:5873-5787, 1993).

**[00107]** The term “vector” is used to refer to any molecule (e.g., nucleic acid, plasmid or virus) used to transfer coding information to a host cell.

**[00108]** A “cloning vector” is a small piece of DNA into which a foreign DNA fragment can be inserted. The insertion of the fragment into the cloning vector is carried out by treating the vehicle and the foreign DNA with the same restriction enzyme, then ligating the fragments together. There are many types of cloning vectors and all types of cloning vectors are used in the invention. Genetically engineered plasmids and bacteriophages (such as phage  $\lambda$ ) are perhaps most commonly used for this purpose. Other types of cloning vectors include bacterial artificial chromosomes (BACs) and yeast artificial chromosomes (YACs).

**[00109]** An “expression vector” is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. In certain aspects, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

**[00110]** The term “coding sequence” is defined herein as a nucleic acid sequence that is transcribed into mRNA, which is translated into a polypeptide when placed under the control of the appropriate control sequences. The boundaries of the coding sequence are generally determined by the ATG start codon, which is normally the start of the open reading frame at the 5' end of the mRNA and a

transcription terminator sequence located just downstream of the open reading frame at the 3' end of the mRNA. A coding sequence can include, but is not limited to, genomic DNA, cDNA, semisynthetic, synthetic, and recombinant nucleic acid sequences. In one aspect, a promoter DNA sequence is defined by being the DNA sequence located upstream of a coding sequence associated thereto and by being capable of controlling the expression of this coding sequence.

**[00111]** A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation.

**[00112]** The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

**[00113]** The term "transduction" is used to refer to the transfer of nucleic acids from one bacterium to another, usually by a phage. "Transduction" also refers to the acquisition and transfer of eukaryotic cellular sequences by retroviruses.

**[00114]** The term "transfection" is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been "transfected" when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, for example, Graham et al., *Virology*, 52:456 (1973); Sambrook et al., *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratories, New York, (1989); Davis et al., *Basic Methods in Molecular Biology*, Elsevier, (1986); and Chu et al., *Gene*, 13:197 (1981). Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

**[00115]** The term "transformation" as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell. In some instances, the DNA is maintained transiently as an episomal element without being replicated, or it replicates independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.

**[00116]** The term "endogenous" refers to a polypeptide or polynucleotide or other compound that is expressed naturally in the host organism, or originates within a cell, tissue or organism. "Exogenous" refers to a polypeptide, polynucleotide or other compound that originates outside a cell, tissue or organism.

**[00117]** The term "agent" or "compound" describes any molecule, e.g. protein or pharmaceutical, with the capability of affecting a biological parameter in the invention.

**[00118]** A "control," as used herein, can refer to an active, positive, negative or vehicle control. As will be understood by those of skill in the art, controls are used to establish the relevance of experimental results, and provide a comparison for the condition being tested.

**[00119]** The term "reduces the severity," when referring to a symptom of Lyme or Lyme disease, means that the symptom has delayed onset, reduced severity, or causes less damage to the subject. Generally, severity of a symptom is compared to a control, e.g., that does not receive an active prophylactic or therapeutic composition. In that case, a composition can be said to reduce the severity of a symptom of Lyme if the symptom is reduced by 10%, 25%, 30%, 50%, 80%, or 100% (i.e., essentially eliminated), as compared to the control level of the symptom.

**[00120]** The term "antigen" refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antibody, and additionally capable of being used in a subject to produce antibodies capable of binding to an epitope of each antigen. An antigen, in various aspects, has one or more epitopes.

**[00121]** The term "antibody" refers to a molecule or molecules having specificity for an OspA polypeptide. As used herein the terms, "specific," "specificity," and "specifically binds" refer to the ability of the antibody to bind to OspA polypeptides and not to bind to non-OspA polypeptides. In certain aspects, the antibody is a "neutralizing antibody," wherein the antibody reacts with an infectious agent and destroys or inhibits its infectiveness or virulence. The invention includes immunogenic compositions comprising antibodies that "neutralize" *Borrelia*.

**[00122]** The terms "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refer to one or more formulation materials suitable for accomplishing or enhancing the delivery of the OspA polypeptide, OspA nucleic acid molecule or OspA antibody as a pharmaceutical composition.

**[00123]** The term "stabilizer" refers to a substance or vaccine excipient which protects the immunogenic composition of the vaccine from adverse conditions, such as those which occur during heating or freezing, and/or prolongs the stability or shelf-life of the immunogenic composition in a stable and immunogenic condition or state. Examples of stabilizers include, but are not limited to, sugars, such as sucrose, lactose and mannose; sugar alcohols, such as mannitol; amino acids, such as glycine or glutamic acid; and proteins, such as human serum albumin or gelatin.

**[00124]** The term "antimicrobial preservative" refers to any substance which is added to the immunogenic composition or vaccine that inhibits the growth of microorganisms that may be introduced upon repeated puncture of multidose vials, should such containers be used. Examples of antimicrobial preservatives include, but are not limited to, substances such as thimerosal, 2-phenoxyethanol, benzethonium chloride, and phenol.

**[00125]** The term "immunogenic composition" refers to a composition comprising an antigen (e.g., chimeric OspA molecules) against which antigen-specific antibodies are raised, an adjuvant that stimulates the subject host's immune response, and a suitable immunologically-inert, pharmaceutically-acceptable carrier. Optionally, an immunogenic composition comprises one or more stabilizers. Optionally, an immunogenic composition comprises one or more antimicrobial preservatives.

**[00126]** The terms "vaccine" or "vaccine composition" refer to a biological preparation that improves immunity to a particular disease (e.g., Lyme disease or

*Borrelia* infection). A vaccine typically contains an agent that resembles a disease-causing microorganism (e.g., chimeric OspA molecules (antigen) of *Borrelia*). The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines, in various aspects, are prophylactic (prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (vaccines against present infection). As set forth above, such vaccine compositions include formulations comprising pharmaceutically acceptable carriers. Optionally, a vaccine also comprises one or more stabilizers and/or one or more antimicrobial preservatives.

**[00127]** The terms "effective amount" and "therapeutically effective amount" each refer to the amount of nucleic acid molecule, polypeptide, composition, or antibody used to support an observable level of one or more biological activities of the OspA polypeptides as set forth herein. For example, an effective amount, in some aspects of the invention, would be the amount necessary to prevent, neutralize, or reduce a *Borrelia* infection.

**[00128]** The term "combination" refers to two or more nucleic acid molecules of the invention, or two or more polypeptides of the invention. In some aspects, combinations of molecules of the invention are administered to provide immunity or fight infection from at least four of the six serotypes (1-6) of *Borrelia* described herein. In various aspects, combinations of two or three molecules or polypeptides of the invention are used. In certain aspects, combinations of molecules of the invention are administered to a subject to provide immunity from all six serotypes (1-6) of *Borrelia* described herein. The latter combination has been shown to provide immunity to heterologous strains of *Borrelia* expressing OspA types not present in the combination of nucleic acid molecules or polypeptides.

**[00129]** The term "combination vaccine" refers to a vaccine formulation containing more than one vaccine composition or more than one protective antigen to one or more diseases. The invention includes a combination vaccine comprising OspA chimeric antigens against Lyme disease or *Borrelia* in addition to an antigen against one or more other diseases. In various aspects, one or more of the other diseases is a tick-borne disease. In certain aspects, the other tick-borne disease is Rocky Mountain Spotted Fever, Babesiosis, Relapsing Fever, Colorado tick fever, Human

monocytic ehrlichiosis (HME), Human granulocytic ehrlichiosis (HGE), Southern Tick-Associated Rash Illness (STARI), Tularemia, Tick paralysis, Powassan encephalitis, Q fever, Crimean-Congo hemorrhagic fever, Cytauxzoonosis, boutonneuse fever, or tick-borne encephalitis. In particular aspects, the invention includes a combination vaccine which comprises one or more vaccines, including a tick-borne encephalitis vaccine, a Japanese encephalitis vaccine, and a Rocky Mountain Spotted Fever vaccine. In some aspects, the combination vaccine comprises vaccine compositions that have a seasonal immunization schedule compatible with immunization against *Borrelia* infection or Lyme disease. In more particular aspects, combination vaccines are useful in the prevention of multiple diseases for use in geographical locations where these diseases are prevalent.

**[00130]** The term “*Borrelia*” refers to a species of Gram negative bacteria of the spirochete class of the genus *Borrelia*. In one aspect, “*Borrelia burgdorferi sensu lato (s.l.)*” refers to *Borrelia burgdorferi* in the wider sense. Almost all cases of Lyme disease or Borreliosis are caused by one of three genospecies, *Borrelia afzelii*, *Borrelia garinii* and *Borrelia burgdorferi sensu stricto (s.s.)*, which refers to *B. burgdorferi* in the stricter sense). OspA serotypes of *Borrelia* correlate with species; serotype 1 corresponds to *B. burgdorferi s.s.*, serotype 2 corresponds to *B. afzelii* and serotypes 3 to 7 correspond to *B. garinii*. Recent literature indicates that OspA serotype 4 is proposed to have its own species status as *Borrelia bavariensis* (Margos et al., Appl. Environ. Microbiol. 75: 5410-6, 2009). In various aspects, the immunogenic or vaccine compositions of the invention also provide protection against other species of *Borrelia* including, but not limited to, *Borrelia japonica*, *Borrelia andersonii*, *Borrelia bissettii*, *Borrelia sinica*, *Borrelia turdi*, *Borrelia tanukii*, *Borrelia valaisiana*, *Borrelia lusitaniae*, *Borrelia spielmanii*, *Borrelia miyamotoi* or *Borrelia lonestari*.

**[00131]** A “subject” is given its conventional meaning of a non-plant, non-protist living being. In most aspects, the subject is an animal. In particular aspects, the animal is a mammal. In more particular aspects, the mammal is a human. In other aspects, the mammal is a pet or companion animal, a domesticated farm animal, or a zoo animal. In certain aspects, the mammal is a cat, dog, horse, or cow. In various other aspects, the mammal is a deer, mouse, chipmunk, squirrel, opossum, or raccoon.



**Lyme Disease (Borreliosis or Lyme Borreliosis)**

**[00132]** In some aspects, the invention includes chimeric OspA molecules and compositions comprising these molecules in the prevention of Lyme disease or *Borrelia* infection. Lyme Disease is also known in the art as Borreliosis or Lyme Borreliosis and, therefore, all of these terms are included in the invention. Likewise, the invention includes methods of preventing or treating Lyme disease comprising administering the chimeric OspA molecules described herein. Lyme disease, or borreliosis, is an infectious disease caused by at least three species of Gram-negative spirochetal bacteria belonging to the genus *Borrelia*. There are at least 13 *Borrelia* species which have been discovered, three of which are known to be Lyme-related. The *Borrelia* species that cause Lyme disease are collectively known as *Borrelia burgdorferi sensu lato*, and show a great deal of genetic diversity. The group *Borrelia burgdorferi sensu lato* is made up of three closely-related species that are probably responsible for the large majority of cases. *Borrelia burgdorferi sensu stricto* is the main cause of Lyme disease in the United States (but it is also present in Europe), whereas *Borrelia afzelii* and *Borrelia garinii* cause most European cases. Recent literature indicates that *Borrelia bavariensis*, first found in Bavaria, could be considered a new species. However, to date, OspA serotype 4 has been considered to be a strain of *Borrelia garinii* (Margos et al., *Id*). Some studies have also proposed that *Borrelia* species (e.g. *Borrelia bissettii*, *Borellia spielmanii*, *Borrellia lusitaniae*, and *Borrelia valaisiana*) may sometimes infect humans. Although these species do not seem to be important causes of disease, immunogenic protection against these species is also include in the invention.

**[00133]** Lyme disease is the most common tick-borne disease in the Northern Hemisphere. The disease is named after the village of Lyme, Connecticut where a number of cases were identified in 1975. *Borrelia* is transmitted to humans by the bite of infected ticks belonging to a few species of the genus *Ixodes* ("hard ticks"). Early symptoms, in some instances, include fever, headache, fatigue, depression, and a characteristic circular skin rash called erythema migrans. Left untreated, later symptoms can often involve the joints, heart, and central nervous system. In most cases, the infection and its symptoms are eliminated by antibiotics, especially if the illness is treated early. However, late, delayed, or inadequate treatment can lead to the more serious symptoms, which can be disabling and difficult to treat.

Occasionally, symptoms such as arthritis persist after the infection has been eliminated by antibiotics.

**[00134]** Some groups have argued that "chronic" Lyme disease is responsible for a range of medically unexplained symptoms beyond the recognized symptoms of late Lyme disease, and that additional, long-term antibiotic treatments are needed. However, long-term treatment is controversial and the dispute regarding such treatment has led to legal action over treatment guidelines.

**[00135]** Lyme disease is classified as a zoonosis, as it is transmitted to humans from a natural reservoir which includes rodents and birds by ticks that feed on both sets of hosts. Hard-bodied ticks of the genus *Ixodes* are the main vectors of Lyme disease. Most human infections are caused by ticks in the nymphal stage, as the nymphal ticks are very small and may feed for long periods of time undetected. Tick bites often go unnoticed because of the small size of the tick in its nymphal stage, as well as tick secretions that prevent the host from feeling any itch or pain from the bite.

**[00136]** Lyme disease is diagnosed clinically based on symptoms, objective physical findings (such as erythema migrans, facial palsy, or arthritis), a history of possible exposure to infected ticks, as well as serological blood tests. Approximately half of the patients with Lyme disease will develop the characteristic bulls-eye rash, but many may not recall a tick bite. Laboratory testing is not recommended for persons who do not have symptoms of Lyme disease.

**[00137]** Because of the difficulty in culturing *Borrelia* bacteria in the laboratory, diagnosis of Lyme disease is typically based on the clinical exam findings and a history of exposure to endemic Lyme areas. The Erythema migrans (EM) rash, which only occurs in about 50% of all cases, is considered sufficient to establish a diagnosis of Lyme disease even when serologic blood tests are negative. Serological testing can be used to support a clinically suspected case but is not diagnostic by itself. Diagnosis of late-stage Lyme disease is often difficult because of the multi-faceted appearance which can mimic symptoms of many other diseases. For this reason, a reviewer called Lyme the new "great imitator." Lyme disease, in some instances, is misdiagnosed as multiple sclerosis, rheumatoid arthritis, fibromyalgia, chronic fatigue syndrome (CFS), lupus, or other autoimmune and

neurodegenerative diseases. Thus, there is a great need in the art for a vaccine to prevent or treat Lyme disease.

### **Outer Surface Protein A (OspA) of *Borrelia***

**[00138]** In various aspects, the invention includes chimeric OspA molecules of *Borrelia* and compositions comprising these molecules in the prevention and treatment of Lyme disease or *Borrelia* infection. Several *Borrelia* outer surface proteins have been identified over the past decade that are up-regulated by temperature- and/or mammalian host-specific signals as this spirochete is transmitted from ticks to mammals.

**[00139]** The major outer surface protein, OspA, of *Borrelia burgdorferi* is a lipoprotein of particular interest because of its potential as a vaccine candidate. Serotypic and genetic analysis of OspA from both European and North American strains of *Borrelia* have demonstrated antigenic and structural heterogeneities. OspA is described in published PCT patent application WO 92/14488, in Jiang et al. (*Clin. Diagn. Lab. Immunol.* 1: 406-12, 1994) and is known in the art. Osp A has been shown to induce protective immunity in mouse, hamster and dog challenge studies. Clinical trials in humans have shown the formulations of OspA to be safe and immunogenic in humans (Keller et al., JAMA (1994) 271:1764 1768).

**[00140]** While OspA is expressed in the vast majority of clinical isolates of *Borrelia burgdorferi* from North America, a different picture has emerged from examination of the clinical *Borrelia* isolates in Europe. In Europe, Lyme disease is mainly caused by three genospecies of *Borrelia*, namely *B. burgdorferi*, *B. garinii* and *B. afzelii*. Recent literature indicates that *Borrelia bavariensis* may be its own genospecies. Thus, *Borrelia bavariensis* has been proposed as a new name for OspA serotype 4, also known as a strain of *Borrelia garinii* (Margos et al., *Id*). The invention is directed to chimeric OspA molecules that provide protective immunity against all genospecies of *Borrelia*. The invention describes the design and synthesis of three chimeric OspA genes that encode for three distinct lipidated OspA molecules that share common features. Each gene represents two OspA serotypes and the genes were designed to encode stable OspA molecules that are safe and highly immunogenic, and afford a subject protection against infection with *B. burgdorferi sensu lato* (*s.l.*). The invention also describes three original chimeric OspA genes without mutations and

without codon optimization that encode three distinct lipidated OspA molecules that share common features. Each gene represents two OspA serotypes and encode molecules that afford a subject protection against infection with *B. burgdorferi sensu lato* (s.l.).

**[00141]** Seven principal OspA serotypes have been recognized among European isolates (designated serotypes 1 to 7, Wilske et al., *J. Clin. Microbiol.* 31:340-50, 1993). OspA serotypes correlate with species; serotype 1 corresponds to *B. burgdorferi s.s.*, serotype 2 corresponds to *B. afzelii* and serotypes 3 to 7 correspond to *B. garinii*. Serotype 4, in some aspects, is alternatively considered *Borrelia bavariensis*. (See Margos et al., *Id*). Epidemiological studies of European *Borrelia* isolates indicate that a vaccine based on OspA types 1, 2, 3, 4, 5 and 6 would provide theoretical coverage in Europe of 98.1% of Lyme disease and cover 96.7% of invasive disease isolates. The invention provides six chimeric OspA nucleic acid molecules (SEQ ID NOS: 1, 3, and 5, and SEQ ID NOS: 168, 170, and 172) and six chimeric OspA polypeptide molecules (SEQ ID NOS: 2, 4, and 6, and SEQ ID NOS: 169, 171, and 173) that can provide protective immunity against all six serotypes 1-6. Six synthetic OspA genes were designed to encode OspA molecules with the protective epitopes from OspA serotypes 1 and 2 (lipB sOspA 1/2<sup>251</sup> (SEQ ID NOS: 1 (nucleic acid) and 2 (amino acid) and orig sOspA 1/2 (SEQ ID NOS: 168 (nucleic acid) and 169 (amino acid))); OspA serotypes 6 and 4 (lipB sOspA 6/4 (SEQ ID NOS: 3 (nucleic acid) and 4 (amino acid) and orig sOspA 6/4 (SEQ ID NOS: 170 (nucleic acid) and 171 (amino acid))); and OspA serotypes 5 and 3 (lipB sOspA 5/3 (SEQ ID NOS: 5 (nucleic acid) and 6 (amino acid) and orig sOspA 5/3 (SEQ ID NOS: 172 (nucleic acid) and 173 (amino acid))). The chimeric OspA genes were made using synthetic overlapping oligonucleotides. These recombinant proteins are, in certain aspects, produced at high yield and purity and, in various aspects, manipulated to maximize desirable activities and minimize undesirable ones.

### **Chimeric OspA Nucleic Acid Molecules and Polypeptide Molecules**

**[00142]** In various aspects, the invention includes chimeric OspA nucleic acid and polypeptide molecules of *Borrelia*. The OspA nucleic acids of the invention include a nucleic acid molecule comprising, consisting essentially of, or consisting of a nucleotide sequence as set forth in SEQ ID NO: 1 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 3 (lipB sOspA 6/4), SEQ ID NO: 5 (lipB sOspA 5/3), SEQ ID NO: 7 (sOspA 1/2<sup>251</sup>),

SEQ ID NO: 9 (sOspA 6/4), SEQ ID NO: 11 (sOspA 5/3), SEQ ID NO: 168 (orig sOspA 1/2), SEQ ID NO: 170 (orig sOspA 6/4), or SEQ ID NO: 172 (orig sOspA 5/3), or a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3).

**[00143]** The nucleic acid sequences of SEQ ID NOS: 7, 9, and 11 lack the nucleic acid sequence encoding the lipB leader sequence (MRLIGFALALALIG (SEQ ID NO: 13). In addition, the nucleic acid sequences of SEQ ID NOS: 7, 9, and 11 encode a methionine residue at the amino terminus of SEQ ID NOS: 8, 10, and 12 in place of the cysteine residue present at the carboxy terminus of the lipB leader sequence in SEQ ID NOS: 2, 4, and 6. SEQ ID NOS: 1, 3, and 5 are lipB sOspA polynucleotides, and SEQ ID NOS: 2, 4, and 6 are lipB sOspA polypeptides.

**[00144]** In some aspects, the invention includes original ("orig") chimeric OspA nucleic acid and polypeptide molecules of *Borrelia* without mutations and without codon optimization. The OspA nucleic acids of the invention, therefore, include a nucleic acid molecule comprising, consisting essentially of, or consisting of a nucleotide sequence as set forth in SEQ ID NO: 168 (orig sOspA 1/2), SEQ ID NO: 170 (orig sOspA 6/4), or SEQ ID NO: 172 (orig sOspA 5/3), or a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3).

**[00145]** Sequence identification numbers for DNA and amino acid sequences for the chimeric OspA molecules are set out in Table 1 below.

**Table 1. Chimeric OspA DNA and Amino Acid Sequences**

Sequence	DNA SEQ ID NO:	Amino Acid SEQ ID NO:	Complementary Strand SEQ ID NO:
lipB sOspA 1/2 <sup>251</sup>	1	2	48
lipB sOspA 6/4	3	4	49
lipB sOspA 5/3	5	6	50
sOspA 1/2 <sup>251</sup>	7	8	56
sOspA 6/4	9	10	57
sOspA 5/3	11	12	58
Orig sOspA 1/2	168	169	
Orig sOspA 6/4	170	171	
Orig sOspA 5/3	172	173	

**lipB sOspA 1/2<sup>251</sup>****Amino Acid Sequence (SEQ ID NO: 2)**

MRLLI GFALALALIGCAQKGAESIGSVSVDLPGEMKVLVSKEKDKNGKYDLIATVDKLELKGTSDKNNGS  
GVLEGVKTNKS VKLTIISDDL GQTTLLEVFKEDGKTLVSKKVT SKDKS STEEFNEKGEVSEKIIITMADGT  
RLEYTG IKS DGTG KAKYVLKNFTLEGKVANDKTTLEVKEGTVTL SMNISKSGEVSVELNDTDS SAATKKT  
AAWNSKTSTLTISVNSKKTTLVFTKQDTITVQKYDSAGTNLEGTAVEIKTLDLKNALK

**DNA Sequence (SEQ ID NO: 1)**

catatgcgctctgttgatcggcctttgctctggcgctggctctgatcggctgcgacagaaagggtgctgagt  
ctattgggttcggtttctgtagatctgcccggtgaaatgaagggtctggtgagcaaagaaaaagacaagaa  
cggcaagtacgatctcatcgcaaccgtcgacaagctggagctgaaagggtacttctgataaaaaacaacggc  
tctgggtgtgctggaggggcgtaaaactaacaagagcaaaagtaaaagcttacgatctctgacgatctcggtc  
agaccacgctggaagttttcaaagaggatggcaagaccctcggtgtccaaaaagtaacttccaaagacaa  
gtcctctacggaagaaaaattcaacgaaaaagggtgaggtgtctgaaaagatcatcaccatggcagacggc  
accggtcttgaatacacccggtattaaaaagcgatggtagccggtaaaagcgaaatatgttctgaaaaacttca  
ctctggaaggcaaaagtggctaatagataaaaccaccttggaaagtcaaggaaggcaccgttactctgagcat  
gaatatctccaaatctgggtgaagtttccggttgaactgaacgacactgacagcagcgctgcgactaaaaaa  
actgcagcggtggaattccaaaacttctactttaaccattagcggttaacagcaaaaaaactaccagctgg  
tggttactaaacaagacacgatcactgtgcagaaatacgactccgcaggcaccacttaagaaggcacggc  
agtcgaaattaaaacccttgatgaactgaaaaacgcgctgaaataagctgagcggatcc

**Complementary Strand (SEQ ID NO: 48)**

catatgcgctctgttgatcggcctttgctttggcgctggctttaatcggctgtgcacagaaagggtgctgagt  
ctattgggttcggtttctgtagatctgcccggtgaaatgaagggtctggtgagcaaagaaaaagacaaaaa  
cggtaaaatacagcctgatggcaaccgtagaaaaagctggagcttaaaaggcacttctgataaaaaacaacggt  
tctggcaccctggaagggtgaaaaaactaacaaaagcaaaagtaaaagcttactattgctgaggatctgagca  
aaaccacctttgaaatcttcaaagaagatggcaaaaactctggtatctaaaaaagtaaccctgaaagacaa  
gtcttctaccgaagaaaaattcaacgaaaaagggtgaaatctctgaaaaaactatcgtaatggcaaatggt  
accggtctggaatacacccgacatcaaaagcgataaaaccggcaaaagctaaatacgttctgaaagacttta  
ctctggaaggcactctggctgctgacggcaaaaaccactctgaaagttaccgaaggcactgttactctgag  
catgaacatttctaaatccggcgaaatcaccgttgcactggatgacactgactctagcggcaataaaaaa  
tccggcacctgggattctgatacttctactttaaccattagcaaaaaacagccagaaaaactaaacagctgg  
tattcaccaagaaaaacactatcaccgtacagaactataaccggtgcaggcaatgcgctggaaggcagccc  
ggctgaaattaaagatctggcagagctgaaagccgctttgaaataagctgagcggatcc

**lipB sOspA 6/4****Amino Acid Sequence (SEQ ID NO: 4)**

MRLLI GFALALALIGCAQKGAESIGSVSVDLPGGMTVLVSKEKDKNGKYSLEATVDKLELKGTSDKNNGS  
 GTLEGEKTNKSKVKLTIADDL SQTKEIFKEDAKTLVSKKVT LKDKS STEEFNEKGETSEKTIVMANGT  
 RLEYTDIKSDGSGKAKYVLKDF TLEGT LAADGKTTLKVTEGTVVLSMNILKSGEITVALDDSDTTQATKK  
 TGKWD SNTSTLTISVNSKKTKNIVFTKEDTITVQKYDSAGTNLEGNAVEIKTLDELKNALK

**DNA Sequence (SEQ ID NO: 3)**

catatg cgtctgttgatcggc tttgctctggcgctggctctgatcggctgcgcacagaaaggctgctgagt  
 ctattgggttcggtttctgtagatctgcccggtggcatgaccgttctggtcagcaaagaaaaagacaaaaa  
 cggtaaat acagcctcgaggcgaccgtcgacaagcttgagctgaaaggcacctctgataaaaaacaacggt  
 tccggcaccctggaagggtgaaaaaactaacaaaagcaaaagtgaactgaccattgctgatgacctcagcc  
 agaccaaattcgaaat tttcaaagaagatgccaaaaccttagtatccaaaaaagtgaccctgaaagacaa  
 gtcctctaccgaagaaaaattcaacgaaaagggtgaaacctctgaaaaaacctcgtaatggcaaagtgt  
 acccgtctggaatacaccgacatcaaaagcgatggctccggcaaaagccaaatacgttctgaaagacttca  
 ccctggaaggcacccctcgctgccgacggcaaaaccaccttgaaagttaccgaaggcactgttggtttaag  
 catgaacatcttaaaatccgggtgaaatcaccgttgcgctggatgactctgacaccactcaggccactaaa  
 aaaaccggcaaatgggattctaacacttccactctgaccatcagcgtgaattccaaaaaaactaaaaaca  
 tcgtgttcaccaaagaagacaccatcaccgtccagaaatacgactctgcgggcaccaacctcgaaggcaa  
 cgcagtcgaaatcaaaaccctggatgaactgaaaaacgctctgaaataagctgagcggatcc

**Complementary Strand (SEQ ID NO: 49)**

ggatccgctcagcttatttccagcgcgtttttcagttcatcaagggttttaatttcgactgccgtgccttc  
 taagttgggtgctgcggagtcgtatttctgcacagtgatcgtgtcttggttagtgaacaccagctgggta  
 gtttttttgcgtgtaacgctaattggttaaagtagaagttttggaattccacgctgcagtttttttagtcg  
 cagcgtctgtcagtgctggttcagttcaacggaaaacttcaccagatttgagatattcatgctcagagt  
 aacgggtgccttccttgacttccaagggtggttttatcattagccactttgccttcacagagtgaagtttttc  
 agaacataatttcgctttaccgggtaccatcgcttttaataaccgggtgtattcaagacgggtgccgtctgcca  
 tggtgatgatcttttcagacacctcacctttttcggttgaaat tttcttccgtagaggacttgctcttgga  
 agttacttttttgacacgaggggtcttgccatcctctttgaaaacttccagcgtggctctgaccgagatcg  
 tcagagatcgtaagctttactttgctcttggttagttttgacgccctccagcacaccagagccgttggttt  
 tatcagaagtacctttcagctccagcttgctcgacgggtgcgatgagatcgtacttgccgttcttgctctt  
 ttctttgctcaccagaaccttcatttcaccgggcagatctacagaaacggaaccaatagactcagcacct  
 ttctgtgcgcagccgatcagagccagcgcagagcaaaagccgatcaacagacgcatatg

**lipB sOspA 5/3****Amino Acid Sequence (SEQ ID NO: 6)**

MRLLI GFALALALIGCAQKGAESIGSVSVDLPGGMKVLVSKEKDKNGKYS L MATVEKLELKGTS DKNNGS  
GTLEGEKTNKSKVKLTIAEDLSKTTFEIFKEDGKTLVSKKVTLLKDKS STEEFNEKEGEI SEKTIVMANGT  
RLEYTDIKSDKTGKAKYVLKDF TLEGLAADGKTT LKVTEGTVT L SMNISKSGEIT VALDDTDSSGNKKS  
GTWSDSTLT LTISKNSQKTKQLVFTKENTITVQNYNRAGNALEGSPAEIKDLAELKAALK

**DNA Sequence (SEQ ID NO: 5)**

catatgcgtctgttgatcggctttgctttggcgctggctttaatcggctgtgcacagaaaggtgctgagt  
ctattgggttcggtttctgtagatctgcccggggtatgaaagttctggtaagcaaagaaaaagacaaaaa  
cggtaaatacagcctgatggcaaccgtagaaaagctggagcttaaaaggcacttctgataaaaaacaacggt  
tctggcaccctggaaggtgaaaaaactaacaaaagcaaagtaaaagcttactattgctgaggatctgagca  
aaaccacctttgaaatcttcaaagaagatggcaaaactctggatctaaaaaagtaaccctgaaagacaa  
gtcttctaccgaagaaaaattcaacgaaaaggggtgaaatctctgaaaaaactatcgtaatggcaaatggt  
accggtctggaatacacccgacatcaaaaagcgataaaaaccggcaaaagctaaatacgttctgaaagacttta  
ctctggaaggcactctggctgctgacggcaaaaaccactctgaaagtaccgaaggcactgttactctgag  
catgaacatttctaaatccggcgaaatcacctgtgactggatgacactgactctagcggcaataaaaaa  
tccggcacctgggattctgatacttctactttaaccattagcaaaaaacagccagaaaactaaacagctgg  
tattcaccaaagaaaacactatcacctacagaactataaccgtgcaggcaatgcgctggaaggcagccc  
ggctgaaattaaagatctggcagagctgaaagccgctttgaaataagctgagcggatcc

**Complementary Strand (SEQ ID NO: 50)**

ggatccgctcagcttatttccagagcgtttttcagttcatccagggttttgatttcgactgcgttgccctc  
gaggttggtgcccgcagagtcgtatttctggacggtgatggtgtcttctttggtgaacacgatgttttta  
gtttttttggaattcacgctgatggtcagagtggaagtgttagaatccatttgcgggttttttttagtgg  
cctgagtggtgtcagagtcacccagcgcaacggtgatttcaccggatttttaagatgttcattgcttaaaac  
aacagtgcccttcggttaactttcaaggtggttttgccgtcggcagcgaggggtgccttcagggtgaaagtct  
ttcagaacgtatttggctttgcccggagccatcgcttttgatgtcggtgtattccagacgggtaccatttg  
ccattacgatgggttttttcagagggtttcaccccttttcggtgaattttttcttcggtagaggacttgcttt  
cagggtcacttttttgataactaagggttttgccatcttctttgaaaatttcgaatttggctctggctgagg  
tcatcagcaatggtcagtttcactttgctttgttagtttttcaccttcagggtgccggaaccgttgt  
ttttatcagagggtgcctttcagctcaagcttgtcgacggtcgctcagaggctgtatttaccgtttttgtc  
tttttctttgctgaccagaacgggtcatgccaccgggcagatctacagaaacggaaccaatagactcagca  
cctttctgtgcgcagccgatcagagccagcgccagagcaaaagccgatcaacagacgcatatg



**sOspA 1/2<sup>251</sup>****Amino Acid Sequence (SEQ ID NO: 8)**

MAQKGAESIGSVSVDLPGEMKVLVSKEKDKNGKYDLIATVDKLELKGTSKNNNGSGVLEGVKTNKSQVVL  
 TISDDLQTTLEVFKEGDKTLVSKKVTSKDKSSTEEKFNEKGEVSEKIITMADGTRLEYTGKSDGTGKA  
 KYVLKNFTLEGKVANDKTILEVKEGTVTLNLSNLSKSGEVSVELNDTDSSAATKKTAWNSTSTLTISVN  
 SKKTTQLVFTKQDITITVQKYDSAGTNLEGTAVEIKTLDELKNALK

**DNA Sequence (SEQ ID NO: 7)**

catatggcacagaaaggtgctgagtcattggttccggtttctgtagatctgcccgggtgaaatgaaggttc  
 tgggtgagcaaaagaaaaagacaagaacggcaagtagcatctcatcgcaaccgtcgacaagctggagctgaa  
 aggtacttctgataaaaaacaacggctctggtgtgctggagggcgtaaaaactaacaagagcaaaagtaaag  
 cttacgatctctgacgatctcggtcagaccacgctggaagttttcaagaggatggcaagaccctcggtg  
 ccaaaaaagtaacttccaaagacaagtcctctacggaagaaaaattcaacgaaaaaggtgaggtgtctga  
 aaagatcatcaccatggcagacggcaccctgcttgaatacaccgggtattaaaagcgatggtagccggtaaa  
 gcgaaatatgttctgaaaaacttcactctggaaggcaaaagtggttaataataaaaccaccttggaagtca  
 aggaaggcaccgttactctgagcatgaatatctccaaatctggtgaagtttccggtgaactgaacgacac  
 tgacagcagcgctgcgactaaaaaaactgcagcgtggaattccaaaacttctactttaaccattagcgtt  
 aacagcaaaaaaactaccagctggtgttactaaacaagacacgatcactgtgcagaaatacgaactcca  
 acggcaccaacttagaaggcacggcagtcgaaattaaaacccttgatgaactgaaaaacgcgctgaaata  
 agctgagcggatcc

**Complementary Strand (SEQ ID NO: 56)**

gtataccggtgtctttccacgactcagataaccaaggcaaaagacatctagacggggccactttacttccaag  
 accactcggtttcttttctgttcttgcggttcatgctagagtagcgttggcagctgttcgacctcgactt  
 tccatgaagactatttttgttgcgagaccacacgacctcccgagttttgattgttctcgtttcatttc  
 gaatgctagagactgctagagccagtcctggtgcgaccttcaaaagtttctcctaccgttctgggagcaca  
 ggttttttctattgaaggtttctgttcaggagatgccttctttttaagttgctttttccactccacagact  
 tttctagtagtggtaccgtctgcggtgggcagaaacttatgtggccataattttcgctaccatggccattt  
 cgctttatacaagactttttgaagtgcgaccttccggtttcaccgattactattttggtggaaccttcagt  
 tccttccggtggcaatgagactcgtacttatagaggttttagaccacttcaaaggcaacttgacttgctgtg  
 actgtcgtcgcgacgctgatttttttgacgtcgcaccttaaggttttgaagatgaaattggtaacgcaa  
 ttgtcgtttttttgatgggtcgaccacaagtgatttgttctgtgctagtgcacgctctttatgctgaggt  
 tgccgtgggtgaatcttccgtgcggtcagctttaattttgggaactacttgactttttgcgcgactttat  
 tcgactcgccatagg

**sOspA 6/4****Amino Acid Sequence (SEQ ID NO: 10)**

MAQKGAESIGSVSVDLPGGMTVLVSKEKDKNGKYSLEATVDKLELKGTSKNNNGSGTLEGEKTNKSQVVL  
 TIADDLSQTKFEIFKEDAKTLVSKKVTSLKDKSSTEEKFNEKGETSEKTIVMANGTRLEYTDIKSDGSGKA  
 KYVLKDFTEGLTAADGKTTLVTEGTVVLSMNLKSGEITVALDDSDTTQATKKTGKWDSTSTLTISV  
 NSKKTKNIVFTKEDTITVQKYDSAGTNLEGNAVEIKTLDELKNALK

**DNA Sequence (SEQ ID NO: 9)**

catatggcacagaaaggtgctgagtcattggttccggtttctgtagatctgcccgggtggcatgaccgttc  
 tgggtcagcaaaagaaaaagacaaaaacggtaaatacagcctcgaggcgaccgtcgacaagcttgagctgaa  
 aggcacctctgataaaaaacaacggttccggcaccctggaaggtgaaaaaactaacaagcaaaagtgaaa  
 ctgaccattgtgatgacctcagccagaccaaattcgaaattttcaagaagatgccaaaaccttagtat  
 ccaaaaaagtgacctgaaagacaagtcctctaccgaagaaaaattcaacgaaaagggtgaaacctctga  
 aaaaaccatcgtaaatggcaaatggtacccgtctggaatacaccgacatcaaaagcgatgggtccggcaaa  
 gccaaatacgttctgaaagacttcacctggaaggcaccctcgctgccgacggcaaaaccaccttgaaag  
 ttaccgaaggcactggtgttttaagcatgaacatcttaaaatccggtgaaatcaccgttgcgctggatga  
 ctctgacaccactcaggccactaaaaaaaccggcaaatgggattctaacacttccactctgaccatcagc  
 gtgaattccaaaaaaactaaaaacatcggtgttcaccaaagaagacaccatcaccgtccagaaatacgaact  
 ctgcgggcaccaacctcgaaggcaacgcagtcgaaatcaaaaccctggatgaactgaaaaacgcgtctgaa  
 ataagctgagcggatcc

**Complementary Strand (SEQ ID NO: 57)**

gtataccgtgtctttccacgactcagataaccaaggcacaagacatctagacggggccaccgtactggcaag  
accagtcgtttctttttctgtttttgccatttatgtcggagctccgctggcagctgttcgaactcgactt  
tccgtggagactatttttgttgccaaggccgtgggaccttccacttttttgattgttttcgtttcacttt  
gactggtaacgactactggagtcggtctggtttaagctttaaaagtttcttctacggttttggaatcata  
ggttttttcactgggactttctgttcaggagatggcttctttttaagttgcttttccacttttgagact  
tttttggtagcattaccgtttaccatgggcagaccttatgtggctgtagttttcgctaccgaggccgttt  
cggtttatgcaagactttctgaagtgggaccttccgtgggagcgacggctgccgttttggtggaactttc  
aatggcttccgtgacaacaaaattcgacttgtagaatttttaggccacttttagtggaacgcgacactact  
gagactgtggtgagtcgggtgattttttggccgtttaccctaagattgtgaaggtgagactggtagtcg  
cacttaagggttttttgattttttagtcacaagtggtttcttctgtggtagtggcaggtctttatgctga  
gacgcccgtggttgagacttccgttcgctcagcttttagttttgggacactacttgactttttgcgagactt  
tattcgactcgccatagg

**sOspA 5/3****Amino Acid Sequence (SEQ ID NO: 12)**

MAQKGAESIGSVSVDLPGGMKVLVSKEKDKNGKYSIMATVEKLELKGTSKNNNGSGTLEGEKTNKSKVKL  
TIAEDLSKTTFEIFKEDGKTLVSKKVTLLKDKSSSTEEKFNEKGEISEKTIVMANGTRLEYTDIKSDKTGKA  
KYVLKDFTLLEGTLAADGKTLKVTEGTVTLNISKSGEITVALDDTDSSGNKKSgtWSDTSTLTISK  
NQKTKQLVFTKENTITVQNYNRAGNALEGSPAIEIKDLAELKAALK

**DNA Sequence (SEQ ID NO: 11)**

catatggcacagaaaggtgctgagtcatttggttccgtttctgtagatctgcccgggggtatgaaagtcc  
tggttaagcaaaagaaaaagacaaaaacggttaatacagcctgatggcaaccgtagaaaagctggagcttaa  
aggcacttctgataaaaaacaacggttctggcaccctggaaggtgaaaaaactaacaagcaaaagtaaag  
cttactattgctgaggatctgagcaaaaccacctttgaaatcttcaagaagatggcaaaactctggtat  
ctaaaaaagtaaccctgaaagacaagtccttctaccgaagaaaaattcaacgaaaaggggtgaaatctctga  
aaaaactatcgtaatggcaaatggtaccgctctggaatacacccgacatcaaaagcgataaaaaccggcaaa  
gctaaatacgttctgaaagactttactctggaaggcactctggctgctgacggcaaaaccactctgaaag  
ttaccgaaggcactgttactctgagcatgaacatttctaaatccggcgaaatcaccgttgactggatga  
cactgactctagcggcaataaaaaatccggcacctgggattctgatacttctactttaaccattagcaaa  
aacagccagaaaactaaacagctggtattcaccaagaaaaacactatcaccgtacagaactataaccgtg  
caggcaatgcgctggaaggcagcccggctgaaattaaagatctggcagagctgaaagccgctttgaaata  
agctgagcggatcc

**Complementary Strand (SEQ ID NO: 58)**

gtataccgtgtctttccacgactcagataaccaaggcacaagacatctagacggggcccccatactttcaag  
accattcggtttctttttctgtttttgccatttatgtcggactaccgttggcatcttttcgacctcgaatt  
tccgtgaagactatttttgttgccaaggaccgtgggaccttccacttttttgattgttttcgtttcatttc  
gaatgataacgactcctagactcgttttggtggaaactttagaagtttcttctaccgttttgagaccata  
gattttttcattgggactttctgttcagaagatggcttctttttaagttgcttttccacttttagagact  
tttttgatagcattaccgtttaccatgggcagaccttatgtggctgtagttttcgctattttgccgtttt  
cgatttatgcaagactttctgaaatgagaccttccgtgagaccgacgactgccgttttggtgagactttc  
aatggcttccgtgacaatgagactcgacttgtaaagatttaggccgttttagtggaacgtgacactact  
gtgactgagatcgccgttattttttaggccgtggaccctaagactatgaagatgaaattggtaatcgttt  
ttgtcggctcttttgatttgcgaccataagtggtttcttttgatagtggtcatgtcttgatattggcac  
gtccgttacgcgaccttccgtcgggcccgaactttaatttctagaccgtctcgaactttcggcgaaactttat  
tcgactcgccatagg

**Orig sOspA 1/2****Amino Acid Sequence (SEQ ID NO: 169)**

MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDLPGEMKVLVSKEKNKDGKYDLIATVDKLEL  
 KGTSKNNNGSGVLEGVKADKSKVKLTISDDLQTTLEVFKEGKTLVSKKVTSKDKSSTEEKF  
 NEKGEVSEKIIITRADGTRLEYTGIKSDGSGKAKEVLKNFTLEGKVANDKVTLEVKEGTVTLISK  
 NISKSGEVSVELNDTDSSAATKKTAAWNSKTSTLTISVNSKKTQLVFTKQDTITVQKYDSAG  
 TNLEGTAVEIKTLDELKNALK

**DNA Sequence (SEQ ID NO: 168)**

atgaaaaaatatatttattgggaataggtctaataattagccttaatagcatgtaagcaaaatgt  
 tagcagccttgacgagaaaaacagcggtttcagtagatttgcttggtgaaatgaaagttcttg  
 taagcaaagaaaaaaacaaagacggcaagtacgatctaattgcaacagtagacaagcttgag  
 cttaaaggaacttctgataaaaacaatggatctggagtacttgaaggcgtaaaagctgacaa  
 aagtaaagtaaaattaacaatttctgacgatctaggtcaaaccacacttgaagttttcaaag  
 aagatggcaaaacactagtatcaaaaaaagtaacttccaaagacaagtcataacagaagaa  
 aaattcaatgaaaaaggtgaagtatctgaaaaaataataacaagagcagacggaaccagact  
 tgaatacacaggaattaaaagcgatggatctggaaaagctaagagaggttttaaaaaacttta  
 ctcttgaaaggaaaagtagctaataatgataaagtaacattggaagtaaaagaaggaaccgttact  
 ttaagtaaaaaatatttcaaaatctggggaagtttcagttgaacttaatacactgacagtag  
 tgctgctactaaaaaaactgcagccttggaattcaaaaacttctactttaacaattagtgtta  
 acagcaaaaaaactacacaacttggtgtttactaaacaagacacaataactgtacaaaaatac  
 gactccgcaggtaccaatttagaaggcacagcagtcgaaattaaaacacttgatgaacttaa  
 aaacgcctttaaaatag

**Orig sOspA 6/4****Amino Acid Sequence (SEQ ID NO: 171)**

MKKYLLGIGLILALIACKQNVSTLDEKNSVSVDLPGGMTVLVSKEKDKDGKYSLEATVDKLE  
 LKGTSDKNNNGSGTLEGEKTDKSKVKLTIAADDLSQTKFEIFKEDAKTLVSKKVTLKDKSSTEE  
 KFNEKGETSEKTIVRANGTRLEYTDIKSDGSGKAKEVLKDFTEGTLAADGKTTTLKVTEGTV  
 VLSKNILKSGEITVALDDSDTTQATKKTGKWDSTSTLTISVNSKKTKNIVFTKEDTITVQK  
 YDSAGTNLEGNAVEIKTLDELKNALK

**DNA Sequence (SEQ ID NO: 170)**

atgaaaaaatatatttattgggaataggtctaataattagccttaatagcatgtaagcaaaatgt  
 tagcacgccttgatgaaaaaaatagcggtttcagtagatttacctggtggaatgacagttcttg  
 taagtaaagaaaaagacaaagacggtaaatagtagaggcaacagtagacaagcttgag  
 cttaaaggaacttctgataaaaacaacgggttctggaacacttgaaggtgaaaaaactgacaa  
 aagtaaagtaaaattaacaattgctgatgacctaagtcaaactaaattttgaaattttcaaag  
 aagatgccaaaacatttagtatcaaaaaaagtaacccttaaagacaagtcataacagaagaa  
 aaattcaacgaaaaggggtgaaacatctgaaaaaacaatagtaagagcaaatggaaccagact  
 tgaatacacagacataaaaagcgatggatccggaaaagctaagaaggttttaaaagacttta  
 ctcttgaaaggaactctagctgctgacggcaaaaacaacattgaaagttacagaaggcactgtt  
 gttttaagcaagaacatttttaaaatccggagaaataacagttgcacttgatgactctgacac  
 tactcaggctactaaaaaaactggaaaatgggattcaataacttccactttaacaattagtgt  
 tgaatagcaaaaaaactaaaaacattgtatttacaaaagaagacacaataacagtacaaaaa  
 tacgactcagcaggcaccaatctagaaggcaacgcagtcgaaattaaaacacttgatgaact  
 taaaaacgcctttaaaataa

**Orig sOspA 5/3****Amino Acid Sequence (SEQ ID NO: 173)**

MKKYLLGIGLILALIACKQNVSSLDEKNSVSVDLPGGMKVLVSKEKDKDGKYSMATVEKLE  
 LKGTSDKNNGSGTLEGEKTDKSKVKLTIAEDLSKTTFEIFKEDGKTLVSKKVTLKDKSSTEE  
 KFNEKGEISEKTIVRANGTRLEYTDIKSDKTGKAKEVLKDFTLLEGTLAADGKTTLVTEGTV  
 TLSKNISKSGEITVALDDTDSSGNKKS GTWSDTSTLTISKNSQKTKQLVFTKENTITVQNY  
 NRAGNALEGSPA EIKDLAELKAALK

**DNA Sequence (SEQ ID NO: 172)**

atgaaaaaatattttattgggaataggtctaataattagccttaatagcatgtaagcaaaatgt  
 tagcagccttgatgaaaaaaatagcggtttcagtagatttacctggtggaatgaaagttcttg  
 taagtaaagaaaaagacaaagatggtaaatacagtcctaattggcaacagtagaaaaagccttgag  
 cttaaaggaacttctgataaaaacaacgggttctggaacacttgaaggtgaaaaaactgacaa  
 aagtaaagtaaaattaacaattgctgaggatctaagtaaaaccacatttgaaatcttcaaag  
 aagatggcaaaacatttagtatcaaaaaaagtaacccttaagacaagtcataacagaagaa  
 aaattcaacgaaaaggggtgaaatatctgaaaaaacaatagtaagagcaaatggaaccagact  
 tgaatacacagacataaaaagcgataaaaaccggaaaagctaaagaagtttttaaagacttta  
 ctcttgaaaggaactctagctgctgacggcaaaacaacattgaaagttacagaaggcactgtt  
 actttaagcaagaacattttcaaaatccggagaaataacagttgcacttgatgacactgactc  
 tagcggcaataaaaaatccggaacatgggattcagatacttctactttaacaattagtaaaa  
 acagtcaaaaaactaaacaacttgatttcacaaaagaaaacacaataacagtacaaaactat  
 aacagagcaggcaatgcgcttgaaggcagcccagctgaaattaaagatcttgcagagcttaa  
 agccgctttaaaataa

**[00146]** The OspA polypeptides of the invention include a polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3) and related polypeptides. Related polypeptides include OspA polypeptide analogs, OspA polypeptide variants and OspA polypeptide derivatives. In some aspects, an OspA polypeptide has an amino terminal methionine residue, depending on the method by which they are prepared. In related aspects, the OspA polypeptide of the invention comprises OspA activity.

**[00147]** In one embodiment, related nucleic acid molecules comprise or consist of a nucleotide sequence that is about 70 percent (70%) identical or similar to the nucleotide sequence as shown in SEQ ID NO: 1 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 3 (lipB sOspA 6/4), SEQ ID NO: 5 (lipB sOspA 5/3), SEQ ID NO: 7 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 9 (sOspA 6/4), SEQ ID NO: 11 (sOspA 5/3), SEQ ID NO: 168 (orig sOspA 1/2), SEQ ID NO: 170 (orig sOspA 6/4), or SEQ ID NO: 172 (orig sOspA 5/3), in certain aspects, comprise, consist essentially of, or consist of a nucleotide

sequence encoding a polypeptide that is about 70 percent (70%) identical to the polypeptide as set forth in SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3). In various embodiments, the nucleotide sequences are about 70 percent, or about 71, 72, 73, 74, 75, 76, 77, 78, or 79 percent, or about 80 percent, or about 81, 82, 83, 84, 85, 86, 87, 88, or 89 percent, or about 90 percent, or about 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent identical to the nucleotide sequence as shown in SEQ ID NO: 1 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 3 (lipB sOspA 6/4), SEQ ID NO: 5 (lipB sOspA 5/3), SEQ ID NO: 7 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 9 (sOspA 6/4), SEQ ID NO: 11 (sOspA 5/3), SEQ ID NO: 168 (orig sOspA 1/2), SEQ ID NO: 170 (orig sOspA 6/4), or SEQ ID NO: 172 (orig sOspA 5/3), or the nucleotide sequences encode a polypeptide that is about 70 percent, or about 71, 72, 73, 74, 75, 76, 77, 78, or 79 percent, or about 80 percent, or about 81, 82, 83, 84, 85, 86, 87, 88, or 89 percent, or about 90 percent, or about 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent identical to the polypeptide sequence as set forth in SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3).

**[00148]** In some embodiments, methods to determine sequence identity and/or similarity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are described in publicly available computer programs. In some aspects, computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux et al., *Nucl. Acid. Res.*, 12:387 (1984); Genetics Computer Group, University of Wisconsin, Madison, WI, BLASTP, BLASTN, and FASTA (Altschul et al., *J. Mol. Biol.*, 215:403-410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, MD 20894; Altschul et al., *supra* (1990)). The well-known Smith Waterman algorithm is also used to determine identity.

**[00149]** Certain alignment schemes for aligning two amino acid sequences, in some aspects, result in the matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, in one embodiment the selected alignment method (GAP program) will result in an alignment that spans at least 50 contiguous amino acids of the target polypeptide. For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, WI), two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal; the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually 1/10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. A standard comparison matrix (see Dayhoff et al., *Atlas of Protein Sequence and Structure*, 5(3)(1978) for the PAM 250 comparison matrix; Henikoff et al., *Proc. Natl. Acad. Sci USA*, 89:10915-10919 (1992) for the BLOSUM 62 comparison matrix) is also used by the algorithm.

**[00150]** In various aspects, parameters for a polypeptide sequence comparison include the following:

Algorithm: Needleman et al., *J. Mol. Biol.*, 48:443-453 (1970);

Comparison matrix: BLOSUM 62 from Henikoff et al., *supra* (1992);

Gap Penalty: 12

Gap Length Penalty: 4

Threshold of Similarity: 0

**[00151]** The GAP program is useful with the above parameters. The aforementioned parameters are the default parameters for polypeptide comparisons (along with no penalty for end gaps) using the GAP algorithm.

**[00152]** In some aspects, parameters for nucleic acid molecule sequence comparisons include the following:

Algorithm: Needleman et al., *supra* (1970);

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

**[00153]** The GAP program is also useful with the above parameters. The aforementioned parameters are the default parameters for nucleic acid molecule comparisons. Other exemplary algorithms, gap opening penalties, gap extension penalties, comparison matrices, thresholds of similarity, and the like, are used by those of skill in the art, including those set forth in the Program Manual, Wisconsin Package, Version 9, September, 1997. The particular choices to be made will be apparent to those of skill in the art and will depend on the specific comparison to be made, such as DNA-to-DNA, protein-to-protein, protein-to-DNA; and additionally, whether the comparison is between given pairs of sequences (in which case GAP or BestFit are generally preferred) or between one sequence and a large database of sequences (in which case FASTA or BLASTA are preferred).

**[00154]** Differences in the nucleic acid sequence, in some aspects, result in conservative and/or non-conservative modifications of the amino acid sequence relative to the amino acid sequence of SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3).

**[00155]** Conservative modifications to the amino acid sequence of SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3) (and corresponding modifications to the encoding nucleotides) will produce OspA polypeptides having functional and chemical characteristics similar to those of a naturally occurring OspA polypeptide. In

contrast, substantial modifications in the functional and/or chemical characteristics of OspA polypeptides are accomplished by selecting substitutions in the amino acid sequence of SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>), SEQ ID NO: 4 (lipB sOspA 6/4), SEQ ID NO: 6 (lipB sOspA 5/3), SEQ ID NO: 8 (sOspA 1/2<sup>251</sup>), SEQ ID NO: 10 (sOspA 6/4), SEQ ID NO: 12 (sOspA 5/3), SEQ ID NO: 169 (orig sOspA 1/2), SEQ ID NO: 171 (orig sOspA 6/4), or SEQ ID NO: 173 (orig sOspA 5/3) that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

**[00156]** For example, a "conservative amino acid substitution," in some aspects, involves a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide, in certain aspects, is also substituted with alanine, as has been previously described for "alanine scanning mutagenesis."

**[00157]** Conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.

**[00158]** Naturally occurring residues, in various aspects, are divided into classes based on common side chain properties:

- 1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
- 2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- 3) acidic: Asp, Glu;
- 4) basic: His, Lys, Arg;
- 5) residues that influence chain orientation: Gly, Pro; and
- 6) aromatic: Trp, Tyr, Phe.

**[00159]** For example, non-conservative substitutions, in some aspects, involve the exchange of a member of one of these classes for a member from another class. Such substituted residues, in various aspects, are introduced into regions of the



OspA polypeptide that are homologous, or similar, with OspA polypeptide orthologs, or into the non-homologous regions of the molecule.

**[00160]** In making such changes, the hydropathic index of amino acids is often considered. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

**[00161]** The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is understood in the art. Kyte et al., *J. Mol. Biol.*, 157:105-131 (1982). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is, in certain aspects, preferred, those which are within  $\pm 1$  are, in other aspects, particularly preferred, and those within  $\pm 0.5$  are, in various aspects, more particularly preferred.

**[00162]** It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional equivalent protein or peptide thereby created is intended, in part, for use in immunological embodiments, as in the present case. The greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein.

**[00163]** The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5  $\pm$  1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5) and tryptophan (-3.4). In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  is, in certain aspects, preferred, those which are within  $\pm 1$  are in other aspects, particularly

preferred, and those within  $\pm 0.5$  are, in various aspects, more particularly preferred. One of skill also identifies epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as "epitopic core regions."

**[00164]** Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. For example, amino acid substitutions can be used to identify important residues of the OspA polypeptide, or to increase or decrease the affinity of the OspA polypeptides for their substrates, described herein.

**[00165]** In some aspects, substitutions of nucleotides in nucleotide sequences and amino acids in amino acid sequences are included in the invention. The substitutions include one to 5, one to 10, one to 15, one to 20, one to 25, one to 30, one to 35, one to 40, one to 45, one to 50, one to 55, one to 60, one to 65, one to 70, one to 75, one to 80, one to 85, one to 90, one to 95, one to 100, one to 150, and one to 200 nucleotides. Likewise, substitutions include one to 5, one to 10, one to 15, one to 20, one to 25, one to 30, one to 35, one to 40, one to 45, one to 50, one to 55, one to 60, one to 65, one to 70, one to 75, one to 80, one to 85, one to 90, one to 95, and one to 100 amino acids. The substitutions, in various aspects, are conservative or non-conservative.

**Exemplary amino acid substitutions are set forth in Table 2.**

**Table 2. Amino Acid Substitutions**

Original Residues	Exemplary Substitutions	Preferred Substitutions
Ala	Val, Leu, Ile	Val
Arg	Lys, Gln, Asn	Lys
Asn	Gln	Gln
Asp	Glu	Glu
Cys	Ser, Ala	Ser
Gln	Asn	Asn
Glu	Asp	Asp
Gly	Pro, Ala	Ala
His	Asn, Gln, Lys, Arg	Arg
Ile	Leu, Val, Met, Ala, Phe, Norleucine	Leu
Leu	Norleucine, Ile, Val, Met, Ala, Phe	Ile
Lys	Arg, 1,4 Diamino-butyric Acid, Gln, Asn	Arg
Met	Leu, Phe, Ile	Leu
Phe	Leu, Val, Ile, Ala, Tyr	Leu
Pro	Ala	Gly
Ser	Thr, Ala, Cys	Thr
Thr	Ser	Ser
Trp	Tyr, Phe	Tyr
Tyr	Trp, Phe, Thr, Ser	Phe
Val	Ile, Met, Leu, Phe, Ala, Norleucine	Leu

**[00166]** A skilled artisan can determine suitable analogs or variants of the polypeptide as set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173 using well-known techniques. For identifying suitable areas of the molecule that may be changed without destroying activity, one skilled in the art may target areas not believed to be important for activity. For example, when similar polypeptides with

similar activities from the same species or from other species are known, one skilled in the art may compare the amino acid sequence of an OspA polypeptide to such similar polypeptides. With such a comparison, one can identify residues and portions of the molecules that are conserved among similar polypeptides. It will be appreciated that changes in areas of an OspA polypeptide that are not conserved relative to such similar polypeptides would be less likely to adversely affect the biological activity and/or structure of the OspA polypeptide. One skilled in the art would also know that, even in relatively conserved regions, one may substitute chemically similar amino acids for the naturally occurring residues while retaining activity (conservative amino acid residue substitutions).

**[00167]** In some embodiments, OspA polypeptide variants include glycosylation variants wherein the number and/or type of glycosylation sites has been altered compared to the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173. In one embodiment, OspA polypeptide variants comprise a greater or a lesser number of N-linked glycosylation sites than the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X may be any amino acid residue except proline. The substitution of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain. Also provided is a rearrangement of N-linked carbohydrate chains wherein one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Additional OspA variants include cysteine variants wherein one or more cysteine residues are deleted from or substituted for another amino acid (e.g., serine) as compared to the amino acid sequence set forth in SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173. Cysteine variants are useful when OspA polypeptides must be refolded into a biologically active conformation such as after the isolation of insoluble inclusion bodies. Cysteine variants generally have fewer cysteine residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

**[00168]** The invention further provides polypeptides that comprise an epitope-bearing portion of a protein as shown in SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173. The term, "epitope" refers to a region of a protein to which an antibody can bind. See e.g., Geysen et al., *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984). Epitopes can be linear or conformational, the latter being composed of discontinuous regions of the protein that form an epitope upon folding of the protein. Linear epitopes are generally at least 6 amino acid residues in length. Relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, Sutcliffe et al., *Science* 219:660-666 (1983). Antibodies that recognize short, linear epitopes are particularly useful in analytic and diagnostic applications that employ denatured protein, such as Western blotting. See Tobin, *Proc. Natl. Acad. Sci. USA*, 76:4350-4356 (1979). Antibodies to short peptides, in certain instances, also recognize proteins in native conformation and will thus be useful for monitoring protein expression and protein isolation, and in detecting OspA proteins in solution, such as by ELISA or in immunoprecipitation studies.

#### **Synthesis of Chimeric OspA Nucleic Acid Molecules and Polypeptide Molecules**

**[00169]** The nucleic acid molecules encode a polypeptide comprising the amino acid sequence of an OspA polypeptide and can readily be obtained in a variety of ways including, without limitation, recombinant DNA methods and chemical synthesis.

**[00170]** Recombinant DNA methods are generally those set forth in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989), and/or Ausubel et al., eds., *Current Protocols in Molecular Biology*, Green Publishers Inc. and Wiley and Sons, NY (1994).

Recombinant expression techniques conducted in accordance with the descriptions set forth below, in various aspects, are followed to produce these polynucleotides and to express the encoded polypeptides. For example, by inserting a nucleic acid sequence which encodes the amino acid sequence of an OspA polypeptide into an appropriate vector, one skilled in the art can readily produce large quantities of the desired nucleotide sequence. The sequences can then be used to generate detection probes or amplification primers. Alternatively, a polynucleotide encoding

the amino acid sequence of an OspA polypeptide can be inserted into an expression vector. By introducing the expression vector into an appropriate host, the encoded OspA polypeptide or OspA polypeptides are, in some aspects, produced in large amounts.

**[00171]** Likewise, chemical synthesis of nucleic acids and polypeptides are well known in the art, such as those described by Engels et al., *Angew. Chem. Intl. Ed.*, 28:716-734 (1989). These methods include, *inter alia*, the phosphotriester, phosphoramidite and H-phosphonate methods for nucleic acid synthesis. In one aspect, a method for such chemical synthesis is polymer-supported synthesis using standard phosphoramidite chemistry. Typically, the DNA encoding the amino acid sequence of an OspA polypeptide will be several hundred nucleotides in length. Nucleic acids larger than about 100 nucleotides are synthesized as several fragments using these methods. The fragments are then ligated together to form the full-length nucleotide sequences of the invention. In particular aspects, the DNA fragment encoding the amino terminus of the polypeptide has an ATG, which encodes a methionine residue.

**[00172]** In a particular aspect of the invention, chimeric OspA coding sequences are made using synthetic overlapping oligonucleotides. Because DNA from *Borrelia* cells is not used, a further benefit of the synthetic approach is the avoidance of contamination with adventitious agents contained in material of animal origin (i.e. serum or serum albumin) present in *Borrelia* culture medium. This strategy also substantially reduces the number of manipulations required to make the chimeric genes, since it allows sequence alterations to be made in a single step, such as modifications to optimize expression (OspB leader sequence), to introduce restriction sites to facilitate cloning, or to avoid potential intellectual property issues. It also enables codon usage to be optimized for an *E. coli* host, since the presence of codons that are rarely used in *E. coli* is known to present a potential impediment to high-level expression of foreign genes (Makoff et al., *Nucleic Acids Res.* 17:10191-202, 1989; Lakey et al., *Infect. Immun.* 68:233-8, 2000). Other methods known to the skilled artisan are used as well.

**[00173]** In certain embodiments, nucleic acid variants contain codons which have been altered for the optimal expression of an OspA polypeptide in a given host cell. Particular codon alterations depend upon the OspA polypeptide(s) and host cell(s)

selected for expression. Such "codon optimization" can be carried out by a variety of methods, for example, by selecting codons which are preferred for use in highly expressed genes in a given host cell. Computer algorithms which incorporate codon frequency tables such as "Ecohigh.cod" for codon preference of highly expressed bacterial genes are used, in some instances, and are provided by the University of Wisconsin Package Version 9.0, Genetics Computer Group, Madison, WI. Other useful codon frequency tables include "Celegans\_high.cod", "Celegans\_low.cod", "Drosophila\_high.cod", "Human\_high.cod", "Maize\_high.cod", and "Yeast\_high.cod."

**[00174]** A nucleic acid molecule encoding the amino acid sequence of an OspA polypeptide, in certain aspects, is inserted into an appropriate expression vector using standard ligation techniques. The vector is typically selected to be functional in the particular host cell employed (i.e., the vector is compatible with the host cell machinery such that amplification of the gene and/or expression of the gene can occur). A nucleic acid molecule encoding the amino acid sequence of an OspA polypeptide, in various aspects, is amplified/expressed in prokaryotic, yeast, insect (baculovirus systems), and/or eukaryotic host cells. Selection of the host cell depends in part on whether an OspA polypeptide is to be post-translationally modified (e.g., glycosylated and/or phosphorylated). If so, yeast, insect, or mammalian host cells are preferable. For a review of expression vectors, see Meth. Enz., vol.185, D.V. Goeddel, ed., Academic Press Inc., San Diego, CA (1990).

**[00175]** Cloning vectors include all those known in the art. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1989. In one aspect, pUC18 is used as the cloning vector for all intermediate steps, because genetic manipulations and sequencing are easier with this plasmid than with the vector pET30a. The principal features are notably, the lacZ gene fragment coding for LacZ alpha peptide from base pairs 149 to 469 (lac promoter at base pairs 507), the bla gene encoding the ampicillin resistance determinant from base pairs 1629 to 2486 (bla promoter at base pairs 2521), the origin of replication at base pairs 867 and multiple cloning sites from base pairs 185 to 451 (Fig. 12).

**[00176]** Expression vectors include all those known in the art, including without limitation cosmids, plasmids (e.g., naked or contained in liposomes) and viruses that incorporate the recombinant polynucleotide. The expression vector is inserted (e.g.,

via transformation or transduction) into an appropriate host cell for expression of the polynucleotide and polypeptide via transformation or transfection using techniques known in the art. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1989. In one aspect, pET30a (Novagen) is used as the expression vector for the final complete OspA gene insert. In pET vectors, genes are cloned under the control of a T7 promoter and expression is induced by providing a source of T7 RNA polymerase in the host cell (no expression occurs until a source of T7 RNA polymerase is provided). The principal features are the gene encoding kanamycin resistance (kan) at base pairs 4048 to 4860, the lacI gene base pairs 826 – 1905, the F1 origin of replication at base pairs 4956-5411 and multiple cloning sites from base pairs 158 to 346 (Fig. 13).

**[00177]** After the vector has been constructed and a nucleic acid molecule encoding an OspA polypeptide has been inserted into the proper site of the vector, the completed vector is inserted into a suitable host cell for amplification and/or polypeptide expression. The transformation of an expression vector for an OspA polypeptide into a selected host cell is, in various aspects, accomplished by well-known methods such as transfection, infection, calcium chloride-mediated transformation, electroporation, microinjection, lipofection or the DEAE-dextran method or other known techniques. The method selected will in part be a function of the type of host cell to be used. These methods and other suitable methods are well known to the skilled artisan and are set forth, for example, in Sambrook et al., *supra*.

**[00178]** Host cells, in some aspects, are prokaryotic host cells (such as *E. coli*) or eukaryotic host cells (such as yeast, insect or vertebrate cells). The host cell, when cultured under appropriate conditions, synthesizes an OspA polypeptide which can subsequently be collected from the culture medium (if the host cell secretes it into the medium) or directly from the host cell producing it (if it is not secreted). The selection of an appropriate host cell depends upon various factors, such as desired expression levels, polypeptide modifications that are desirable or necessary for activity (such as glycosylation or phosphorylation), and ease of folding into a biologically active molecule. Such host cells include, but are not limited to, host cells of bacterial, yeast, fungal, viral, invertebrate, and mammalian sources. For examples of such host cells, see Maniatis et al., *Molecular Cloning: A Laboratory*



Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989). In additional aspects, host cells used in the art since the publication of the Maniatis (*supra*) manual are also used in the invention.

**[00179]** In one aspect, the host cell is an *E. coli* cell. Suitable strains of *E. coli* include, but are not limited to, BL21, DH5 $\alpha$ , HMS174(DE3), DH10B, or E. CLONI 10G (Lucigen, Middleton, Wis.). In some embodiments, host cells are engineered to enhance transformation efficiency and/or maintenance of the vector.

**[00180]** In one aspect, the *E. coli* strain DH5 $\alpha$  [genotype: end A1 hsdR17 (rK-mK+) supE44 thi-1 recA1 gyrA (Nal<sup>r</sup>) relA1 D(lacZYA-argF)U169 deoR (F80dlacD(lacZ)M15)] (Gibco BRL) is used for all intermediate cloning steps. This strain is derived from *E. coli* strain K12, one of the most widely used hosts in genetic engineering. The strain is amp<sup>-</sup> to allow selection of transformants with vectors containing the ampicillin resistance gene (amp).

**[00181]** In another aspect, the *E. coli* strain HMS174(DE3) is used as the host for expression. *E. coli* HMS174(DE3) host cells [genotype : F- recA1 hsdR (rk12-mk12+) Rif<sup>R</sup> (DE3)] (Novagen) are used in various examples described herein for the final cloning steps. The strain is kan<sup>-</sup> to allow selection of transformants with vectors containing the kanamycin resistance gene (kan).

**[00182]** Host cells comprising an OspA polypeptide expression vector are cultured using standard media well known to the skilled artisan. The media will usually contain all nutrients necessary for the growth and survival of the cells. Suitable media for culturing *E. coli* cells include, for example, Luria Broth (LB) and/or Terrific Broth (TB). Suitable media for culturing eukaryotic cells include Roswell Park Memorial Institute medium 1640 (RPMI 1640), Minimal Essential Medium (MEM) and/or Dulbecco's Modified Eagle Medium (DMEM), all of which, in some instances, are supplemented with serum and/or growth factors as indicated by the particular cell line being cultured. A suitable medium for insect cultures is Grace's medium supplemented with yeastolate, lactalbumin hydrolysate and/or fetal calf serum, as necessary.

**[00183]** Typically, an antibiotic or other compound useful for selective growth of transformed cells is added as a supplement to the media. The compound to be used will be dictated by the selectable marker element present on the plasmid with which

the host cell was transformed. For example, where the selectable marker element is kanamycin resistance, the compound added to the culture medium will be kanamycin. Other compounds for selective growth include ampicillin, tetracycline and neomycin.

**[00184]** The amount of an OspA polypeptide produced by a host cell can be evaluated using standard methods known in the art. Such methods include, without limitation, Western blot analysis, SDS-polyacrylamide gel electrophoresis, non-denaturing gel electrophoresis, chromatographic separation such as High Performance Liquid Chromatography (HPLC), immunodetection such as immunoprecipitation, and/or activity assays such as DNA binding gel shift assays.

**[00185]** In some cases, an OspA polypeptide is not biologically active upon isolation. Various methods for “refolding” or converting the polypeptide to its tertiary structure and generating disulfide linkages are used to restore biological activity. Such methods include exposing the solubilized polypeptide to a pH usually above 7 and in the presence of a particular concentration of a chaotrope. The selection of chaotrope is very similar to the choices used for inclusion body solubilization, but usually the chaotrope is used at a lower concentration and is not necessarily the same as chaotropes used for the solubilization. In some instances, the refolding/oxidation solution also contains a reducing agent or the reducing agent plus its oxidized form in a specific ratio to generate a particular redox potential allowing for disulfide shuffling to occur in the formation of the protein’s cysteine bridge(s). Some of the commonly used redox couples include cysteine/cystamine, glutathione (GSH)/dithiobis GSH, cuprous chloride, dithiothreitol(DTT)/ dithiane DTT, and 2-2mercaptoethanol(bME)/dithio-b(ME). A cosolvent is often used to increase the efficiency of the refolding, and the more common reagents used for this purpose include glycerol, polyethylene glycol of various molecular weights, arginine and the like.

**[00186]** If inclusion bodies are not formed to a significant degree upon expression of an OspA polypeptide, then the polypeptide will be found primarily in the supernatant after centrifugation of the cell homogenate. The polypeptide is further isolated from the supernatant using methods such as those described herein or otherwise known in the art.

**[00187]** The purification of an OspA polypeptide from solution can be accomplished using a variety of techniques known in the art. If the polypeptide has been synthesized such that it contains a tag such as Hexahistidine (OspA polypeptide/hexaHis) or other small peptide such as FLAG (Eastman Kodak Co., New Haven, CT) or myc (Invitrogen, Carlsbad, CA) at either its carboxyl or amino terminus, the polypeptide is often purified in a one-step process by passing the solution through an affinity column where the column matrix has a high affinity for the tag. For example, polyhistidine binds with great affinity and specificity to nickel; thus an affinity column of nickel (such as the Qiagen® nickel columns) can be used for purification of OspA polypeptide/polyHis. See for example, Ausubel et al., eds., *Current Protocols in Molecular Biology*, Section 10.11.8, John Wiley & Sons, New York (1993).

**[00188]** Additionally, the OspA polypeptide may be purified through use of a monoclonal antibody which is capable of specifically recognizing and binding to the OspA polypeptide. Suitable procedures for purification thus include, without limitation, affinity chromatography, immunoaffinity chromatography, ion exchange chromatography, molecular sieve chromatography, High Performance Liquid Chromatography (HPLC), electrophoresis (including native gel electrophoresis) followed by gel elution, and preparative isoelectric focusing ("Isoprime" machine/technique, Hoefer Scientific, San Francisco, CA). In some cases, two or more purification techniques are combined to achieve increased purity.

**[00189]** OspA polypeptides are also prepared by chemical synthesis methods (such as solid phase peptide synthesis) using techniques known in the art, such as those set forth by Merrifield et al., *J. Am. Chem. Soc.*, 85:2149 (1963), Houghten et al., *Proc. Natl. Acad. Sci. USA*, 82:5132 (1985), and Stewart and Young, "Solid Phase Peptide Synthesis", Pierce Chemical Co., Rockford, IL (1984). Such polypeptides are synthesized with or without a methionine on the amino terminus. Chemically synthesized OspA polypeptides, in some aspects, are oxidized using methods set forth in these references to form disulfide bridges. Chemically synthesized OspA polypeptides are expected to have comparable biological activity to the corresponding OspA polypeptides produced recombinantly or purified from natural sources, and thus are often used interchangeably with a recombinant OspA polypeptide. It is appreciated that a number of additional methods for producing

nucleic acids and polypeptides are known in the art, and the methods can be used to produce OspA polypeptides.

### **Chemical Derivatives of OspA Polypeptide Molecules**

**[00190]** Chemically modified derivatives of the OspA polypeptides are prepared by one skilled in the art, given the disclosures set forth herein below. OspA polypeptide derivatives are modified in a manner that is different either in the type or location of the molecules naturally attached to the polypeptide. Derivatives, in some aspects, include molecules formed by the deletion of one or more naturally-attached chemical groups. The polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173, or an OspA polypeptide variant, in one aspect, is modified by the covalent attachment of one or more polymers. For example, the polymer selected is typically water soluble so that the protein to which it is attached does not precipitate in an aqueous environment, such as a physiological environment. Included within the scope of suitable polymers is a mixture of polymers. In certain aspects, for therapeutic use of the end-product preparation, the polymer will be pharmaceutically acceptable.

**[00191]** The polymers each are, in various aspects, of any molecular weight and are branched or unbranched. The polymers each typically have an average molecular weight of between about 2kDa to about 100kDa (the term "about" indicating that in preparations of a water-soluble polymer, some molecules will weigh more, some less, than the stated molecular weight). The average molecular weight of each polymer is, in various aspects, between about 5kDa to about 50kDa, between about 12kDa to about 40kDa, and between about 20kDa to about 35kDa.

**[00192]** Suitable water-soluble polymers or mixtures thereof include, but are not limited to, N-linked or O-linked carbohydrates; sugars; phosphates; polyethylene glycol (PEG) (including the forms of PEG that have been used to derivatize proteins, including mono-(C1-C10) alkoxy- or aryloxy-polyethylene glycol); monomethoxy-polyethylene glycol; dextran (such as low molecular weight dextran of, for example, about 6 kDa);, cellulose; or other carbohydrate-based polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol. Also encompassed by the present invention are bifunctional

crosslinking molecules which are sometimes used to prepare covalently attached multimers of the polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173, or an OspA polypeptide variant.

**[00193]** In some aspects, chemical derivatization is performed under any suitable condition used to react a protein with an activated polymer molecule. Methods for preparing chemical derivatives of polypeptides generally comprise the steps of (a) reacting the polypeptide with the activated polymer molecule (such as a reactive ester or aldehyde derivative of the polymer molecule) under conditions whereby the polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 169, 171, or 173, or an OspA polypeptide variant becomes attached to one or more polymer molecules, and (b) obtaining the reaction product(s). The optimal reaction conditions are determined based on known parameters and the desired result. For example, the larger the ratio of polymer molecules:protein, the greater the percentage of attached polymer molecule. In one embodiment, the OspA polypeptide derivative has a single polymer molecule moiety at the amino terminus (see, for example, U.S. Patent No. 5,234,784).

**[00194]** The pegylation of the polypeptide, in certain aspects, is specifically carried out by any of the pegylation reactions known in the art, as described for example in the following references: Francis et al., Focus on Growth Factors, 3:4-10 (1992); EP 0154316; EP 0401384 and U.S. Patent No. 4,179,337. For example, pegylation is carried out via an acylation reaction or an alkylation reaction with a reactive polyethylene glycol molecule (or an analogous reactive water-soluble polymer) as described herein. For the acylation reactions, the polymer(s) selected should have a single reactive ester group. For reductive alkylation, the polymer(s) selected should have a single reactive aldehyde group. A reactive aldehyde is, for example, polyethylene glycol propionaldehyde, which is water stable, or mono C1-C10 alkoxy or aryloxy derivatives thereof (see U.S. Patent No. 5,252,714).

**[00195]** In another embodiment, OspA polypeptides are chemically coupled to biotin, and the biotin/ OspA polypeptide molecules which are conjugated are then allowed to bind to avidin, resulting in tetravalent avidin/biotin/ OspA polypeptide molecules. OspA polypeptides are also covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugates precipitated with anti-DNP or anti-TNP-IgM to form decameric conjugates with a valency of 10. The OspA polypeptide

derivatives disclosed herein, in certain aspects, have additional activities, enhanced or reduced biological activity, or other characteristics, such as increased or decreased half-life, as compared to the non-derivatized molecules.

### **Immunogenic Compositions, Vaccines, and Antibodies**

**[00196]** Some aspects of the invention include immunogenic compositions and vaccines. Immunogenic chimeric OspA molecules of the invention are used in combination as antigen(s) to elicit an anti-OspA immune response in a subject (i.e., act as a vaccine). Exemplary immunogenic OspA polypeptides (SEQ ID NOS: 2, 4, 6, 169, 171, and 173) are delivered in combination to elicit an immune response to any one or more of serotypes 1-6 of *Borrelia*, and more generally to many other species of *Borrelia* as discussed herein. An immune response can also be raised by delivery of plasmid vectors encoding the OspA polypeptides of the invention (i.e., administration of "naked DNA"). In some aspects, OspA nucleic acid molecules (SEQ ID NOS: 1, 3, 5, 168, 170, and 172) are delivered by injection, via liposomes, or by other means of administration described herein. Once immunized, the subject elicits a heightened immune response against the OspA protein of serotypes 1-6 of *Borrelia* and against other species of *Borrelia*.

**[00197]** As set out above, therefore, both OspA polypeptides and OspA nucleic acid molecules are included as antigens for use in the immunogenic and/or vaccine compositions of the invention. In certain aspects, both the nucleic acid and the protein are delivered to the subject. In particular aspects, the immune response to a nucleic acid vaccine is proposed to be enhanced by simultaneous administration of a cognate protein (see WO 99/30733). The nucleic acid and protein do not need to be administered in the same composition. Both must merely be administered during the induction phase of the immune response with the protein, in some aspects, being masked or held back until after the nucleic acid has primed the immune system. In a particular aspect, vaccines are intended to deliver nucleic acid and protein antigen into antigen presenting cells (see WO 97/28818). In various aspects, the nucleic acid and protein are complexed, e.g., by covalent conjugation. In further aspects, liposomal formulations are also included to enhance the immunogenicity of vaccine antigens.

**[00198]** In certain aspects, an immunogenic composition of the invention includes any one or more of the OspA molecules described herein in combination with a pharmaceutical carrier, wherein the composition induces production of an antibody that specifically binds an Outer surface protein A (OspA) protein. In some aspects, the immunogenic composition also comprises a stabilizer or antimicrobial preservative. In particular aspects, the immunogenic composition induces production of an antibody that specifically binds *Borrelia*. In other aspects, the composition induces production of an antibody that neutralizes *Borrelia*.

**[00199]** In some aspects, the invention includes the use of adjuvants in the immunogenic compositions comprising the chimeric OspA molecules (antigens) described herein. In certain aspects, immunogenicity is significantly improved if an antigen is co-administered with an adjuvant. In some aspects, an adjuvant is used as 0.001% to 50% solution in phosphate buffered saline (PBS). Adjuvants enhance the immunogenicity of an antigen but are not necessarily immunogenic themselves.

**[00200]** Adjuvants, in various aspects, have a number of positive effects on vaccination. In some instances, adjuvants accelerate the generation of a robust immune response in subjects. Adjuvants, in other instances, increase the level of immune response, prolong its duration and improve immune memory. Adjuvants are often used to overcome weakened immunity of particular subject groups (e.g., the elderly or immune-suppressed patients) or to improve the immunogenicity of particular "at risk group" (such as, but not limited to, the very young or elderly). The immune enhancing effects of an adjuvant, in various instances, leads to a reduction of the amount of antigen required in the final formulation to give a protective response (i.e. dose-sparing).

**[00201]** In general, adjuvants are classified, based on their dominant mechanism of action, into two main groups: The first group are the agonists of innate immunity system receptors or sensors, such as Toll-like-receptor (TLR) agonists, C-type lectin receptor agonists, retinoic acid inducible gene 1 (RIG-1) like receptor (RLR) agonists, and nucleotide-binding domain and leucine rich repeat-containing receptor (NLR) agonists. The second group are the substances which act as delivery systems, also known as TLR-independent adjuvants. Examples of TLR agonist adjuvants are ASO4 (Glaxo Smith Kline), a TLR-4 agonist, used as an adjuvant in commercial Hepatitis B and papilloma virus vaccines; Vaxinate, a flagellin-fusion

protein TLR-5 agonist; and numerous TLR-9 agonist adjuvants, such as those that use double-stranded DNA (dsDNA) and oligonucleotides CpG or ODN1a. Other TLR-agonists falling into this category of adjuvants include glycolipids (TLR-1), lipoteichoic acid and lipoprotein (TLR-1/TLR-2 and TLR-2/TLR-6) lipopolysaccharide, lipooligocaccharides and monophosphoryl lipid A (MPL) (TLR-4), double-stranded RNA (TLR-3); peptidoglycan (TLR-6), single stranded RNA (TLR-7). Examples of two C-type lectin receptor agonist adjuvants include  $\beta$ -glucans (Dectin-1) and mannans (Dectin-2), both derived from fungal cell walls. RLR receptor agonist adjuvants include single-stranded viral RNA and double-stranded viral DNA, while NLR agonist adjuvants include peptidoglycan degradation products, microbial products, and non-infectious crystal particles. In all cases, the agonists act by directly activating the innate immune system receptor to trigger an immune enhancing inflammatory response. The second group of adjuvants, the TLR independent adjuvants, mostly act as delivery systems and enhance antigen uptake and presentation by an antigen presenting cell. In some instances, these adjuvants can also act by retaining the antigen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants also attract cells of the immune system to an antigen depot and stimulate such cells to elicit immune responses. Examples of TLR independent adjuvants include mineral salts, such as aluminum hydroxide and aluminum phosphate (collectively referred to as alum) and calcium phosphate; oil-in-water emulsion (e.g., MF59, AS03 and ProVax); water in oil emulsion (Montanide, TiterMax); biopolymers (Advax); plant derivatives, especially fractions of saponin, a triterpenoid extract from the bark of the South American Molina soap tree *Quillaja saponaria* (SFA-1, QS21, Quil A); immune stimulating complexes (ISCOM and ISCOM matrix) composed of saponin fractions, sterol and, optionally, phospholipids (ISCOMATRIX and Matrix-M); liposomes, which are phospholipid spheres of various sizes and charge (Vaxfectin and Vaxisome); virus-like particles and virosomes, which are liposomes containing viral surface antigens, such as Influenza haemagglutinin and neuraminidase; nanoparticles of various composition; chitosan, peptides such as polyarginine and a peptide known as the KLK peptide.

**[00202]** The adjuvants listed herein above are used singly or in combination. Combinations of TLR-dependent and a TLK-independent adjuvants are often



preferred as the antigen and the TLR-dependent adjuvant are believed to be trafficked to antigen presenting cells by the TLR-independent adjuvant, which would also stimulate uptake and stability, while the TLR-dependent adjuvant would directly enhance immunity through the activation of TLR signaling.

**[00203]** Examples of TLR-dependent and TLR-independent adjuvant combinations include AS01: a mixture of MPL (a TLR-4 agonist), liposomes and QS-21 (both TLR-independent adjuvant); AS04: MPL (a TLR-4 agonist) and aluminum hydroxide/phosphate; IC31: ODN1a (a TLR-9 agonist) and KLK peptide (a TLR-independent adjuvant); and Freund's complete adjuvant, a membrane extract of *Mycobacterium tuberculosis* (TLR-4 agonist) and an oil-in-water emulsion (a TLR-independent adjuvant).

**[00204]** Combinations consisting of multiple TLR-dependent adjuvants are also used to maximize the immune enhancing effect of adjuvanted vaccine formulations. Agonists of TLRs, which use different adaptor proteins, are often combined (e.g., a combination of an agonist for the plasma membrane-bound TLR-3 or TLR-4 receptor which utilizes the TRIF (Toll/interleukin 1 receptor domain-containing adaptor protein inducing  $\text{INF-}\beta$ ) adaptor pathway with an agonist of the TLRs (TLR-7, TLR-8 and TLR-9), which are expressed in endosomal or lysosomal organelles and utilize the MyD88 (myeloid differentiating primary response protein) adaptor protein pathway).

**[00205]** These immunostimulatory agents or adjuvants improve the host immune response in vaccines as well. In some cases, substances such as lipopolysaccharides can act as intrinsic adjuvants since they normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants, such as those listed herein above, are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune response.

**[00206]** A wide range of extrinsic adjuvants can provoke potent immune responses to antigens. These include saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and

liposomes. To efficiently induce humoral immune response (HIR) and cell-mediated immunity (CMI), immunogens are, in certain aspects, emulsified in adjuvants.

**[00207]** Desirable characteristics of ideal adjuvants include any or all of: lack of toxicity; ability to stimulate a long-lasting immune response; simplicity of manufacture and stability in long-term storage; ability to elicit both CMI and HIR to antigens administered by various routes; synergy with other adjuvants; capability of selectively interacting with populations of antigen presenting cells (APC); ability to specifically elicit appropriate  $T_{H1}$  or  $T_{H2}$  cell-specific immune responses; and ability to selectively increase appropriate antibody isotype levels (for example IgA) against antigens.

**[00208]** U.S. Pat. No. 4,855,283, incorporated herein by reference, thereto teaches glycolipid analogs including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immune-modulators or adjuvants. U.S. Pat. No. 4,855,283 reported that N-glycolipids analogs displaying structural similarities to the naturally occurring glycolipids, such as glycosphingolipids and glyco glycerolipids, are capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain alkylamines and fatty acids that are linked directly with the sugar through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

**[00209]** In some aspects, the immunogenic composition contains an amount of an adjuvant sufficient to enhance the immune response to the immunogen. Suitable adjuvants include, but are not limited to, aluminium salts (aluminium phosphate or aluminium hydroxide), squalene mixtures (SAF-1), muramyl peptide, saponin derivatives, mycobacterium cell wall preparations, monophosphoryl lipid A, mycolic acid derivatives, non-ionic block copolymer surfactants, Quil A, cholera toxin B subunit, polphosphazene and derivatives, and immunostimulating complexes (ISCOMs) such as those described by Takahashi et al. (*Nature* 344:873-875, 1990). In some aspects, the adjuvant is a synthetic adjuvant. In a particular aspect, the synthetic adjuvant is glucopyranosyl lipid adjuvant (GLA). In exemplary aspects, the adjuvant is aluminum hydroxide.

**[00210]** A further aspect of the invention is a vaccine comprising the immunogenic composition of the invention and a pharmaceutically acceptable carrier. As

discussed herein above, the vaccine, in certain aspects, includes one or more stabilizers and/or one or more preservatives.

**[00211]** In one aspect, there is provided a vaccine comprising at least one recombinant expression construct which comprises a promoter operably linked to a nucleic acid sequence encoding an antigen (chimeric OspA polypeptide described herein) and an adjuvant. In one embodiment the recombinant expression construct (expression vector comprising the OspA polynucleotide) is present in a viral vector, which in certain further embodiments is present in a virus that is selected from an adenovirus, an adeno-associated virus, a herpesvirus, a lentivirus, a poxvirus, and a retrovirus.

**[00212]** Further aspects of the invention include antibodies to the chimeric OspA molecules described herein. In various aspects, the invention includes the chimeric OspA molecules to make anti-OspA antibodies and to provide immunity from *Borrelia* infection. In some aspects, these anti-OspA antibodies, e.g., murine, human, or humanized monoclonal antibodies or single chain antibodies, are administered to a subject (e.g., passive immunization) to effect an immune response against the OspA protein of any one or more of serotypes 1-6 of *Borrelia*. As used herein, the term “antibodies” refers to a molecule which has specificity for one or more OspA polypeptides. Suitable antibodies are prepared using methods known in the art. In certain aspects, an OspA antibody is capable of binding a certain portion of the OspA polypeptide thereby inhibiting the binding of the polypeptide to the OspA polypeptide receptor(s). Antibodies and antibody fragments that bind the chimeric OspA polypeptides of the invention are within the scope of the present invention.

**[00213]** In some aspects, antibodies of the invention include an antibody or fragment thereof that specifically binds one or more OspA polypeptides produced by immunizing an animal with a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 169, 171, and 173. In other aspects, the invention includes an antibody or fragment thereof that specifically binds to a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 168, 170, and 172. In various aspects, the antibody or fragment thereof is human, humanized, polyclonal, or monoclonal. In further aspects, the antibody is an Fab or an Fab' antibody. In

particular aspects, the antibody comprises a detectable label. In some aspects, the antibody is a chemically modified derivative of the antibody.

**[00214]** The administration of the chimeric OspA molecules in accordance with the invention stimulates an immune or antibody response in humans or animals. In some aspects, three chimeric OspA molecules (e.g., lipidated OspA 1/2<sup>251</sup>, lipidated OspA 6/4 OspA, and lipidated OspA 5/3; or original OspA 1/2, original OspA 6/4, and original OspA 5/3) are administered together to elicit antibody response against all six serotypes (1-6) discussed herein. This antibody response means that the inventive methods are, in various aspects, used for merely stimulating an immune response (as opposed to also being a protective response) because the resultant antibodies (without protection) are nonetheless useful. From eliciting antibodies, by techniques well-known in the art, monoclonal antibodies are prepared; and, those monoclonal antibodies are employed in well known antibody binding assays, diagnostic kits or tests to determine the presence or absence of *Borrelia burgdorferi* s.l. or to determine whether an immune response to the spirochete has simply been stimulated. The monoclonal antibodies, in certain aspects, are employed in immunoabsorption chromatography to recover or isolate *Borrelia* antigens such as OspA.

**[00215]** The OspA antibodies of the invention, in various aspects, are polyclonal, including monospecific polyclonal, monoclonal (MAbs), recombinant, chimeric, humanized such as CDR-grafted, human, single chain, and/or bispecific, as well as fragments, variants or derivatives thereof. Antibody fragments include those portions of the antibody which bind to an epitope on the OspA polypeptide. Examples of such fragments include Fab and F(ab') fragments generated by enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions.

**[00216]** Polyclonal antibodies directed toward an OspA polypeptide generally are produced in a subject (including rabbits, mice, or other animal or mammal) by means of multiple subcutaneous, intramuscular or intraperitoneal injections of OspA polypeptide and an adjuvant. It is useful, in certain aspects, to conjugate an OspA polypeptide of the invention to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet hemocyanin, serum, albumin, bovine

thyroglobulin, or soybean trypsin inhibitor. Also, adjuvants, such as alum, are used to enhance the immune response. After immunization, blood samples are drawn from the subject immunized and the serum is assayed for anti-OspA polypeptide antibody titer.

**[00217]** Monoclonal antibodies (mAb) directed toward an OspA polypeptide are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the hybridoma methods of Kohler et al., *Nature*, 256:495-497 (1975) and the human B-cell hybridoma method, Kozbor, J. Immunol., 133:3001 (1984) and Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987). Also provided by the invention are hybridoma cell lines which produce monoclonal antibodies reactive with OspA polypeptides.

**[00218]** Monoclonal antibodies of the invention, in some instances, are modified for use as therapeutics. One embodiment is a "chimeric" antibody in which a portion of the heavy and/or light chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is/are identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies, so long as they exhibit the desired biological activity. See, U.S. Patent No. 4,816,567 and Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851-6855 (1985).

**[00219]** In another embodiment, a monoclonal antibody of the invention is a "humanized" antibody. Methods for humanizing non-human antibodies are well known in the art (see U.S. Patent Nos. 5,585,089, and 5,693,762). Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. Humanization can be performed, for example, using methods described in the art (Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature* 332:323-327 (1988); Verhoeven et al., *Science* 239:1534-1536 (1988)), by substituting at least a portion of a rodent complementarity-determining region (CDR) for the corresponding regions of a human antibody.

**[00220]** In an alternative embodiment, human antibodies are produced from phage-display libraries (Hoogenboom et al., *J. Mol. Biol.* 227:381 (1991) and Marks et al., *J. Mol. Biol.* 222:581 (1991)). These processes mimic immune identification through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in PCT Application No. PCT/US98/17364 (Adams et al.), which describes the isolation of high affinity and functionally agonistic antibodies for MPL- and msk-receptors using such an approach.

**[00221]** Chimeric, CDR grafted, and humanized antibodies are typically produced by recombinant methods. Nucleic acids encoding the antibodies are introduced into host cells and expressed using materials and procedures described herein or known in the art. In one embodiment, the antibodies are produced in mammalian host cells, such as CHO cells. Monoclonal (e.g., human) antibodies are, in various aspects, produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein. In some aspects, the monoclonal antibody or fragment thereof is humanized. In a particular aspect, the monoclonal antibody is F237/BK2 as described herein.

**[00222]** In certain aspects, the invention includes methods for preventing or treating a *Borrelia* infection or Lyme disease in a subject, the method comprising the step of administering an antibody or fragment thereof as described herein to the subject in an amount effective to prevent or treat the *Borrelia* infection or Lyme disease. In particular aspects, the antibody or fragment thereof is a hyperimmune serum, a hyperimmune plasma, or a purified immunoglobulin fraction thereof. In other aspects, the antibody or fragment thereof is a purified immunoglobulin preparation or an immunoglobulin fragment preparation.

**[00223]** The anti-OspA antibodies of the invention, in various aspects, are employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Sola, *Monoclonal Antibodies: A Manual of Techniques*, pp. 147-158 (CRC Press, Inc., 1987)) for the detection and quantitation of OspA polypeptides. The antibodies will bind OspA polypeptides with an affinity which is appropriate for the assay method being employed.

**[00224]** For diagnostic or clinical applications, in certain embodiments, anti-OspA antibodies are labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, in certain aspects, the detectable moiety is a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ ; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase,  $\beta$ -galactosidase, or horseradish peroxidase (Bayer et al., *Meth. Enzym.* 184:138-163 (1990)).

**[00225]** Competitive binding assays rely on the ability of a labeled standard (e.g., an OspA polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (an OspA polypeptide) for binding with a limited amount of anti- OspA antibody. The amount of an OspA polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies typically are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies are conveniently separated from the standard and analyte which remain unbound.

**[00226]** Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Patent No. 4,376,110. The second antibody itself, in some instances, is labeled with a detectable moiety (direct sandwich assays) or is measured using an anti-immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the detectable moiety is an enzyme.

**[00227]** The anti-OspA antibodies are also useful for *in vivo* imaging. An antibody labeled with a detectable moiety, in certain aspects, is administered to an animal into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. The antibody, in various aspects, is labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other

detection means known in the art. In some aspects of the invention, OspA antibodies are used as therapeutics.

### **Chimeric OspA Compositions and Administration**

**[00228]** To administer OspA chimeric polypeptides described herein to subjects, OspA polypeptides are formulated in a composition comprising one or more pharmaceutically acceptable carriers. The phrase “pharmaceutically or pharmacologically acceptable” refers to molecular entities and compositions that do not produce allergic, or other adverse reactions when administered using routes well-known in the art, as described below. “Pharmaceutically acceptable carriers” include any and all clinically useful solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. In some aspects, the composition forms solvates with water or common organic solvents. Such solvates are included as well.

**[00229]** The immunogenic composition or vaccine composition of the invention is, in various aspects, administered orally, topically, transdermally, parenterally, by inhalation spray, vaginally, rectally, or by intracranial injection. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intracisternal injection, or infusion techniques. Administration by intravenous, intradermal, intramuscular, intramammary, intraperitoneal, intrathecal, retrobulbar, intrapulmonary injection and or surgical implantation at a particular site is contemplated as well. Generally, compositions are essentially free of pyrogens, as well as other impurities that could be harmful to the recipient.

**[00230]** Formulation of the pharmaceutical composition will vary according to the route of administration selected (e.g., solution, emulsion). An appropriate composition comprising the composition to be administered is prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles, in some aspects, include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles, in certain aspects, include various additives, preservatives, or fluid, nutrient or electrolyte replenishers.



**[00231]** Pharmaceutical compositions useful in the compounds and methods of the present invention containing OspA polypeptides as an active ingredient contain, in various aspects, pharmaceutically acceptable carriers or additives depending on the route of administration. Examples of such carriers or additives include water, a pharmaceutical acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, glycerin, propylene glycol, polyethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like. Additives used are chosen from, but not limited to, the above or combinations thereof, as appropriate, depending on the dosage form of the present invention.

**[00232]** A variety of aqueous carriers, e.g., water, buffered water, 0.4% saline, 0.3% glycine, or aqueous suspensions contain, in various aspects, the active compound in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, in some instances, are a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions, in some aspects, contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate.

**[00233]** In some aspects, OspA compositions are lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immunoglobulins. Any suitable lyophilization and reconstitution techniques known in the art are employed. It is appreciated by those

skilled in the art that lyophilization and reconstitution leads to varying degrees of antibody activity loss and that use levels are often adjusted to compensate.

**[00234]** Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.

**[00235]** In certain aspects, the concentration of OspA in these formulations varies widely, for example from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected. Thus, for example, and without limitation, a typical pharmaceutical composition for parenteral injection is made up to contain 1 ml sterile buffered water, and 50 mg of blood clotting factor. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of blood clotting factor. Actual methods for preparing parenterally administrable compositions are known or are apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa. (1980). An effective dosage is usually within the range of 0.01 mg to 1000 mg per kg of body weight per administration.

**[00236]** In various aspects, the pharmaceutical compositions are in the form of a sterile injectable aqueous, oleaginous suspension, dispersions or sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The suspension, in some aspects, is formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation, in certain aspects, is a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. In some embodiments, the carrier is a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, vegetable oils, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil is

employed, in various aspects, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

**[00237]** In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. The proper fluidity is maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The prevention of the action of microorganisms is brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be desirable to include isotonic agents, for example, sugars or sodium chloride. In certain aspects, prolonged absorption of the injectable compositions is brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

**[00238]** Compositions useful for administration, in certain aspects, are formulated with uptake or absorption enhancers to increase their efficacy. Such enhancers, include, for example, salicylate, glycocholate/linoleate, glycholate, aprotinin, bacitracin, SDS, caprate and the like. See, e.g., Fix (*J. Pharm. Sci.*, 85:1282-1285, 1996) and Oliyai et al. (*Ann. Rev. Pharmacol. Toxicol.*, 32:521-544, 1993).

**[00239]** In addition, the properties of hydrophilicity and hydrophobicity of the compositions used in the compounds and methods of the invention are well balanced, thereby enhancing their utility for both in vitro and especially in vivo uses, while other compositions lacking such balance are of substantially less utility. Specifically, compositions in the invention have an appropriate degree of solubility in aqueous media which permits absorption and bioavailability in the body, while also having a degree of solubility in lipids which permits the compounds to traverse the cell membrane to a putative site of action.

**[00240]** In particular aspects, the OspA polypeptides described herein are formulated in a vaccine composition comprising adjuvant. Any adjuvant known in the art is used in various aspects of the vaccine composition, including oil-based adjuvants such as Freund's Complete Adjuvant and Freund's Incomplete Adjuvant,

mycolate-based adjuvants (e.g., trehalose dimycolate), bacterial lipopolysaccharide (LPS), peptidoglycans (i.e., mureins, mucopeptides, or glycoproteins such as N-Opaca, muramyl dipeptide [MDP], or MDP analogs), proteoglycans (e.g., extracted from *Klebsiella pneumoniae*), streptococcal preparations (e.g., OK432), Biostim™ (e.g., 01K2), the "Iscoms" of EP 109 942, EP 180 564 and EP 231 039, aluminum hydroxide, saponin, DEAE-dextran, neutral oils (such as miglyol), vegetable oils (such as arachis oil), liposomes, Pluronic® polyols, the Ribi adjuvant system (see, for example GB-A-2 189 141), or interleukins, particularly those that stimulate cell mediated immunity. An alternative adjuvant consisting of extracts of *Amycolata*, a bacterial genus in the order *Actinomycetales*, has been described in U.S. Patent No. 4,877,612. Additionally, proprietary adjuvant mixtures are commercially available. The adjuvant used depends, in part, on the recipient subject. The amount of adjuvant to administer depends on the type and size of the subject. Optimal dosages are readily determined by routine methods.

**[00241]** The vaccine composition optionally includes vaccine-compatible pharmaceutically acceptable (i.e., sterile and non-toxic) liquid, semisolid, or solid diluents that serve as pharmaceutical vehicles, excipients, or media. Any diluent known in the art is used. Exemplary diluents include, but are not limited to, polyoxyethylene sorbitan monolaurate, magnesium stearate, methyl- and propylhydroxybenzoate, talc, alginates, starches, lactose, sucrose, dextrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, and oil of theobroma.

**[00242]** The vaccine composition is packaged in forms convenient for delivery. The compositions are enclosed within a capsule, caplet, sachet, cachet, gelatin, paper, or other container. These delivery forms are preferred when compatible with entry of the immunogenic composition into the recipient organism and, particularly, when the immunogenic composition is being delivered in unit dose form. The dosage units are packaged, e.g., in tablets, capsules, suppositories, vials, or cachets.

**[00243]** The invention includes methods for inducing an immunological response in a subject, including OspA antibodies in a mammalian host comprising administering an effective amount of the Osp A compositions described herein. Likewise, the invention includes methods for preventing or treating a *Borrelia*

infection or Lyme disease in a subject, the method comprising the step of administering an effective amount of the vaccine compositions described herein to the subject.

**[00244]** The vaccine composition is introduced into the subject to be immunized by any conventional method as described herein in detail above. In certain aspects, the composition is administered in a single dose or a plurality of doses over a period of time (as described in more detail below). In some aspects, the terms “dose” and “unit dose” are used interchangeably herein.

#### **Dosing of a Chimeric OspA Composition/Methods for Inducing an Immunological Response**

**[00245]** The useful dosage of immunogenic composition or vaccine composition to be administered will vary depending on various factors which modify the action of drugs, e.g. the age, condition, body weight, sex and diet of the subject, the severity of any infection, time of administration, mode of administration, and other clinical factors.

**[00246]** In some aspects, formulations or compositions of the invention are administered by an initial bolus followed by booster delivery after a period of time has elapsed. A booster immunization (or “booster”), in some aspects, is important to achieve high titers of circulating antibody for protection against the bacteria. In some aspects, the compositions of the invention are formulated in a dose or unit dose effective to increase *Borrelia* antibody production to increase geometric mean titer (GMT) level of the subject. In some aspects, GMT level is increased to a level of about 1,000 to about 10,000 at about 60 days after initial dosing. In further aspects, GMT level is increased to a level of about 2,000 to about 30,000 at about 90 days after initial dosing. In even further aspects, GMT level is increased to greater levels after administration of a booster. For example, GMT level increased to a level of about 15,000 to 50,000 after booster administration. In certain aspects, GMT level increased greater than 50,000 after booster administration. In certain aspects, formulations of the invention are administered by an initial bolus followed by a continuous infusion to maintain therapeutic circulating levels of drug product. In particular aspects, immunogenic compositions or vaccine compositions of the invention are administered in a vaccination scheme after various periods of time. In some aspects, the vaccination is delivered in a rapid immunization scheme for

travelers to regions that are prone to *Borrelia* infection. As another example, the composition or formulation of the invention is administered as a one-time dose. Those of ordinary skill in the art readily optimize effective dosages and administration regimens as determined by good medical practice and the clinical condition of the individual subject. The frequency of dosing depends on the pharmacokinetic parameters of the agents and the route of administration.

**[00247]** The pharmaceutical formulation is determined by one skilled in the art depending upon the route of administration and desired dosage. See for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712, the disclosure of which is hereby incorporated by reference. Such formulations, in some instances, influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the administered composition. Depending on the route of administration, a suitable dose is calculated, in particular aspects, according to body weight, body surface area or organ size. In some aspects, appropriate dosages are ascertained through use of established assays for determining blood level dosages in conjunction with appropriate dose-response data. In certain aspects, the antibody titer of an individual is measured to determine optimal dosage and administration regimens. The final dosage regimen will be determined by the attending doctor or physician, considering various factors which modify the action of the pharmaceutical compositions, e.g. the composition's specific activity, the responsiveness of the subject, the age, condition, body weight, sex and diet of the subject, the severity of any infection or malignant condition, time of administration and other clinical factors. As studies are conducted, further information will emerge regarding the appropriate dosage levels and duration of treatment for the prevention and/or treatment of relevant conditions.

**[00248]** In certain aspects, the OspA immunogenic or vaccine composition comprises any dose of OspA nucleic acid molecule(s) or polypeptide(s) sufficient to evoke an immune response in the subject. The effective amount of an OspA immunogenic or vaccine composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for vaccination or treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the OspA molecule(s) are being used, the route of administration, and the size (body

weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician, in some instances, titers the dosage and modifies the route of administration to obtain the optimal therapeutic effect.

**[00249]** A typical dosage, in various aspects, ranges from about 0.1  $\mu\text{g/kg}$  to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1  $\mu\text{g/kg}$  up to about 100 mg/kg; or 1  $\mu\text{g/kg}$  up to about 100 mg/kg; or 5  $\mu\text{g/kg}$  up to about 100 mg/kg. By way of example, a dose of a OspA polypeptide useful in the present invention is approximately 10  $\mu\text{g/ml}$ , 20  $\mu\text{g/ml}$ , 30  $\mu\text{g/ml}$ , 40  $\mu\text{g/ml}$ , 50  $\mu\text{g/ml}$ , 60  $\mu\text{g/ml}$ , 70  $\mu\text{g/ml}$ , 80  $\mu\text{g/ml}$ , 90  $\mu\text{g/ml}$ , 100  $\mu\text{g/ml}$ , 110  $\mu\text{g/ml}$ , 120  $\mu\text{g/ml}$ , 130  $\mu\text{g/ml}$ , 140  $\mu\text{g/ml}$ , 150  $\mu\text{g/ml}$ , 160  $\mu\text{g/ml}$ , 170  $\mu\text{g/ml}$ , 180  $\mu\text{g/ml}$ , 190  $\mu\text{g/ml}$ , 200  $\mu\text{g/ml}$ , 210  $\mu\text{g/ml}$ , 220  $\mu\text{g/ml}$ , 230  $\mu\text{g/ml}$ , 240  $\mu\text{g/ml}$ , 250  $\mu\text{g/ml}$ , 260  $\mu\text{g/ml}$ , 270  $\mu\text{g/ml}$ , 280  $\mu\text{g/ml}$ , 290  $\mu\text{g/ml}$ , 300  $\mu\text{g/ml}$ , 320  $\mu\text{g/ml}$ , 340  $\mu\text{g/ml}$ , 360  $\mu\text{g/ml}$ , 380  $\mu\text{g/ml}$ , 400  $\mu\text{g/ml}$ , 420  $\mu\text{g/ml}$ , 440  $\mu\text{g/ml}$ , 460  $\mu\text{g/ml}$ , 480  $\mu\text{g/ml}$ , 500  $\mu\text{g/ml}$ , 520  $\mu\text{g/ml}$ , 540  $\mu\text{g/ml}$ , 560  $\mu\text{g/ml}$ , 580  $\mu\text{g/ml}$ , 600  $\mu\text{g/ml}$ , 620  $\mu\text{g/ml}$ , 640  $\mu\text{g/ml}$ . In particular aspects, a typical dose comprises 0.1 to 5.0 ml per subject. In more particular aspects, a typical dose comprises 0.2 to 2.0 ml per subject. In certain aspects, a dose comprises 0.5 to 1.0 ml per subject.

**[00250]** In more particular aspects, the dose or unit dose administered to a subject is about 10  $\mu\text{g}$ , about 20  $\mu\text{g}$ , about 30  $\mu\text{g}$ , about 40  $\mu\text{g}$ , about 50  $\mu\text{g}$ , about 60  $\mu\text{g}$ , about 70  $\mu\text{g}$ , about 80  $\mu\text{g}$ , about 90  $\mu\text{g}$ , or about 100  $\mu\text{g}$ . Thus, compositions and formulations comprising the OspA chimeric polypeptides are designed for easy administration of such doses to a subject. In even more particular aspects, the dose or unit dose administered per subject is administered once or is administered about once a month for two or more months and then, optionally, is followed by a booster. In some aspects, the booster is administered at about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months after the initial unit dose or the initial multiple unit doses. In some aspects, boosters are administered about yearly or about once every two or three or four or five or six or seven or eight or nine years to provide protective immunity.

**[00251]** The frequency of dosing will depend upon the pharmacokinetic parameters of the OspA molecule in the formulation used. Typically, a clinician will

administer the composition until a dosage is reached that achieves the desired effect. The composition, in various aspects, is therefore administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages are often ascertained through use of appropriate dose-response data which is routinely obtained.

### **Kits**

**[00252]** As an additional aspect, the invention includes kits which comprise one or more pharmaceutical formulations for administration of OspA polypeptide(s) to a subject packaged in a manner which facilitates their use for administration to subjects.

**[00253]** In a specific embodiment, the invention includes kits for producing a single dose administration unit. The kits, in various aspects, each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

**[00254]** In another embodiment, such a kit includes pharmaceutical formulation described herein (e.g., a composition comprising a therapeutic protein or peptide), packaged in a container such as a sealed bottle or vessel, with a label affixed to the container or included in the package that describes use of the compound or composition in practicing the method. In one embodiment, the pharmaceutical formulation is packaged in the container such that the amount of headspace in the container (e.g., the amount of air between the liquid formulation and the top of the container) is very small. Preferably, the amount of headspace is negligible (i.e., almost none).

**[00255]** In one aspect, the kit contains a first container having a therapeutic protein or peptide composition and a second container having a physiologically acceptable reconstitution solution for the composition. In one aspect, the pharmaceutical formulation is packaged in a unit dosage form. The kit optionally further includes a device suitable for administering the pharmaceutical formulation



according to a specific route of administration. In some aspects, the kit contains a label that describes use of the pharmaceutical formulations.

**[00256]** Each publication, patent application, patent, and other reference cited herein is incorporated by reference in its entirety to the extent that it is not inconsistent with the present disclosure.

**[00257]** It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

### **EXAMPLES**

**[00258]** Additional aspects and details of the invention will be apparent from the following examples, which are intended to be illustrative rather than limiting.

#### **EXAMPLE 1:**

#### **ANALYSIS OF THE SEQUENCE OF OSPA FROM EUROPEAN *BORRELIA BURGDORFERI SENSU LATO* STRAINS (MOLECULAR EPIDEMIOLOGY) FOR THE DETERMINATION OF AN OSPA VACCINE FORMULATION**

**[00259]** The objective of the study was to determine a suitable formulation for a Lyme disease OspA vaccine for Europe. The study was based on sequence analysis of the OspA gene (molecular epidemiology) from a large and diverse strain collection of *B. burgdorferi sensu lato*, which adequately represents a broad geographic coverage of Europe, the various clinical syndromes associated with disease, and each of the three pathogenic genospecies (*B. afzelii*, *B. garinii* and *B. burgdorferi ss*) associated with Lyme disease. Lyme disease is caused by *Borrelia burgdorferi sensu lato*, which comprises 13 genospecies in total, three of which (*B. afzelii*, *B. garinii* and *B. burgdorferi ss*) are recognized as being pathogenic in humans.

**[00260]** At the outset, a large scale epidemiological study (see Table 3 below) was carried out which evaluated *Borrelia burgdorferi sensu lato* strains from patients

with Lyme disease (and from ticks) from 21 countries in Europe. A total of 553 European *Borrelia* isolates collected from 16 European countries were studied. Each species was determined by PCR using primer sets specific for the 16s rRNA genes of each species.

**[00261]** Isolates from each of the three *Borrelia* species known to cause human Lyme disease in Europe were well represented: *B. afzelii* (n=309, 55.9%), *B. burgdorferi sensu stricto* (n=67, 12.1%), and *B. garinii* (n=173, 31.3%). Of the 359 human isolates, 56.8 % were *B. afzelii* and *B. afzelii* was the predominant species determined from human isolates in most locations. Similarly, *B. afzelii* was isolated from 54.1% of tick isolates. *B. burgdorferi s.s.* was isolated from 11.7% of human strains and 12.9% of tick isolates. *B. burgdorferi s.s.* was isolated from human isolates from South Eastern Europe, notably Italy, Hungary, Slovenia and Austria. *B. garinii* strains were isolated from 30.4% of human isolates and accounted for 33% of tick isolates. *B. garinii* strains isolated from humans and ticks were obtained from most of the geographic regions throughout Europe. The data from this study correlated well with the data presented from other European studies and suggests that the collection of isolates studied represents an accurate picture of Lyme disease in Europe.

**[00262]** OspA sequencing was carried out to determine an optimal vaccine formulation for Europe. Based on this data, a vaccine including OspA types 1 to 6 would cover 98.1% of the strains and 96.7% of invasive disease cases. Epidemiological study results of European *Borrelia* isolates indicate that a vaccine based on OspA types 1, 2, 3, 4, 5 and 6 would provide theoretical coverage in Europe of 98% of Lyme disease and 96.7% of invasive neuroborreliosis isolates.

**Table 3. Epidemiological Study Results**

OspA type	Human isolates		Isolates from invasive disease cases		Vaccine coverage total <sup>1</sup>	Vaccine coverage of invasive disease <sup>2</sup>
<i>B. afzelii</i> type 2	56.8%	(204)	3%	(7)	56.8 %	11.7%
<i>B. b s.s.</i> type 1	11.7%	(42)	17%	(7)	68.5%	23.3%
<i>B. garinii</i> type 6	15.9%	(57)	40%	(23)	84.4%	61.7%
<i>B. garinii</i> type 5	7.2%	(26)	35%	(9)	91.6%	76.7%
<i>B. garinii</i> type 4	4.5%	(16)	44%	(7)	96.1%	88.3%
<i>B. garinii</i> type 3	2.0%	(7)	71%	(5)	98.1%	96.7%
<i>B. garinii</i> type 7	0.8%	(3)	67%	(2)	98.9%	100%
<i>B. spielmanii</i>	1.1%	(4)	0%		100%	

<sup>1</sup> Predicted vaccine coverage based on numbers of isolates; totals are cumulative.

<sup>2</sup> Predicted vaccine coverage of isolates from cases of neuroborreliosis; totals are cumulative.

<sup>3</sup> Serotype 4 is alternatively considered *Borrelia bavariensis*. (See Margos et al., *Id*).

**[00263]** Hence a vaccine comprising three novel recombinant OspAs (1/2, 6/4, and 5/3), each representing 2 OspA serotypes, would retain key structural elements necessary for protection against all 6 prevalent OspA serotypes (1-6) associated with Lyme borreliosis in Europe and against the single OspA serotype associated with Lyme borreliosis in the USA.

**[00264]** Inclusion of an OspA 5/3 construct, representing *B. garinii* OspA serotypes 5 and 3, (together with OspA serotypes 1/2 and 6/4), should protect against 98.1% of disease and 96.7% of invasive isolates. A vaccine without OspA 5/3 would be expected to protect against only about 88.9% of disease, and only about 73.4% of invasive disease. Thus, a vaccine comprising all six serotypes is more effective in the prevention of Lyme disease than a vaccine with only four serotypes.

### **EXAMPLE 2:**

#### **STRATEGY FOR THE CONSTRUCTION OF SYNTHETIC OSPA GENES**

##### **ENCODING LIPIDATED OSPA**

**[00265]** The aim of the study was to prepare lipidated OspA chimeric constructs from several strains of *Borrelia* in order to make a vaccine that would protect the

recipient from Lyme disease caused by any of these several strains of *Borrelia*. The general strategy is summarized in Fig. 1 and is described below.

**[00266]** For each novel OspA gene, four sets of oligonucleotides of between 30-60 bases were synthesized. Each oligonucleotide set consisted of between 8-12 complementary overlapping oligonucleotides. The oligonucleotides from each set were annealed together, in separate experiments, to generate double-stranded DNA fragments with specific restriction enzyme recognition sites at either end, i.e. fragments N-H (*Nde I* - *Hind III*), H-K (*Hind III* - *Kpn I*), K-E (*Kpn I* - *EcoR I*) and E-B (*EcoR I* - *BamH I*). Each of the four fragments was cloned independently into pUC18, cut with the corresponding restriction enzymes and transformed into the *E. coli* host DH5 $\alpha$ , after which the sequence of the cloned fragment was verified.

**[00267]** *E. coli* strain DH5 $\alpha$  [genotype: *end A1 hsdR17* ( $r_K^- m_K^+$ ) *supE44 thi-1 recA1 gyrA* (Nal<sup>r</sup>) *relA1*  $\Delta(lacZYA-argF)U169 deoR$  ( $\Phi80dlac\Delta(lacZ)M15$ )] (Gibco BRL) was used for all intermediate cloning steps. This strain is derived from *E. coli* strain K12, one of the most widely used hosts in genetic engineering. The strain is *amp*<sup>r</sup> to allow selection of transformants with vectors containing the ampicillin resistance gene (*amp*). *E. coli* HMS174(DE3) was selected as the host for expression. *E. coli* HMS174(DE3) host cells [genotype : F- *recA1 hsdR* ( $r_{K12}^- m_{K12}^+$ ) Rif<sup>R</sup> (DE3)] (Novagen) were used for the final cloning steps. The strain is *kan*<sup>r</sup> to allow selection of transformants with vectors containing the kanamycin resistance gene (*kan*).

**[00268]** pUC18 (Gibco BRL, Basel, Switzerland) was used as the cloning vector for all intermediate steps, because genetic manipulations and sequencing were easier with this plasmid than with pET30a. The principal features are notably, the *lacZ* gene fragment coding for LacZ alpha peptide from base pairs 149 to 469 (*lac* promoter at base pairs 507), the *bla* gene encoding the ampicillin resistance determinant from base pairs 1629 to 2486 (*bla* promoter at base pairs 2521), the origin of replication at base pairs 867 and multiple cloning sites from base pairs 185 to 451 (Fig. 12).

**[00269]** pET30a (Novagen) was used as the expression vector for the final complete OspA gene insert. In pET vectors genes are cloned under the control of a T7 promoter and expression is induced by providing a source of T7 RNA polymerase

in the host cell (no expression occurs until a source of T7 RNA polymerase is provided). The principal features are the gene encoding kanamycin resistance (*kan*) at base pairs 4048 to 4860, the *lacI* gene base pairs 826 – 1905, the F1 origin of replication at base pairs 4956-5411 and multiple cloning sites from base pairs 158 to 346 (Fig. 13).

**[00270]** The four fragments needed to make a full-length OspA gene were excised from a DNA miniprep. DNA was isolated from each of the four clones using the same restriction enzymes used for the original cloning step. The DNA fragments were purified and ligated together with pUC18 DNA cut with *Nde I* and *BamH I* and were transformed into *E. coli* DH5 $\alpha$  competent cells. The full-length OspA gene cloned in pUC18 was sequenced to confirm that no errors had been introduced in this step.

**[00271]** The OspA gene was then sub-cloned into a pET-30a expression vector using the restriction enzymes *Nde I* and *BamH I* and transformed into the *E. coli* host HMS 174(DE3). In the pET30a vector, the OspA gene is controlled by the bacteriophage T7 promoter.

**[00272]** Three synthetic OspA genes were designed to encode OspA molecules with the protective epitopes from serotype 1 and 2 OspAs (lipB sOspA 1/2<sup>251</sup>), serotype 6 and 4 OspAs (lipB sOspA 6/4) and serotype 5 and 3 OspAs (lipB sOspA 5/3) of *Borrelia*. The primary amino acid sequences of these molecules (SEQ ID NOS: 2, 4, and 6, respectively) are shown in Figures 2-8 and described herein with a full description of the main features incorporated into their design.

**[00273]** The oligonucleotides for the lipB sOspA 1/2 construct were synthesized in-house on an ABI 394 DNA/RNA synthesizer. The oligonucleotides for the lipB sOspA 5/3 and lipB sOspA 6/4 constructs were purchased from GenXpress (Wiener Neudorf, Austria) and were HPLC purified.

31315/47123A

**Table 4. Oligonucleotides for lipB sOspA 1/2\* gene fragments**

Name	Sequence (5' – 3')	L	S	SEQ ID NO
<i>Hin</i> dIII – <i>Kpn</i> I fragment				
NH1	TATGCGTCTGTTGATCGGCTTTGCTCTGGCGTGCGCTGATCGG	45	C	59
NH2	CTGCGCACAGAAAGGTGCTGAGTCTATTGGTTCCGTTTCTGTAGATCTGC	50	C	60
NH3	CCGGTGAAATGAAGGTTCTGGTGAGCAAAAAGAAAAAGACAAGAACGGCAAG	50	C	61
NH4	TACGATCTCATCGCAACCGTCGACAAAGCTGGAGCTGAAAGGTACTTCTGA	50	C	62
NH5	TAAAAACAACGGCTCTGGTGTCTGGAGGGCGTCAAAACTAACAAGAGCAAAAGTAA	56	C	63
NH6	AGCTTTACTTTTGTCTCTTTGTTAGTTTTGACGCCCTCCAGCA	40	C'	64
NH7	CACCAGAGCCGTTGTTTTATCAGAAAGTACCTTTTCAGCTCCAGCTTGTCG	50	C'	65
NH8	ACGGTTGCGATGAGATCGTACTTGCCGTTCTTGCTTTTCTTTGCTCAC	50	C'	66
NH9	CAGAACCTTCATTTACCCGGGCAGATCTACAGAAACGGAAACCAATAGACT	50	C'	67
NH10	CAGCACCTTTCTGTGCGCAGCCGATCAGAGCCAGCCAGCAAGCCGATCAACAGACGCA	63	C'	68
<i>Hin</i> dIII – <i>Kpn</i> I fragment				
HK1	AGCTTACGATCTCTGACGATCTCGGTCAGACCAC	34	C	69
HK2	GCTGGAAGTTTTCAAAAGAGGATGGCAAGACCCTCGTGTCCAAAAAAGTAA	50	C	70
HK3	CTTCCAAAGACAAGTCTCTACGGAAGAAAAATTCACGAAAAAAGGTGAG	50	C	71
HK4	GTGCTGAAAAGATCATCAACCATGGCAGACGGCACCCGTC	40	C	72
HK5	TTGAATACACCGGTATTAAAAAGCGATGGTAC	31	C	73
HK6	CATCGCTTTTAATACCGGTGTATTCAAGACGGGTGCCGTCTGCCATG	47	C'	74
HK7	GTGATGATCTTTTCAGACACCTCACCTTTTTCGTTGAAATTTTCTTCCGT	50	C'	75
HK8	AGAGGACTTGCTTTGGAAAGTTACTTTTTGGACACGAGGGTCTTGCCAT	50	C'	76
HK9	CCTCTTTGAAAACTTCCAGCGTGGTCTGACCGAGATCGTCAGAGATCGTA	40	C'	77
<i>Kpn</i> I – <i>Eco</i> RI fragment				
KE1	CGGTAAAGCGGAAATATGTTCTGAAAAACTTCACCTCTGGA	39	C	78
KE2	AGGCAAGTGGCTAATGATAAAACCACCTTGAAGTCAAGGAAGGCACCG	50	C	79
KE3	TACTCTGAGCATGAATATCTCCAAATCTGGTGAAGTTTCCGTTGAACTG	50	C	80
KE4	AACGACACTGACAGCAGCGCTGCGACTAAAAAAACTGCAGCGTGG	45	C	81
KE5	AATCCACGCTGCAGTTTTTTTAGTCGCA	29	C'	82
KE6	GCGGTGCTGTCAGTGTCTGTTCAAGTTCAGTTCAACGGAACCTTACCAGATTGGA	50	C'	83
KE7	GATATTGATGCTCAGAGTAACGGTGCCCTTCTTGACTTCCAAGGTGTTT	50	C'	84
KE8	TATCATTAGCCACTTGCCTCCAGAGTGAAGTTTTTCAGAACATATTGCGTTTACCAGGTAC	63	C'	85

31315/47123A

<i>EcoRI</i> – <i>BamHI</i> / fragment				
EB1	AATCCAAACTTCTACTTTAACCATTAGCGTTACAGCAAAAAA	45	C	86
EB2	ACTACCCAGCTGGTGTTCACATAACAAGACACGATCACTGTGCAGAAATA	50	C	87
EB3	CGACTCCAACGGCACCAACTTAGAAGGCACGGCAGTCGAAATTAACACCC	50	C	88
EB4	TTGATGAAC TGAAAAACGCGCTGAAATAAGCTGAGCG	40	C	89
EB5	GATCGCTCAGCTTATTCAGCGGTTTTTCAGTTCATCAAGGGTTTTAATTTTCGACTGCC	60	C'	90
EB6	GTGCCCTTCTAAGTTGGTCCGTTGGAGTCGTATTTCTGCACAGTGATCGT	50	C'	91
EB7	GTCTTGTTAGTGAACACACGAGCTGGGTAGTTTTTTTGCTGTTAACGCTAA	50	C'	92
EB8	TGGTTAAAGTAGAAGTTTTGG	21	C'	93

\* A single amino acid change was introduced by PCR, lipB sOspA 1/2 was the name of the construct before the introduced change and lipB sOspA 1/2<sup>251</sup> was the name after the introduced change.

L Length of oligonucleotide in bases

S Strand, C (coding) or complementary (C')

**Table 5. Oligonucleotides for lipB sOspA 5/3 gene fragments**

Name	Sequence (5' – 3')	L	S	SEQ ID NO
<i>Nde I</i> - <i>Hin dIII</i> fragment				
N51	TATGCGTCTGTTGATCGGCTTTGCTTTGGCGCTGGCTTTAATCGGCTG	48	C	94
N52	TGCACAGAAAGGTGCTGAGTCTATTGGTTCCGTTTCTGTAGATCTGCCCG	50	C	95
N53	GGGTATGAAAGTCTGGTAAGCAAGAAAAAGACAAAAACGGTAAATAC	50	C	96
N54	AGCCTGATGGCAACCGTAGAAAAAGCTGGAGCTTAAAGGCAC TTCTGATAA	50	C	97
N55	AAACAACGGTTCTGGCACCCCTGGAAGGTGAAAAAATAACAAAAAGCAAAAGTAA	53	C	98
N56	AGCTTACTTTTGCTTTTGTAGTTTTTTCACCTTCCA	37	C'	99
N57	GGTGCCAGAACCGTTGTTTTATCAGAAAGTGCCTTTAAGCTCCAGCTTT	50	C'	100
N58	TCTACGGTTGCCATCAGGCTGTATTACCGTTTTTGCTTTTCTTTGCT	50	C'	101
N59	TACCAGAACTTTCATACCCCGGGGAGATCTACAGAAACCGGAACCAATAG	50	C'	102
N510	ACTCAGCACCTTCTGTGCACAGCCGATTA	30	C'	103
N511	AAGCCAGCGCCAAAGCAAAAGCCGATCAACAGACGCA	36	C'	104

31315/47123A

<i>Hin</i> dIII – <i>Kpn</i> I fragment				
H51	AGCTTACTATTGCTGAGGATCTGAGCAAAACCCCTTTGAAATCTTC	47	C	105
H52	AAAGAAAGATGGCAAAACCTCTGGTATCTAAAAAGTAACCCCTGAAAGACAA	50	C	106
H53	GTCTTCTACCCGAAGAAAAATTCAACGAAAAGGGTGAAATC	40	C	107
H54	TCTGAAAAAACTATCGTAATGGCAAAATGGTAC	32	C	108
H55	AAGGTGGTTTTGCTCAGATCCTCAGCAATAGTA	33	C'	109
H56	AGAGTTTTGCCATCTTCTTTGAAGATTCA	30	C'	110
H57	ATTTTCTTCGGTAGAAGACTTGCTTTTCAGGGTTACTTTTTAGATACC	50	C'	111
H58	CATTGGCATTACGATAGTTTTTTCAGAGATTTCACCCCTTTTCGTTGA	48	C'	112
<i>Kpn</i> I – <i>Eco</i> RI fragment				
K51	CCGTCGTGGAATACACCGACATCAAAAAGCGATATAAAACCGGCAAAAGCTAA	48	C	113
K52	ATACGTTCTGAAAGACTTTACTCTGGAAGGCACCTCTGGCTGCTGACGGCA	50	C	114
K53	AAACCACTCTGAAAGTTACCGAAGGCACCTGTTACTCTGAGCATGAACATT	50	C	115
K54	TCTAAATCCGGCGAAATCACCGTTGCACTGGATGACACTGACTCTAGCGG	50	C	116
K55	CAATAAAAAATCCGGCACCTGGGATTTCTGATACTTTCTACTTTAACCATTA	50	C	117
K56	GCAAAAAACAGCCAGAAAAACTAAACAGCTGGG	31	C	118
K57	GCTTTGATGTGGTGTTATCCAGACGGGTAC	31	C'	119
K58	CCTCCAGAGTAAAGTCTTTCAGAACGTATTTAGCTTTGCCGGTTTTATC	50	C'	120
K59	CAGTGCCTTCGGTAACCTTCAGAGTGGTTTGCCGTCAGCAGCCAGAGTG	50	C'	121
K510	CAGTGCAACGGTGATTCGCCGGATTTAGAAATGTTCAATGCTCAGAGTAA	50	C'	122
K511	TCAGAAATCCAGGTGCCGGATTTTTATTGCCGCTAGAGTCAGTGTATC	50	C'	123
K512	AATTCACAGCTGTTTAGTTTTCTGGCTGTTTTGCTAATGTTAAAGTAGAAGTA	55	C'	124
<i>Eco</i> RI I – <i>Bam</i> HI fragment				
E51	AATTCAAACAGCTGGTATTCACCAAAAGAAACACTATCACCGTAC			125
E52	AGAACTATAACCGTGCAGGCAATGCGCTGGAAGGCAGCCC	45	C	126
E53	GGCTGAAATTAAAGATCTGGCAGAGCTGAAAGCCGCTTTGAAATAAGCTGAGCG	40	C	127
E54	GATCCGCTCAGCTTATTTCAAAGCGGCT	54	C	128
E55	TTACAGCTCTGCCAGATCTTTAATTCAGCCGGGCTGCCATCCAGCGCATT	28	C'	129
E56	GCCTGCACGGTTATAGTCTGTACGGTGATAGTGTTCCTTGGTGAATACCAGCTGTTTG	50	C'	130

L Length of oligonucleotide in bases

S Strand, C (coding) or complementary (C')



31315/47123A

**Table 6. Oligonucleotides for lipB sOspA 6/4 gene fragments**

Name	Sequence (5' – 3')	L	S	SEQ ID NO
<i>Nde</i> I - <i>Hin</i> dIII fragment				
KNH1	TATGCGTCTGTTGATCGGCTTTGCTCTGGCGCTGGCTCTGATCGGCTG			131
KNH2	CGCACAGAAAGGTGCTGAGTCTATTGTTCCGTTTCTGATGATCGCCCG	48	C	132
KNH3	GTGGCATGACCGTTCTGGTCAGCAAGAAAAAGACAAAAACG	50	C	133
KNH4	GTAATACAGCTCGAGGCGACCGTCGACA	42	C	134
KNH5	AGCTTGTCGACGGTCGCTCGAGGCTGATTTACCGTTTTTGCTTTTGGCT	30	C	135
KNH6	GACCAGAACGGTCATGCCACCGGGCAGATCTACAGAAACG	56	C'	136
KNH7	GAACCAATAGACTCAGCACCTTTCTGTGCGCAGCCGATCAGAGCCAGCGC	40	C'	137
KNH8	CAGAGCAAGCCGATCAACACAGACGCA	50	C'	138
<i>Hin</i> dIII – <i>Kpn</i> I fragment				
KHK1	AGCTTGAGCTGAAAGGCACCTCTGTATAAAAAACAACGGTTCGGCACCCCTG	50	C	139
KHK2	GAAGGTGAAAAAATAACAAAAGCAAAAGTGAACCTGACCATTTGCTGAT	48	C	140
KHK3	GACCTCAGCCAGACCAATTCGAAATTTCAAAGAAGATGCCAAAACCTT	50	C	141
KHK4	AGTATCCAAAAAAGTGACCCCTGAAAGACAAGTCTCTACCGAAGAAAAAT	50	C	142
KHK5	TCAACGAAAAAGGTGAAACCTCTGAAAAAACCATGTAAATGGCAATGGTAC	52	C	143
KHK7	CATTGGCCATTACGATGGTTTTTTCAGA	28	C'	144
KHK8	GGTTACCCCTTTTCGTTGAATTTTCTCGGTAGAGGAC	40	C'	145
KHK9	TTGTCTTTCAGGGTCACITTTTGGATAGTAAAGTTTGGCATCTTCTTT	50	C'	146
KHK10	GAATAATTCGAATTTGGTCTGGCTGAGGTGATCAGCAATGGTCAGTTTCA	50	C'	147
KHK11	CTTTGCTTTTGTAGTTTTTTCACCTTCCAGGGTGCCGGA	40	C'	148
KHK12	ACCGTTGTTTTATCAGAGGTGCCTTTTCAGCTCA	34	C'	149
<i>Kpn</i> I – <i>Eco</i> R I fragment				
KKE1	CCGTCTGGAATACACCGACATCAAAAGCGATGGCTCCGGCAAGCCAA	48	C	150
KKE2	ATACGTTCTGAAAGACTTCACCCCTGGAAGGACCCCTCGCTGCCGACGG	48	C	151
KKE3	CAAAACCACTTGAAAGTTACCGAAGGCACGTGTTTTAAG	42	C	152
KKE4	CATGAACATCTTAAATCCGGTGAATCACCGTTGCGCTG	40	C	153
KKE5	GATGACTCTGACACCACTCAGGCCACTAAAAAAACCGGCAATGGGATTG	50	C	154
KKE6	TAACACTTCCACTCTGACCATCAGCGTG	28	C	155
KKE7	AATTCACGCTGATGTCAGAGTGAAGTGTAGAATCCCATTTGCCG	47	C'	156
KKE8	GTTTTTTTAGTGGCTGAGTGGTGCAGAGTCATCCAGCGCAACGGTGATTTTCA	55	C'	157
KKE9	CGGATTTAAGATGTTTCATGCTTAAACACACAGTGCCTTCGGTAACCTTC	50	C'	158
KKE10	AAGGTGGTTTTGCCGTCGGCAGCGAGGGTGCCCTCCAGGG	40	C'	159
KKE11	TGAAGTCTTTCAGAACGTAATTTGGCTTTGCCGGAGGCCATC	40	C'	160
KKE12	GCTTTTGATGTCGGTGTATTCAGACGGGTAC	32	C'	161

EcoRI – BamHI / fragment					
KEB1	AATTC	AAAAAACTAAAAACATCGTGTTCACCA	AAAGACACCATCACCG		162
KEB2	TCCAG	AAATACGACTCTGCGGCACCAACCTCGAAGGCAACGCAGTCGAA		52 C	163
KEB3	ATCAAA	CCCTGGATGAAC	TGAAAAACGCTCTGAAATAAGCTGAGCG	50 C	164
KEB4	GATCC	GCTCAGCTTATTT	TCAGAGCGTTTTTCAGTTCATCCAGGGTTTTGATTT	47 C	165
	CGACT	GCCTTCGA			
KEB5	GGTTGGT	GCCCGCAGATCGTATTTCTGGACGGTGATGGTGCTTCTTTG		71 C'	166
KEB6	GTGAAC	ACGATGTTTTTAGTTTTTTGG		50 C'	167

L      Length of oligonucleotide in bases  
S      Strand, C (coding) or complementary (C')

**[00274]** *Preparation of E. coli competent cells.* A single colony was used to inoculate 5 ml modified LB broth (5.5 g NaCl, 5 g yeast extract, 10 g soya peptone, which was not obtained from an animal or genetically modified plant source - per liter of water). The culture was incubated until it became turbid, after which the culture was diluted to a volume of 25 ml with pre-warmed modified LB broth. The culture was incubated further until it had reached an OD<sub>600nm</sub> of 0.2 to 0.6 (40 – 60 min) and was diluted to a volume of 125 ml, transferred to a 500 ml flask and incubated until an OD<sub>600nm</sub> of 0.6 was reached. The culture was chilled quickly by gentle shaking for 5 min in an ice bath and the cells were pelleted directly (Beckman centrifuge, 4000 rpm for 10 min.), washed carefully with TfBI buffer (Teknova Hollister, CA) (30 mM K-acetate, 50 mM MnCl<sub>2</sub>, 100 mM KCL, 10 mM CaCl<sub>2</sub> 15% glycerol), resuspended in 5 ml of TfBII (10 mM Na-MOPS, 75 mM CaCl<sub>2</sub>, 10 mM KCL, 15% glycerol) and held on ice for 15 min. The cells were then pipetted into 100 µl aliquots and were snap frozen directly in dry ice.

**[00275]** *Annealing of oligonucleotide mixtures to form OspA gene fragments (de novo synthesis).* Three synthetic OspA genes were designed to encode OspA molecules with the protective epitopes from serotype 1 and 2 OspAs (lipB sOspA 1/2), serotype 6 and 4 OspAs (lipB sOspA 6/4) and serotype 5 and 3 OspAs (lipB sOspA 5/3). For each novel OspA gene (lipidated), four sets of oligonucleotides of between 30 - 60 base pairs were synthesized (see Tables 4–6). Figures 16-18 show the codon optimized sequences for each of the constructs aligned with the nucleotide sequences predicted from published sequences). Each oligonucleotide set consisted of between 8-12 complementary overlapping oligonucleotides. The oligonucleotides from each set were annealed together, in separate experiments, to generate double-stranded DNA fragments with specific restriction enzyme recognition sites at either end i.e. fragments N-H (*Nde* I - *Hind* III), H-K (*Hind* III - *Kpn* I), K-E (*Kpn* I - *EcoR* I) and E-B (*EcoR* I - *BamH* I).

**[00276]** The lyophilized oligonucleotides were reconstituted with distilled water, the OD<sub>260nm</sub> was measured and the concentration was adjusted to 10 µM. For each OspA fragment, 2 µl of each of the oligonucleotides were mixed together with 1 µl of T4 polynucleotide kinase and T4 DNA ligase buffer (10x) and the mixture was incubated at room temperature for 30 minutes to enable phosphorylation of the oligos (for the lipB sOspA 6/4 construct this step was omitted as the oligos were

already phosphorylated). The mixture was heated to 95 °C for 1 minute (denaturing step) and then the oligos were allowed to anneal by leaving the mix to cool slowly to room temperature. The annealed mix was used directly in ligations, or was stored at -20 °C until further needed.

**[00277]** *Cloning of OspA gene fragments.* Each of the four fragments required for constructing an individual synthetic OspA gene was cloned independently into pUC18 and transformed into the *E. coli* host DH5 $\alpha$  (see Figure 1).

**[00278]** For each novel OspA gene, four sets of oligonucleotides of between 30-60 bases were synthesized. Each oligonucleotide set consisted of between 8-12 complementary overlapping oligonucleotides. The oligonucleotides from each set were annealed together, in separate experiments, to generate double-stranded DNA fragments with specific restriction enzyme recognition sites at either end, *i.e.* fragments N-H (*Nde* I - *Hind* III), H-K (*Hind* III - *Kpn* I), K-E (*Kpn* I - *Eco*R I) and E-B (*Eco*R I - *Bam*H I). Each of the four (4) fragments was cloned independently into pUC18 cut with the corresponding restriction enzymes and transformed into the *E. coli* host DH5 $\alpha$ , after which the sequence of the cloned fragment was verified.

**[00279]** Plasmid DNA (pUC18) was purified from an overnight *E. coli* culture (LB broth) with a QIAGEN plasmid purification system according to the manufacturer's protocol. Vector DNA was then digested with pairs of restriction enzymes; *Nde* I & *Hind* III, *Hind* III & *Kpn* I, *Kpn* I & *Eco*R I, *Eco*R I & *Bam*H I in accordance with the manufacturers' protocols. The digested samples were applied to a 0.8% agarose gel and electrophoretically separated. The linearized vector DNA was excised and eluted using a commercial gel elution kit (QIAquick Gel Extraction Kit, Qiagen) according to the manufacturer's protocol and ligated, using T4 DNA ligase, to the annealed oligonucleotide mixture. The ligation products were transformed into competent cells of *E. coli* DH5 $\alpha$  and transformants containing the plasmid were selected on LB agar containing ampicillin (100  $\mu$ g/ml).

**[00280]** The presence of the insert of the expected size in the cloning vector, pUC18, was confirmed by purifying plasmid DNA, digesting the DNA with the enzymes used for cloning and analyzing the DNA fragments by agarose gel electrophoresis using the procedures previously described. The cloned DNA fragment was sequenced using purified plasmid DNA as the DNA template and the

sequencing primers 5'-TCGGGGCTGGCTTAACTATG-3 (SEQ ID NO: 14) and 5'-GCTTCCGGCTCGTAT (SEQ ID NO:15) (which are in the pUC18 vector outside the multiple cloning sites, bp 130-150 and bp 530-515, respectively). Sequence reactions were run on an automatic sequencer (ABI 310). Sequences were edited using SequenceEditor and the sequences were imported into VectorNTI for analysis. Only clones with the correct sequences were used as building blocks for constructing full-length *OspA* genes.

**[00281]** For the lipB s*OspA* 5/3 gene a different strategy was employed, since no suitable unique internal site could be found within the *Kpn* I – *Bam*H I fragment and the amino acid sequence did not permit the use of an internal *Eco*R I site (see Figure 14). A *Pvu* II site exists within the *Kpn* I – *Bam*H I fragment, however there are two *Pvu* II sites in the pUC18 vector which mean direct cloning of the fragments in pUC18 is not possible. Hence, the oligos for the constructs were designed to have an *Eco*R I site inserted outside and adjacent to the *Pvu* II site, to permit cloning of the *Kpn* I - *Eco*R I and the *Eco*R I - *Bam*H I fragments into pUC18. Subsequent digestion of the inserted fragments with *Kpn* I, *Eco*R I and *Bam*H I generated fragments, which were subsequently digested with *Pvu* II. The *Pvu* II-digested fragments (*Kpn* I – *Pvu* II and *Pvu* II – *Bam*H I) were then used in a triple ligation with pUC18 vector DNA cut with *Kpn* I and *Bam*H I to generate the *Kpn* I – *Bam*H I fragment.

**[00282]** *Constructing full-length OspA genes.* In the next step, each of the four fragments required for constructing an individual synthetic *OspA* gene was excised from the pUC18 vector and re-cloned, in a single step, into pUC18 vector to generate a full-length *OspA* gene (see Figure 1).

**[00283]** The four fragments needed to make full-length genes were excised from miniprep. DNA isolated using the same restriction enzymes used for the original cloning step. The digested samples were applied to an agarose gel and electrophoretically separated. The DNA for each of the respective 4 insert fragments was excised and eluted using a commercial gel elution kit (QiaQuick Gel Extraction Kit) according to the manufacturer's protocol and ligated, using T4 DNA ligase, to linearized vector DNA digested with *Nde* I and *Bam*H I and purified using a QIAquick Gel Extraction Kit. The ligated DNA was transformed into competent cells of *E. coli* DH5 $\alpha$  and clones containing the plasmid were selected on LB agar containing

ampicillin (100 µg/ml). Colonies were screened by PCR for the presence of inserts of the expected size (approx 830 bp).

**[00284]** Single colonies were used as template DNA in PCR reactions comprising 10X buffer (15 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>), 200 µM dNTPs, 1.25 U Amplitaq DNA polymerase, 400 nM forward primer 5'-TCGGGGCTGGCTTAACTATG-3 (SEQ ID NO: 14) and 400 nM reverse primer 5'-GCTTCCGGCTCGTAT (SEQ ID NO: 15). PCR reaction conditions were as follows; 94°C for 5 min., 35 x (94°C for 30 s, 48°C for 30 s, 72°C for 1 min 30s) followed by a soak at 72°C for 5 minutes and a hold at 4°C. PCR products were used directly or stored at ≤ -15°C until further use. PCR products were analyzed by agarose gel electrophoresis for the presence of inserts of the correct size (approx. 980 bp). Inserts of the correct size were sequenced to confirm that no errors had been introduced i.e. sequence reactions were set up using plasmid DNA isolated (QIAGEN Plasmid Purification kit) from overnight cultures (LB amp broth) and using sequencing primers that flank the cloning sites (5'-TCGGGGCTGGCTTAACTATG-3' (SEQ ID NO: 14) and 5'-GCTTCCGGCTCGTATGTTGT-3' (SEQ ID NO: 16), bp 130-150 and 530-510, respectively). Sequence reactions were run on an automatic sequencer (ABI 310). Sequences were edited using SequenceEditor and the sequences were imported into VectorNTI for analysis.

**[00285]** *Sub-cloning of novel OspA genes into the pET30a expression vector.* Once the full length OspA gene was verified in pUC18, the OspA genes were then sub-cloned into the pET-30a expression vector using the restriction enzymes *Nde*I and *Bam*H I and transformed into the *E. coli* host HMS 174(DE3).

**[00286]** Miniprep DNA from pUC18 clones with the correct sequence was digested with *Nde*I and *Bam*H I. Similarly pET30a vector DNA was digested with *Nde*I and *Bam*H I. The digested DNAs were run on an agarose gel and electrophoretically separated. The insert fragment of approximately 830 bp and the linearized vector DNA were excised and purified as described previously. The vector and insert DNA were ligated, using T4 DNA ligase and the ligation products were transformed into competent cells of *E. coli* HMS174(DE3) (Novagen). The transformants were plated onto LB plates containing kanamycin (30 µg/ml). Single colonies were screened by PCR using the primers 5'-TTATGCTAGTTATTGCTCAGCG-3' (SEQ ID NO: 17) and 5'-

TTCCCCTCTAGAAATAATTTTGT-3' (SEQ ID NO: 18). PCR products were applied to an agarose gel and were electrophoretically separated. Colonies that yielded a product of the correct size (approx. 1 kb) were subsequently used to set up overnight cultures, from which miniprep DNA was isolated using a QIAGEN Plasmid Purification kit according to the manufacturer's protocol. The sequence was again confirmed (using primers 5'-TTATGCTAGTTATTGCTCAGCG-3' (SEQ ID NO: 17) and 5'-TTCCCCTCTAGAAATAATTTTGT-3' (SEQ ID NO: 18), bp 65-86 and 395-373, respectively) and colonies were selected for expression testing.

**[00287]** *Generating lipB sOspA 1/2<sup>251</sup> from lipB sOspA 1/2.* A single amino acid was changed in the lipB sOspA 1/2 construct, namely amino acid alanine at position 251 was changed to an asparagine residue, to enhance immunogenicity. The amino acid change was introduced by PCR. First, PCR was set up with the external forward primer and the internal reverse primer yielding a product of about 730 bp with the introduced amino acid change (see Figure 15). Second, PCR was set up with the internal forward primer and the external reverse primer to yield a product of 100 bp containing the introduced amino acid change. The two PCR products, which overlapped in sequence, were then used as template DNA in a final PCR reaction with the external forward and external reverse primers to yield the final full-length OspA product containing the introduced amino acid change.

**[00288]** The pET30a construct was used as the source of template DNA. PCR reactions were set up comprising 10X buffer [15 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>], 200 μM dNTPs, 1.25 U Amplitaq DNA polymerase, and 400 nM of each primer pair (primer pair 5'- GGA ATT CCA TAT GCG TCT GTT GAT CGG CT (SEQ ID NO: 19) & 5'- TTG GTG CCT GCG GAG TCG (SEQ ID NO:20) and primer pair 5'- AAT ACG ACT CCG CAG GCA CC (SEQ ID NO: 21) & 5'- CTG-GGA TCC GCT CAG CTT ATT TCA (SEQ ID NO: 22)). PCR reactions were set up with the following conditions; 94 °C for 5 min., 35 x (94 °C for 30 s, 48 °C for 30 s, 72 °C for 1 min 30s) followed by a soak at 72 °C for 5 minutes and a hold at 4 °C. The reactions yielded 2 separate overlapping products and the 2 products were used as the template DNA in a third PCR reaction using the external primers 5'- GGA ATT CCA TAT GCG TCT GTT GAT CGG CT (SEQ ID NO: 19) and 5'- CTG-GGA TCC GCT CAG CTT ATT TCA (SEQ ID NO: 22) which incorporated restriction sites for *Nde* I and *Bam*HI. The reaction conditions were 94 °C for 60 sec followed by 35 cycles of

(30 sec 94°C, 60 sec 49°C, 90 sec 72°C) followed by 72°C for 5 min. The amplified product was purified with a QiaQuick purification kit (Qiagen) in accordance with the manufacturer's specifications and the product was digested with Nde I and BamH I and ligated to pET30a vector DNA cut Nde I and BamH I. The ligation products were transformed into competent cells of *E. coli* DH5 $\alpha$ . The transformants were plated onto LB plates containing kanamycin (30  $\mu$ g/ml). Single colonies were screened by PCR using the primers 5'-TTATGCTAGTTATTGCTCAGCG-3' (SEQ ID NO: 17) and 5'-TTCCCCTCTAGAAATAATTTTGT-3' (SEQ ID NO: 18). PCR products were applied to an agarose gel and were electrophoretically separated. Colonies which yielded a product of the correct size (approx. 1 kb) were subsequently used to set up overnight cultures, from which miniprep DNA was isolated using a QIAGEN Plasmid Purification System according to the manufacturer's protocol. The sequence was confirmed (using primers 5'-TTATGCTAGTTATTGCTCAGCG-3' (SEQ ID NO: 17) and 5'-TTCCCCTCTAGAAATAATTTTGT-3' (SEQ ID NO: 18)) and the resulting construct was transformed into *E. coli* HMS174 (DE3) competent cells and the resulting positive transformants were given the name lipB sOspA 1/2<sup>251</sup>.

**[00289]** *Generation of constructs without leader sequence.* Constructs were prepared with a lipB leader sequence, to which a lipid moiety is typically attached at the amino terminal cysteine residue. Experimental testing of the recombinant lipidated OspAs verified the presence of a lipid moiety. However, constructs which did not contain the lipB leader sequence were also prepared. Constructs which did not contain the lipB leader sequence were made by PCR amplification from each of the three lipB constructs (in pET30a) using primers selected to generate a final product of 769-771 bp without the nucleic acid sequence coding for the leader sequence and with the codon for the cysteine residue replaced with a codon for a methionine residue.

**[00290]** PCR reactions comprised 10X buffer [15 mM Tris-HCl (pH 8.0), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>], 200  $\mu$ M dNTPs, 1.25 U Amplitaq DNA polymerase, 400 nM forward primer 5'-CGTGCGTACCATATGGCACAGAAAGGTGCTGAGTCT-3' (SEQ ID NO: 23) and 400 nM reverse primer 5'-CTGGGATCCGCTCAGCTTATTTCA-3' (SEQ ID NO: 22) and template DNA. PCR conditions were; 94°C for 5 min, 35 x (94°C for 30 s, 48°C for 30 s, 72°C for 1 min 30 s) followed by a soak at 72°C for 5



min and a hold at 4°C. PCR reactions were used directly or stored at  $\leq 15^{\circ}\text{C}$  until further use.

**[00291]** The PCR products were purified using a QiaQuick PCR purification kit (Qiagen), were digested with Nde I and BamH I and were ligated to pET30a vector DNA digested with Nde I and BamH I. The ligation mixes were used to transform *E. coli* HMS174 (DE3) and colonies containing recombinant plasmids were selected by their resistance to kanamycin and the sequence was verified from PCR products.

**[00292]** *Evaluation of expression in E. coli HMS 174(DE3).* Selected colonies were tested for their ability to express the respective novel OspA protein. In each case, single colonies were used to inoculate LB broth containing kanamycin (30  $\mu\text{g/ml}$ ) and were incubated at  $37^{\circ}\text{C}$  for 1 to 5 hours until an OD (600 nm) value greater than 0.6 and less than 1 was reached. At this point, a sample of the culture was retained (representing the un-induced sample) and the remainder of the culture was induced by the addition of IPTG to a final concentration of 1 mM. The un-induced sample (1 ml) was centrifuged and the pellet retained and stored at  $-20^{\circ}\text{C}$ . The induced culture was allowed to grow for a further three hours, after which a 1 ml sample was taken, the OD (600 nm) was measured, the sample centrifuged and the pellet retained and stored at  $-20^{\circ}\text{C}$ .

**[00293]** *Preparation of primary cells.* Primary cells were prepared for each of the three lipidated constructs and for each of the three non-lipidated constructs. The primary cells comprised *E. coli* cells (HMS174 (DE3)) carrying a pET30a plasmid expressing the respective OspA. For preparation of primary cells, a single colony from the respective stock was picked from a plate containing kanamycin (30  $\mu\text{g/ml}$ ) and rifampicin (200  $\mu\text{g/ml}$ ) and was used to inoculate 500  $\mu\text{l}$  of SMK medium (SOP 8114) and incubated overnight. One hundred microliters of this culture was then used to inoculate 100 ml of SMK medium (in duplicate) and the culture was incubated for 17 to 20 hours at  $37^{\circ}\text{C}$  shaking. Sterile glycerol was then added to the culture at a final concentration of 15% and the material was pipetted in aliquots in 500  $\mu\text{l}$  amounts into 60 ampoules, thus yielding 60 ampoules of primary cells which were directly stored at  $-80^{\circ}\text{C}$ .

**[00294]** Three synthetic OspA genes were designed to encode OspA molecules with the protective epitopes from serotype 1 and 2 OspAs (lipB sOspA 1/2251),

serotype 6 and 4 OspAs (lipB sOspA 6/4) and serotype 5 and 3 OspAs (lipB sOspA 5/3). The primary amino acid sequences of these molecules and a description of the main features incorporated into their design are set out in the following Examples.

### **EXAMPLE 3:**

#### **DESCRIPTION OF LIPIDATED 1/2<sup>251</sup> OSPA (LIPB SOSPA1/2<sup>251</sup>)**

**[00295]** The aim of the study was to design a novel OspA antigen, lipidated 1/2<sup>251</sup> OspA (lipB sOspA 1/2<sup>251</sup>), comprising serotypes 1 and 2. LipB sOspA 1/2<sup>251</sup>, comprises the proximal portion of a serotype 1 OspA sequence (Strain B31, GenBank Accession No. X14407) fused to the distal portion of a serotype 2 sequence (Strain Pko, GenBank Accession No. S48322). The start of the sequence unique to the type 2 serotype is the lysine (K) residue at position 216. The construct was originally designed to encode the amino acid alanine (A) at position 251. However, the construct was subsequently altered by PCR to encode an asparagine (N) residue (the actual residue in the published sequence from Pko) to enhance immunogenicity, hence the nomenclature lipB sOspA 1/2<sup>251</sup>.

**[00296]** Secondary features of lipB sOspA 1/2<sup>251</sup> are shown in the annotated amino acid sequence of lipB sOspA 1/2<sup>251</sup> in Figure 2 and include:

- the replacement of the putative arthritogenic epitope (Gross et al., 1998), hLFA-1 (YVLEGTTLTA) (SEQ ID NO:24), in the proximal portion of the molecule (amino acids 161 to 185) with an equivalent sequence (shown in italics and a flanking sequence) from a serotype 2 OspA sequence (Strain Pko; GenBank Accession No. S48322): a sequence that is distinct from the hLFA-1 epitope;
- an OspB leader sequence (amino acids 1 to 15 of Figure 2) and various substitutions to avoid prior art. The asparagine (N) and aspartic acid (D) residues at positions 44 and 46 were replaced with an aspartic acid (D) and an asparagine (N), respectively, to produce the sequence KEKDKN (SEQ ID NO: 25). The alanine (A) and aspartic acid (D) residues at positions 78 and 79 were replaced with a threonine (T) and an asparagine (N), respectively, to produce the sequence KTNKSK (SEQ ID NO: 26);
- stabilizing mutations as described in international patent publication number WO 02/16421A2 (Luft & Dunn). For example, methionine (M) replaced

arginine (R) at amino acid 136 (R139M); tyrosine (Y) replaced glutamic acid (E) at amino acid 157 (E160Y); and methionine (M) replaced lysine (K) at amino acid 186 (K189M); and

- additional stabilizing mutations. For example, threonine (T) replaced valine (V) at amino acid 173 (aa 176 of the disclosure). The removal of the putative arthritogenic epitope (position 161-185), by replacing a *B. burgdorferi* sequence with a *B. afzelii* sequence, disrupted the hydrogen bonding between amino acids 173 and 174 (aa 176 and 177 of the disclosure). This led to decreased binding to protective monoclonal antibodies (105.5 and LA-2 (Jiang et al., *J. Immunol.* 144: 284-9, 1990; Golde et al., *Infect. Immun.* 65: 882-9, 1997; and Ding et al., *J. Mol. Biol.* 302: 1153-64, 2000). A threonine (T) was introduced at position 173, instead of a valine (V), to restore the hydrogen bond and increase reactivity to protective monoclonal antibodies 105.5 and LA2.

**[00297]** In addition, amino acids 16-25 (start of the mature protein) are identical to the OspB sequence (GenBank Accession No. X74810).

**[00298]** The nucleotide and deduced amino acid sequences of lipB sOspA 1/2<sup>251</sup> are shown in Figure 3. The leader sequence (green) is cleaved off during protein secretion. The sequence of the mature OspA protein starts with a cysteine residue (underlined), which forms the attachment site for the protein's lipid anchor.

#### **EXAMPLE 4:**

##### **DESCRIPTION OF LIPIDATED 6/4 OSPA (LIPB SOSPA 6/4)**

**[00299]** The aim of the study was to design a novel OspA antigen, lipidated sOspA 6/4 OspA (lipB sOspA 6/4), comprising serotypes 4 and 6. LipB sOspA 6/4 comprises the proximal portion of a serotype 6 OspA sequence (Strain K48, GenBank Accession No. I40098) fused to the distal portion of a serotype 4 sequence (Strain pTroB; GenBank Accession No. I40089). The start of the sequence unique to the type 4 serotype is the asparagine (N) residue at position 217. Secondary features are shown in the annotated amino acid sequence of lipB sOspA 6/4 in Figure 4 and include:

- stabilizing mutations described in International Patent Application No. WO 02/16421A2 (Luft and Dunn): methionine (M) instead of an arginine (R) at amino

acid 136, tyrosine (Y) instead of a glutamic acid (E) at amino acid 157, and methionine (M) instead of a lysine (K) at amino acid 187; and

- like lipB sOspA 1/2<sup>251</sup>, described above, an OspB leader sequence was used (amino acids 1 to 15 in Figure 4) and amino acids 16-25 are identical to sequence from OspB (GenBank Accession No. X74810).

**[00300]** Although the peptide sequence KEKNKD (SEQ ID NO: 27) was absent from the parent OspA type 6 sequence (KEKDKD) (SEQ ID NO: 28), the aspartic acid (D) residue at position 46 was replaced with an asparagine residue (N) in conformity with an equivalent change made in the lipB sOspA 1/2<sup>251</sup> construct to produce the sequence KEKDKN (SEQ ID NO:25).

**[00301]** Although the peptide sequence KADKSK (SEQ ID NO:29) was absent from the parent OspA type 6 sequence (KTDKSK) (SEQ ID NO: 30), the aspartic acid (D) residue at position 79 was replaced with an asparagine residue (N) in conformity with an equivalent change made in the lipB sOspA 1/2<sup>251</sup> construct to produce the sequence KTNKSK (SEQ ID NO:26).

**[00302]** Amino acid 37 was changed from the glutamic acid (E), as present in the parent sequence (Strain K48; GenBank Accession No. I40098), to a valine (V), because almost all type 6 sequences have a valine in this position.

**[00303]** The nucleotide and deduced amino acid sequences of lipB sOspA 6/4 are shown in Figure 5. The leader sequence (green) is cleaved off during protein secretion. The sequence of the mature OspA protein starts with a cysteine residue (underlined, see Figure 5), which forms the attachment site for the protein's lipid anchor.

#### **EXAMPLE 5:**

##### **DESCRIPTION OF LIPIDATED 5/3 OSPA (LIPB SOSPA 5/3)**

**[00304]** The aim of the study was to design a novel OspA antigen, lipidated sOspA 5/3 OspA (lipB sOspA 5/3), comprising serotypes 3 and 5. LipB sOspA 5/3 comprises the proximal portion of a serotype 5 OspA sequence [Database Accession No. emb|X85441|BGWABOSPA, *B. garinii* OspA gene (WABSou substrain)] fused to the distal portion of a serotype 3 sequence (Strain PBr; Genbank Accession No. X80256, *B. garinii* OspA gene) with modifications as shown in SEQ ID NOS: 5 and 6.

The start of the sequence unique to the type 3 serotype is the aspartic acid (D) residue at position 216. Secondary features are shown in the annotated amino acid sequence of lipB sOspA 5/3 in Figure 6 and include:

- stabilizing mutations described in International Patent Application No. WO 02/16421A2 (Luft and Dunn): methionine (M) instead of an arginine (R) at amino acid 136; tyrosine (Y) instead of a glutamic acid (E) at amino acid 157; and methionine (M) instead of a lysine (K) at amino acid 187; and
- like lipB sOspA 1/2<sup>251</sup> and lipB sOspA 6/4, described above, an OspB leader sequence was used (amino acids 1 to 15 in Figure 6) and amino acids 16-25 are identical to sequence from OspB (GenBank Accession No. X74810).

**[00305]** Although the peptide sequence KEKNKD (SEQ ID NO:27) was absent from the parent OspA type 5 sequence (KEKDKD) (SEQ ID NO: 28), the aspartic acid (D) residue at position 46 was replaced with an asparagine residue (N) in conformity with an equivalent change made in the lipB sOspA 1/2<sup>251</sup> construct giving the sequence KEKDKN (SEQ ID NO:25).

**[00306]** Although the peptide sequence KADKSK (SEQ ID NO:29) was absent from the parent OspA type 5 sequence (KTDKSK) (SEQ ID NO: 30), the aspartic acid (D) residue at position 79 was replaced with an asparagine residue (N) in conformity with an equivalent change made in the lipB sOspA 1/2251 construct giving the sequence KTNKSK (SEQ ID NO: 26).

**[00307]** The nucleotide and deduced amino acid sequences of lipB sOspA 5/3 are shown in Figure 7. The leader sequence (green) is cleaved off during protein secretion. The sequence of the mature OspA protein starts with a cysteine codon (underlined, see Figure 7), which forms the attachment site for the protein's lipid anchor.

#### **EXAMPLE 6:**

##### **OPTIMIZATION OF CODON USAGE FOR HIGH LEVEL EXPRESSION IN *E. COLI***

**[00308]** Because the presence of codons that are rarely used in *E. coli* is known to present a potential impediment to high-level expression of foreign genes, low-usage codons were replaced with codons which are used by highly expressed genes in *E. coli*. The nucleotide sequences of the novel OspA genes were designed to

utilize the codons found most frequently (preferred codons) among the highly expressed class II, *E. coli* genes (Guerdoux-Jamet et. al., *DNA Research* 4:257-65,1997). The data for codon usage among the novel OspA genes and for the highly expressed class II *E. coli* genes are summarized in Tables 7 and 8. The data for the less frequent amino acids for which tRNA molecules are less likely to be rate limiting is presented separately (Table 7) from the data for the amino acids which occur most often (Table 8).

**Table 7. Codon usage in novel OspA genes (less common amino acids\*)**

Amino Acid	Codon	OspA 1/2 AA Counts			OspA 5/3 AA Counts			OspA 6/4 AA Counts			Class II Counts (%)
		Total	Codon	%	Total	Codon	%	Total	Codon	%	
Gln	CAA	5	1	20.0	4	0	0.0	4	0	0.0	18.7
	CAG		4	80.0		4	100.0		4	100.0	81.4
Phe	TTT	5	1	20.0	6	3	50.0	6	1	16.7	29.1
	TTC		4	80.0		3	50.0		5	83.3	70.9
Met	ATG	4	4	100.0	5	5	100.0	4	4	100.0	100.0
Tyr	TAT	4	1	25.0	4	1	25.0	4	0	0.0	35.2
	TAC		3	75.0		3	75.0		4	100.0	64.8
Arg	CGT	2	2	100.0	3	3	100.0	2	2	100.0	64.3
	CGC		0	0.0		0	0.0		0	0.0	33.0
	CGA		0	0.0		0	0.0		0	0.0	1.1
	CGG		0	0.0		0	0.0		0	0.0	0.8
	AGA		0	0.0		0	0.0		0	0.0	0.6
	AGG		0	0.0		0	0.0		0	0.0	0.3
Cys	TGT	1	0	0.0	1	1	100.0	1	0	0.0	38.9
	TGC		1	100.0		0	0.0		1	100.0	61.2
Pro	CCT	1	0	0.0	2	0	0.0	1	0	0.0	11.2
	CCC		1	100.0		1	50.0		1	100.0	1.6
	CCA		0	0.0		0	0.0		0	0.0	15.3
	CCG		0	0.0		1	50.0		0	0.0	71.9
Trp	TGG	1	1	100.0	1	1	100.0	1	1	100.0	100.0

\* i.e. Amino acids that, individually, make up <2.5% of the total amino acids by number.

**Table 8. Codon usage in novel OspA genes (more prevalent amino acids)**

Amino Acid	Codon	OspA 1/2 AA Counts			OspA 5/3 AA Counts			OspA 6/4 AA Counts			Class II Counts (%)
		Total	Codon	%	Total	Codon	%	Total	Codon	%	
Lys	AAA	40	30	75.0	40	36	90.0	40	37	92.5	78.6
	AAG		10	25.0		4	10.0		3	7.5	21.5
Thr	ACT	32	13	40.6	31	15	48.4	34	7	20.6	29.1
	ACC		14	43.8		16	51.6		27	79.4	53.6
	ACA		0	0.0		0	0.0		0	0.0	4.7
	ACG		5	15.6		0	0.0		0	0.0	12.7
Leu	CTT	27	3	11.1	28	2	7.1	28	1	3.6	5.6
	CTC		3	11.1		0	0.0		4	14.3	8.0
	CTA		0	0.0		0	0.0		0	0.0	0.8
	CTG		17	63.0		21	75.0		18	64.3	76.7
	TTA		2	7.4		2	7.1		3	10.7	3.4
	TTG		2	7.4		3	10.7		2	7.1	5.5
Ser	TCT	25	9	36.0	25	12	48.0	23	8	34.8	32.4
	TCC		8	32.0		3	12.0		8	34.8	26.6
	TCA		0	0.0		0	0.0		0	0.0	4.8
	TCG		0	0.0		0	0.0		0	0.0	7.4
	AGT		0	0.0		0	0.0		0	0.0	4.5
	AGC		8	32.0		10	40.0		7	30.4	24.3
Gly	GGT	22	11	50.0	23	8	34.8	22	9	40.9	50.8
	GGC		11	50.0		14	60.9		13	59.1	42.8
	GGA		0	0.0		0	0.0		0	0.0	2.0
	GGG		0	0.0		1	4.3		0	0.0	4.4
Val	GTT	22	8	36.4	15	6	40.0	18	7	38.9	39.8
	GTC		4	18.2		0	0.0		4	22.2	13.5
	GTA		3	13.6		9	60.0		3	16.7	20.0
	GTG		7	31.8		0	0.0		4	22.2	26.8
Glu	GAA	21	16	72.7	22	18	81.8	21	18	85.7	75.4
	GAG		5	23.8		4	18.2		3	14.3	24.7
Asp	GAT	17	8	47.1	16	9	56.3	19	8	42.1	46.1
	GAC		9	52.9		7	43.8		11	57.9	54.0
Ala	GCT	16	6	37.5	18	9	50.0	17	6	35.3	27.5
	GCC		0	0.0		1	5.6		4	23.5	16.1
	GCA		5	31.3		6	33.3		3	17.6	24.0
	GCG		5	31.3		2	11.1		4	23.5	32.3
Asn	AAT	13	3	23.1	13	3	23.1	13	2	15.4	17.3
	AAC		10	76.9		10	76.9		11	84.6	82.8
Ile	ATT	12	4	33.3	13	5	38.5	13	3	23.1	33.5
	ATC		8	66.7		8	61.5		10	76.9	65.9
	ATA		0	0.0		0	0.0		0	0.0	0.6

**[00309]** The high degree of concordance between codon usage chosen for the novel OspA genes (common amino acids only) and among *E. coli* class II genes is apparent (i.e. plot of percentage figures from Table 8 for class II genes against individual novel OspA genes; see Figure 8). For the three lipidated constructs, the original sequences had a GC content ranging from 32.8% to 33.8%, while the codon-optimized sequences had a GC content ranging from 43.8% to 46.8%, which is similar to the 50% GC content of *E. coli*.

**EXAMPLE 7:****CONSTRUCTION OF SYNTHETIC NON-LIPIDATED OSPA GENES**

**[00310]** Constructs were also prepared which did not contain the lipB leader sequence. The two sets of constructs (lipidated and non-lipidated) are needed to evaluate their ease of production in the fermentor (biomass, stability, product yield, and the like), to assess how readily the different types of antigen can be purified and to compare their biological characteristics (safety profile and protective potency).

**[00311]** The constructs (SEQ ID NOS: 7, 9, and 11) were generated by PCR amplification from each of the three lipB OspA constructs (SEQ ID NOS: 1, 3, and 5) using PCR primers with incorporated restriction sites. The PCR products were purified, digested with *Nde* I and *Bam*H I and ligated to digested pET30a vector DNA. The ligation mixes were used to transform *E. coli* DH5 $\alpha$  and the OspA sequences were verified. Miniprep DNA was prepared, isolated, and used to transform HMS 174(DE3) host cells. The sequences of the non-lipidated derivatives are identical to the lipidated versions, except they lack the first 45 base pairs coding for the leader sequence and contain an *Nde* I site which contains a methionine codon which replaces the cysteine codon in the lipidated versions (see Figure 9).

**EXAMPLE 8:****EXPRESSION OF NOVEL RECOMBINANT OSPA ANTIGENS**

**[00312]** To express/produce the novel recombinant OspA genes for antigenic purposes, an *E. coli* expression system controlled by the bacteriophage T7 RNA polymerase (Studier et al., *J. Mol. Biol.* 189:113-30, 1986) was used. In this expression system, the novel OspA genes were cloned into the multiple cloning site in one of the pET series of plasmids (e.g., pET30a). Because expression of the foreign gene is under the control of a bacteriophage T7 promoter, which is not recognized by *E. coli* RNA polymerase, expression is dependent on a source of T7 RNA polymerase. This enzyme is provided when the recombinant plasmids are transferred into an appropriate expression host, such as *E. coli* HMS174(DE3), which contains a chromosomal copy of the T7 RNA polymerase gene. Expression of the chromosomally integrated T7 RNA polymerase gene is under control of a lacUV5 promoter, which can be switched on (i.e. induced) by the addition of isopropyl  $\beta$ -D-1-



thiogalactopyranoside (IPTG) or lactose (see Figure 10). Consequently, expression of the foreign gene is also regulated by the addition of the inducer molecule.

**[00313]** The cells were induced at late log-phase and harvested 3-4 hours after induction. In induced cells, the chimeric OspA antigen was the most highly expressed protein as determined by SDS-PAGE of cell lysates. Most of the OspA chimeras were found in the supernatant. Contaminating *E. coli* proteins were removed by anion-exchange chromatography and the chimeric OspA proteins eluted in the void volume were concentrated by ultrafiltration.

**[00314]** The expression of the novel recombinant OspA proteins from each of the constructs was tested, and samples from induced and un-induced cultures were run on an SDS polyacrylamide gel (Figure 11). For the lipidated (SEQ ID NOS: 2, 4, and 6) and non-lipidated (SEQ ID NOS: 8, 10, and 12) antigens, a band of approximately 31 kDa was observed in each case (see Figure 11). The proteins were characterized and the molecular weights determined correlated (+/- 0.5 daltons) with the theoretical molecular weights assuming the terminal methionine is cleaved off. Figure 11 shows that the expressed recombinant lipidated OspA proteins comprise at least 10% of the total protein yield, verifying that the constructs are useful for their intended purpose.

#### **EXAMPLE 9:**

##### **A SINGLE RECOMBINANT OSPA ANTIGEN (R OSPA 1/2) PROTECTS AGAINST INFECTION WITH *B. BURGDORFERI* S.S. AND *B. AFZELII***

**[00315]** The purpose of this study was to determine if a single recombinant antigen (rOspA 1/2; the polypeptide comprising SEQ ID NO: 2 (lipB sOspA 1/2<sup>251</sup>)), designed to retain the protective properties of OspA serotypes 1 and 2, is able to induce antibody responses which protect mice against infection with either *B. burgdorferi* s.s. (OspA serotype 1) or *B. afzelii* (OspA serotype 2). Evidence is provided to show that the inclusion of additional rOspA antigens did not have an antagonistic effect on the protective immunity afforded by the rOspA 1/2 antigen.

**[00316]** *Design and construction of rOspA 1/2.* To eliminate the risk of introducing adventitious agents, complementary overlapping synthetic oligonucleotides were used to generate DNA fragments that were ligated together and cloned into vector

pET30a and the sequence was verified. This approach also enabled codon usage to be optimized for the *E. coli* host HMS174 (DE3) used to express the OspA gene. The novel gene is based on the proximal portion of a serotype-1 OspA sequence (amino acids 29 to 218, Strain B31; GenBank Accession Number X14407) fused to the distal portion of a serotype-2 sequence (amino acids 219 to 273, Strain PKo; Accession Number S48322). The 25 amino acid fragment from *B. burgdorferi* strain B31 (aa 164 to 188) was replaced with sequence from *B. afzelii* strain PKo (aa 164 to 188) because this region of the B31 OspA (aa 165-173) is highly related to the region encompassing the hLFA-1 epitope (aa 332-340). The N-terminal sequence including the leader sequence and the first 11 amino acids were derived from OspB (Strain B31; GenBank Accession Number X74810) in order to optimize lipidated protein expression. Other specific amino acid changes were made to improve the immunogenicity and conformational stability of the rOspA 1/2 molecule and the sequence of rOspA 1/2 (lipB sOspA 1/2<sup>251</sup>) is set out in SEQ ID NO: 2.

**[00317]** *Animal testing.* The ability of a single recombinant OspA antigen (rOspA 1/2) to prevent infection with two species of *Borrelia*, which express different OspA antigens, was assessed in C3H/HeJ mice immunized subcutaneously (days 0 and 28) with purified OspA antigen (0.1µg or 0.03µg doses) formulated with 0.2% (w/v) aluminum hydroxide as adjuvant. Mice were challenged 2 weeks after the booster immunization, either by intradermal injection (needle challenge;  $7 \times 10^4$  cells) or by the natural route of infection (tick challenge). For the latter experiments, 8 nymphal ticks were applied per mouse and allowed to feed for up to 5 days. The nymphs were collected in the vicinity of Budweis (Czech Republic), an area endemic for Lyme disease. The majority of these ticks were infected with *B. afzelii* as determined by testing unfed ticks by PCR. The infectious status of the mice was determined four weeks later. In the tick challenge experiments, the presence of *Borrelia* was confirmed by culture (urinary bladder) and by detection of *Borrelia* DNA by real-time PCR (heart). Animal experiments were conducted in accordance with Austrian laws on animal experimentation and international guidelines (AAALAC and OLAW) and were reviewed by the Institutional Animal Care and Use Committee and approved by the Austrian regulatory authorities. Immunogenicity. The antibody response (µg IgG/ml) to rOspA 1/2 antigen was determined by ELISA using rOspA 1/2 as the

coating antigen and an OspA specific monoclonal antibody (prepared in house) with a defined IgG content as a standard.

**[00318]** *Diagnostic procedures.* For the needle challenge experiments, the presence of antibodies to a conserved epitope in the surface-exposed lipoprotein VlsE protein (C6 ELISA; coated plates from Immunetics® C6 Lyme ELISA™) or to *Borrelia* antigens other than the OspA immunogen (Western blotting) was used to diagnose infection. Western blotting used a cell lysate prepared from *B. burgdorferi* s.s. strain ZS7 as this was the challenge organism. Animals were deemed infected if they were positive in both assays.

**[00319]** For the tick challenge experiments, the C6 ELISA and Western blotting were also done. However, Western blotting used lysates from *B. burgdorferi* s.s. ZS7, *B. afzelii* ACA1 and *B. garinii* KL11, because the identity of the infecting organism was unknown. Animals were considered to have undergone seroconversion only if both assays were positive. In addition, *Borrelia* infection was assessed by culture from the urinary bladder and by detection of *B. burgdorferi* s.l. nucleic acids in genomic DNA extracted from heart tissue using a real-time PCR assay targeting the 5'-region of OspA and a 16S rRNA gene-based assay. Animals were scored as PCR-positive only if a PCR product was detected with both assays. Overall, to judge an animal as infected, mice needed to be positive either by culture, PCR or serology.

**[00320]** *Characterization of infecting Borrelia.* Where possible, the infecting organism was cultured and the OspA sequence and deduced amino acid sequence determined for OspA residues 38–262 (*B. afzelii* VS461, GenBank Accession Number Z29087). This information was compared to OspA reference sequences so that the OspA type and *Borrelia* species could be inferred. For species which express a single OspA serotype, the OspA sequence for the type strain for the species was chosen as a reference, e.g., *B. afzelii* VS461 or *B. valaisiana* VS116 (GenBank Accession Number Z29087; AF095940). As *B. garinii* has multiple OspA types, OspA sequences for OspA genotypes 3-7 were used (i.e. strains PBr, PTrob, WABSou, TIsI and T25; GenBank Accession Numbers X80256, X80186, X85441, X85440 and X80254, respectively). For real-time PCR-based typing, sequence alignments of the OspA gene of 124 *B. burgdorferi* s.l. species deposited in GenBank were inspected for serotype-specific sequences and suitable primer-probe

combinations were designed using Primer Express 3.0 (Applied Biosystems). All assays were run on an ABI Prism® 7900HT sequence detection unit using universal cycling conditions.

**[00321]** *Prevention of B.burgdorferi s.s (OspA serotype-1) infection by immunization with rOspA 1/2.* All of the mice immunized with low doses of two different lots of the rOspA 1/2 antigen developed IgG antibodies specific for the immunogen as determined by ELISA. No antibodies were detected in the control mice which had been treated with vaccine formulation buffer containing aluminum hydroxide. To assess the ability of this immune response to prevent infection with *B. burgdorferi s.s.*, a species that encodes a serotype-1 OspA, the mice were injected intradermally with  $7 \times 10^4$  cells of *B. burgdorferi s.s.* strain ZS7. All of the control mice treated with buffer containing adjuvant showed serological evidence of infection as demonstrated by C6 ELISA and by Western blotting. None of the mice immunized with the rOspA 1/2 antigen became infected and the sera from these mice were negative by both assays. As little as 0.03µg of the rOspA 1/2 antigen, when formulated with aluminum hydroxide as adjuvant and administered in a two dose immunization regimen, conferred 100% protection ( $P < 0.0001$ , Fisher exact two tailed test) against a needle challenge with the virulent *B. burgdorferi s.s.* strain ZS7.

**[00322]** *Prevention of B. afzelii (OspA serotype-2) infection by immunization with rOspA 1/2.* To assess the ability of immunization with the rOspA 1/2 antigen to prevent infection with *B. afzelii*, a species that encodes a serotype-2 OspA, mice were immunized, in two separate experiments, with the same antigen lots and study design as used in the needle challenge experiment described above. However, in this case, the immunized mice were challenged with feral ticks (nymphs) known to be infected mainly with *B. afzelii*. The ability of these feral ticks to transmit *B. burgdorferi s.l.* to mice was confirmed by challenging non-immunized control animals.

**[00323]** Most of the control mice (total 11/14, 79%) became infected. All infected control animals were positive for *Borrelia* DNA by two independent real-time PCR assays (16S rRNA and OspA genes). In 10/11 cases, it was possible to isolate *Borrelia* by culture of the urinary bladder. The remaining mouse was positive by serology and PCR. For 9 of the 10 culture isolates, OspA sequences were retrieved

and all were typed as *B. afzelii* (> 99% OspA sequence identity). Furthermore, all infecting organisms were typed as *B. afzelii* by PCR analysis of the DNA extracted from the heart using a real-time PCR assay specifically targeting serotype 2 OspA genes. These data confirm that *B. afzelii* was the principal *Borrelia* species being transmitted from the infected feral ticks to their mouse host.

**[00324]** Few of the mice immunized with rOspA 1/2 (total 3/32, 9%) became infected. Of these three mice, one was infected as determined by all three diagnostic criteria (serology, PCR and culture) and sequence analysis revealed that the infecting organism was *B. garinii* serotype-6 (> 99% OspA sequence identity). The remaining two animals deemed infected were positive by only two of the three criteria. One mouse was positive by serology and PCR. However, the infecting organism could not be retrieved in culture. Nevertheless, this organism could be typed as *B. garinii* serotype-7 by PCR analysis of the DNA extracted from the heart using PCR specific for the serotype-7 OspA gene. The third mouse was PCR and culture positive but serologically negative. The isolate cultured from this mouse was *B. valaisiana* as determined by sequencing (OspA sequence identity with *B. valaisiana* strain VS116). Importantly, none of the immunized mice (0/32) became infected with *B. afzelii*. As little as 0.03µg of the rOspA 1/2 antigen, when formulated with aluminum hydroxide as adjuvant and administered in a two dose immunization regimen, conferred full protection against *B. afzelii* transmitted by feral ticks.

**[00325]** *Conclusion.* A single recombinant outer surface protein A (OspA) antigen designed to contain protective elements from two different OspA serotypes (1 and 2) was able to induce antibody responses which protect mice against infection with either *B. burgdorferi sensu stricto* (OspA serotype-1) or *B. afzelii* (OspA serotype-2). Protection against infection with *B. burgdorferi s.s.* strain ZS7 was demonstrated in a needle challenge model. Protection against *B. afzelii* species was shown in a tick challenge model using feral ticks. In both models, as little as 0.03µg of antigen, when administered in a two dose immunization schedule with aluminum hydroxide as adjuvant, was sufficient to provide complete protection against the species targeted. As anticipated, the protection afforded by this novel antigen did not extend to other *Borrelia* species as demonstrated by the antigen's inability to provide protection against infection with *B. garinii* and *B. valaisiana* strains. This proof of principle study proves that knowledge of protective epitopes can be used for the

rational design of effective, genetically-modified vaccines requiring fewer OspA antigens and suggests that this approach may facilitate the development of an OspA vaccine for global use.

#### **EXAMPLE 10:**

#### **EFFICIENCY OF MOUSE ANTI-OSPA ANTIBODIES TO BIND TO THE SURFACE OF LIVE *BORRELIA* OR TO INHIBIT GROWTH THEREOF CORRELATES WITH PROTECTION AGAINST NEEDLE CHALLENGE USING *A B. BURGDORFERI S.S. TYPE 1 STRAIN***

**[00326]** The purpose of this study was to establish correlates of protection for mice immunized with the rOspA 1/2 antigen in a needle challenge model using a *Borrelia burgdorferi sensu stricto* OspA type 1 strain. Parameters analyzed were the potency of anti-OspA antibodies to bind to the surface of live *Borreliae* or to inhibit growth of *Borreliae*.

**[00327]** 98 mice were deliberately immunized with a sub-optimal 3 ng dose of the rOspA 1/2 antigen adjuvanted with 0.2% Al(OH)<sub>3</sub>, which was 10-fold lower than the lower dose used in Example 9, in a prime-booster regimen so that, upon challenge, both protected and infected animals would be observed. Vaccination was carried out subcutaneously using a dose volume of 100 µl on days 0, 14 and 28. On day 38, pre-challenge sera samples were taken from 96 mice, and animals were challenged 10 days later with 19.4 x ID<sub>50</sub> of culture grown *B.burgdorferi s.s.* ZS7, and infection status was determined after four weeks. 71 of the 96 mice (72%) were found to be protected after immunizing with this low dose of antigen.

**[00328]** Four weeks post-challenge blood was taken to identify infected mice by Western blotting their sera against a membrane fraction of *B.burgdorferi s.s.* strain ZS7. At the challenge doses used, only infected mice had an antibody response to membrane antigens of strain ZS7 other than OspA (the response to OspA, induced by vaccine, was not scored).

**[00329]** *Quantitation of OspA antibody binding to the surface of live Borreliae.* In this assay, *B. burgdorferi s.s.* strain B31 expressing OspA types 1 were incubated at a fixed dilution (1:100) with the pre-challenge mouse sera at room temperature in the presence of EDTA to prevent complement activation. After washing to remove

unbound antibody, antibodies that were specifically bound to the cell surface were labeled by incubating the treated cells with an r-Phycoerythrin-conjugated anti-mouse Ig polyclonal antibody. Subsequently, a DNA stain (LDS-751) that emits red fluorescence, thereby enhancing detection, was used, and bacteria were then analyzed by flow cytometry (FACSCalibur, Beckton-Dickinson). The fluorescence intensity, which correlates with the number of antibody molecules attached to the cell surface, was recorded for at least 2,000 individual *Borreliae*, and the mean of the fluorescence intensities (MFI) was calculated. Normal mouse serum served as the negative control to evaluate the extent of non-specific surface binding of antibodies, while an OspA serotype 1-specific mAb served as a positive control to confirm the identity of the OspA type and to verify the level of OspA expression of the cells in the bacterial culture.

**[00330]** *A bacterial growth inhibition assay.* To measure the potency of the pre-challenge sera to inhibit growth of the *Borreliae*, *B. burgdorferi* s.s. strain B31 expressing OspA type 1 was cultured at 33°C in the presence of serial dilutions of heat-inactivated pre-challenge or non-immune mouse serum (negative control) in the presence of complement (normal guinea pig serum). When the bacteria in the control cultures incubated with non-immune sera had grown sufficiently, as determined microscopically, accurate cell counts were made by flow cytometric analysis. Cell cultures were mixed with a solution containing a defined number of fluorescence-labeled beads and a DNA-dye was added to fluorescently label the *Borrelia* cells. Samples were processed using a FACSCalibur Flow cytometer until 100 beads were counted, and the absolute cell concentrations were calculated (cells/ml) by comparing the numbers of events in the gate defining the beads and in the gate defining the *Borreliae*. The serum dilution that inhibited bacterial growth by 50% was calculated in comparison to the NMS control and reported as GI-50 titer. A standard serum preparation was used to normalize titers between different assays. Distribution of the measured serum parameters were compared among infected and protected animals by the non-parametric Mann-Whitney U test (*Graphpad Prism Vers. 5.0*).

**[00331]** Results of this study (see Figure 19) clearly demonstrate that a highly significant correlation exists between the functional antibody content of the immune serum at the time of challenge and protection against infection with a high dose (19.4

x ID<sub>50</sub>) needle challenge of *B. burgdorferi* s.s. (ZS7). FACS -based fluorescence intensity measurements of live *Borreliae* expressing OspA type 1, which reflects the number of anti-OspA antibody molecules attached to the cell surface, carried out after incubation of the bacteria with the pre-challenge sera at a fixed dilution, correlated best with protection ( $p < 0.0001$  Mann-Whitney U test). However, growth inhibition titers also correlated highly significantly with protection ( $p = 0.0002$  Mann-Whitney U test, Figure 19).

#### **EXAMPLE 11:**

#### **EFFICIENCY OF MOUSE ANTI-OSPA ANTIBODIES TO BIND TO THE SURFACE OF LIVE *BORRELIA* OR TO INHIBIT GROWTH CORRELATES WITH PROTECTION AGAINST TICK CHALLENGE USING A *B. AFZELII* TYPE 2 STRAIN**

**[00332]** The purpose of this study was to establish correlates of protection of mice immunized with the chimeric OspA 1/2 antigen in a tick challenge model, which utilizes the natural infection route by using feral ticks collected from Budweis in the Czech Republic to infect the mice. Since nymphal ticks from this endemic area are so predominantly infected with *B. afzelii*, they are considered to provide a *B. afzelii* OspA type 2 strain challenge. As set out in Example 10, the parameters analyzed were the potency of anti-OspA antibodies to bind to the surface of live *Borreliae* or to inhibit growth of *Borreliae*, both of which had been shown to correlate well against needle challenge with *Borrelia burgdorferi* s.s. Thus, this study serves to extend the applicability of using these two parameters as correlates of protection against natural infection of *B. afzelii*, the most prominent human disease associated genospecies in Europe.

**[00333]** Forty mice were immunized with a sub-optimal 3 ng dose of the rOspA 1/2 antigen adjuvanted with 0.2% Al(OH)<sub>3</sub>, which was 10-fold lower than the lower dose used in Example 9, in a prime-booster regimen. As in Example 10, this sub-optimal dose was chosen in order to ensure that both protected and infected animals would be observed after challenge. Vaccination was carried out subcutaneously using an injection volume of 100 µl on days 0, 14 and 28. On day 40, individual blood samples were taken from the mice to generate pre-challenge sera. Because the limited number of ticks available did not allow the challenge of all 40 mice, 20



mice were selected based on surface binding and anti-type 2 IgG concentrations to cover a broad range of responses. Eight ticks were applied to each mouse and were allowed to feed on the mice for 5 days. Four weeks after the challenge, the mice were sacrificed and the infectious status of the immunized and control mice was determined by Western blotting of sera against membrane antigens from *B. burgdorferi* s.s., *B. afzelii* and *B. garinii*; culture of *Borrelia* organisms from the bladder; and real time PCR detection of *Borrelia* from DNA extracted from the bladder.

**[00334]** *Quantitation of OspA antibody binding to the surface of live Borreliae.* In this assay, *B. afzelii* strain Arcon expressing OspA type 2 was incubated at a fixed dilution (1:100) with the pre-challenge mouse sera at room temperature in the presence of EDTA to prevent complement activation. After washing to remove unbound antibody, antibodies specifically bound to the cell surface were labeled by incubating the treated cells with an r-Phycoerythrin-conjugated anti-mouse Ig polyclonal antibody. All subsequent steps in the assay were similar to those described in Example 10. Normal mouse serum served as the negative control for non-specific antibody binding. A high titer mouse serum raised against the tri-component rOspA vaccine formulation, together with OspA serotype 2-specific mAbs served as positive controls to confirm OspA serotype specificity and the OspA expression level of cells in the bacterial culture.

**[00335]** *Bacterial growth inhibition assay.* To measure the potency of the pre-challenge sera to inhibit growth of *Borreliae*, the *B. afzelii* strain Arcon expressing OspA type 2 was cultured at 33°C in the presence of serial dilutions of heat-inactivated pre-challenge or non-immune mouse serum (negative control) without complement. When the bacteria in the control cultures, which were incubated with non-immune sera, had grown sufficiently, as determined microscopically, accurate cell counts were made by flow cytometric analysis. The procedure used to count the bacteria was similar to that previously described for the growth inhibition assay in Example 10. The serum dilution which inhibited bacterial growth by 50% was calculated in comparison to the NMS control and reported as GI-50 titer. A standard serum preparation was used to normalize titers between different assays.

**[00336]** *Statistical analysis.* Distribution of the measured serum parameters were compared in infected and protected animals by the non-parametric Mann-Whitney U test (Graphpad Prism Version 5.0).

**[00337]** *Results.* Of the 20 animals immunized three times with 0.003 pg of rOspA 1/2 and challenged with 8 feral ticks, 7/20 (35%) were found to be infected. Due to limited tick availability, it was not possible to determine the exact infection rate of the challenge by challenging a control group of non-immunized mice. However, this challenge was not required for the purpose of the present study, and typically a rate of infection of 70-80% is achieved in challenge experiments with feral ticks from Budweis.

**[00338]** Significant differences were detected between the protected and infected groups for the results of the surface binding ( $p = 0.007$ ) and growth inhibition ( $p = 0.03$ ) assays (Figure 20).

**[00339]** *Conclusion.* In this study it has been shown that a statistically significant correlation exists between the functional antibody content in mouse serum at the time of challenge and the protection against infection with a feral tick challenge applying 8 ticks per mouse. FACS-based fluorescence intensity measurements of live *Borreliae* expressing OspA type 2, which reflects the number of anti-OspA antibody molecules attached to the cell surface performed after incubation of the bacteria with the pre-challenge sera at a fixed dilution, correlated best with protection. Growth inhibition titers also correlated well with protection. In contrast to *Borrelia burgdorferi* s.s. strains, where complement is required for efficient killing, rOspA1/2 antigen induced antibodies that effectively inhibit *Borrelia* growth even in the absence of complement.

**[00340]** The results of the studies presented in Example 10 and 11, when taken together, establish the *in vitro* parameters of the mean fluorescent intensity (MFI) of surface bound antibody to live *Borreliae* and the GI-50 titer of immune mouse sera as “correlates of protection” in both examples where active mouse protection models are currently available (e.g., namely, a needle challenge model for *B. burgdorferi* s.s. OspA Type 1 strains and a tick challenge model for *B. afzelii* OspA Type 2 strains. Moreover, in the absence of reliable active protection models for evaluating protection against homologous *B. garinii* strains expressing OspA types 3-6, by

inference, the aforementioned models can be used as *in vitro* “surrogate markers of protection” to evaluate the protective potential and cross strain coverage of various vaccine formulations for strains expressing all the vaccine homologous OspA types and even for those expressing heterologous OspA types. Indeed, when studies using these functional immune response assays were carried out on immune sera from mice immunized with the 3-component chimeric rOspA vaccine formulation, then comparable MFI and GI-50 titers were obtained for *B. garinii* (OspA types 3, 4, 5, 6) (see Examples 13), thus indicating, through these surrogate markers of protection, that protective responses were also achieved against strains for which currently no active mouse protection model exists. Furthermore, by comparing the immune responses of mice immunized with either (a), individual chimeric rOspA antigens; (b), or any one of the possible 2-component chimeric rOspA antigen vaccine formulation combinations; or (c), the 3-component chimeric rOspA antigen formulation, it was possible to show that the latter 3-component vaccine was required to optimally cover strains expressing OspA types 1-6 (Example 14). Moreover, through the use of these *in vitro* surrogate marker assays, it was possible to show that immune responses produced after immunizing mice with the 3-component chimeric rOspA vaccine formulation (rOspA 1/2, rOspA 6/4 and rOspA 5/3) do induce functional immune responses to all intra type variants (or subtypes) of types 1, 2, 3, 5, and 6 tested to date (see Example 15) and even to heterologous OspA types, other than the homologous OspA types 1-6 present within the vaccine (see Example 16).

#### **EXAMPLE 12:**

##### **MULTIVALENT RECOMBINANT OSPA FORMULATION COMPRISING 3 ANTIGENS (1/2, 6/4, AND 5/3) IS HIGHLY IMMUNOGENIC IN MICE**

**[00341]** A multivalent OspA vaccine (rOspA 1/2, rOspA 5/3, and rOspA 6/4) was evaluated in a tick challenge model. Three recombinant OspA antigens containing the protective epitopes from OspA serotype 1 and 2 (SEQ ID NO: 2), OspA serotype 6 and 4 (SEQ ID NO: 4), and OspA serotype 5 and 3 (SEQ ID NO: 6) were combined in a vaccine.

**[00342]** Groups of ten female C3H/HeJ mice (age at immunization: 11 weeks) were immunized subcutaneously on days 0 and 28 with a fixed dose of 0.3 µg of the

multivalent vaccine (0.1 µg of each, rOspA 1/2, rOspA 5/3, and rOspA 6/4). The tick challenge was done as described herein above with ticks from Budweis, Czech Republic. The ability of the feral ticks to transmit *B.burgdorferi s.l.* to mice was confirmed by challenging un-immunized control animals. The infection status of the challenged mice was determined by Western blotting, real-time PCR, and by culture.

**[00343]** Interim blood samples were taken on day 41 by orbital puncture. Final blood samples (day 70/71) were collected by heart puncture. Individual sera were prepared from whole blood by centrifugation (10 minutes; 1000-2000xG; RT). Sera were stored at ≤ - 20 °C until use.

**[00344]** In this experiment unfed ticks, taken from the same batch used to challenge the mice, were characterized to determine the overall infection rate and to confirm the species of the infecting organisms. When 80 nymphal ticks were tested for the presence of *B.burgdorferi s.l.* DNA by 16S rRNA real-time PCR, 32.5% (26/80) were found to be infected. The OspA-serotype could be determined by PCR-ELISA for 22 of the 26 infected nymphs; 86% (19/22) were typed as *B. afzelii* and 14% (3/22) as *B.burgdorferi s.s.*

**[00345]** All of the non-immunized control mice (100%; 10/10) became infected, whereas only one of the mice immunized with the multivalent rOspA vaccine became infected (10%; 1/10). There was 100% agreement between the different methods used to identify infected mice. The multivalent rOspA vaccine resulted in a statistically highly significant protection ( $p=0.00012$ ; Fisher's exact two tailed test) when compared to the control group.

**[00346]** These data show that immunization with a multivalent rOspA vaccine, which contains the rOspA 1/2 antigen, is able to prevent infection with *B. afzelii*, a *Borrelia* species which expresses a serotype 2 OspA. Further, there is no evidence that the inclusion of additional rOspA antigens has an antagonistic effect on the protective immunity afforded by the rOspA 1/2 antigen.

**[00347]** This vaccine provided protection against tick-transmitted infection with *B. afzelii* which was equivalent to that seen with the OspA 1/2 antigen; 0.3 µg of the vaccine (0.1 µg of each antigen) formulated with 0.2% Al(OH)<sub>3</sub> and administered in a two dose schedule provided 90% protection as determined by Western blot, culture of *Borrelia* and detection of *Borrelia* DNA by PCR.

**EXAMPLE 13:****A VACCINE COMPRISING THE THREE-COMPONENT VACCINE (OSPA 1/2, OSPA 6/4, AND OSPA 5/3) INDUCES HIGH LEVELS OF FUNCTIONAL ANTI-OSPA ANTIBODIES WHICH BIND TO AND INHIBIT GROWTH OF *BORRELIA* STRAINS EXPRESSING OSPA TYPES 1-6**

**[00348]** Since both surface binding (MFI) and growth inhibition (GI-50 titers) were shown to be good correlates of protection in a needle challenge (*B. burgdorferi* s.s.) model (Example 10) and in a tick challenge (*B. afzelii*) mouse model (Example 11), the present study was undertaken to determine if equivalent functional immune responses are induced by the 3-component chimeric rOspA antigen vaccine formulation against *B. garinii* OspA serotypes 3-6, for which no *in vivo* protection model is available to investigate the efficacy of a vaccine.

**[00349]** *Mouse immunization.* Groups of 10 female C3H/HeJ mice were immunized subcutaneously three times (day 0, day 14, day 28) with a 1:1:1 mixture of rOspA-1/2, rOspA-6/4 and rOspA-5/3) at three different doses (1, 0.1, 0.03 µg protein per dose) combined with 0.2% Al(OH)<sub>3</sub> as an adjuvant. Serum was generated from blood samples taken on day 40.

**[00350]** Quantitation of OspA antibody binding to the surface of live *Borreliae*. In this assay, in vitro grown cultures of six representative *Borrelia* strains expressing OspA types 1-6 (*B. burgdorferi* sensu stricto B31/OspA-1; *B. afzelii* Arcon/OspA-2; *B. garinii* PBr/OspA-3; *B. garinii* DK6/OspA-4; *B. garinii* W/OspA-5; and *B. garinii* KL11/OspA-6) were incubated at a fixed dilution (1:100) with pools of the peak titer mouse sera at room temperature in the presence of EDTA to prevent complement activation. The subsequent washing, labeling, detection and analysis procedures were similar to those described in Example 10. Normal mouse serum served as the negative control for non-specific binding of antibodies.

**[00351]** *Bacterial growth inhibition assay.* To measure the potency of the pre-challenge sera to inhibit growth of *Borreliae*, six representative strains expressing OspA types 1-6 (B31, Arcon, PBr, DK6, W, and KL11) were cultured at 33°C in the presence of serial dilutions of heat-inactivated peak titer serum pools or non-immune mouse serum (negative control). B31 was cultured in the presence of complement (guinea pig serum), while the other five strains were tested in the absence of

complement. Once again, growth inhibition assays were carried out as described in Example 10. A standard serum preparation was used to normalize titers between different assays.

**[00352]** *Surface binding and growth inhibiting efficiency of anti-OspA antibody responses.* Intense fluorescence staining with MFI values, ranging from 50 to 200, was observed for all six *Borrelia* strains when tested with the three serum pools derived from the different immunization dose groups (1.0, 0.1 and 0.03 µg protein per dose) of the 3-component vaccine at a dilution of 1:100 (Figure 21). When the serum pools from the 3 dose groups were tested for their capacity to inhibit bacterial growth, the 3-component vaccine was also found to have induced strong GI-50 titers to all six OspA type strains, ranging from 1000 (type 4 strain, 0.03 µg dose) to 20,000 (type 6 strain).

**[00353]** *Conclusion.* Taken together, these results demonstrate that the rOspA antigens are highly immunogenic and induce large quantities of functional antibodies which can bind to the surface of live *Borreliae* and inhibit growth of *Borreliae*. Coverage among the six strains tested was complete, as high fluorescence intensities and high growth inhibition titers were detected, comparable to the levels observed for the OspA types 1 and 2. In summary, the results presented in this study indicate that antibody responses induced by the tri-component rOspA vaccine (1/2 + 5/3 + 6/4), when formulated with Al(OH)<sub>3</sub>, prevent infections by strains expressing OspA types 1-6, which, as epidemiological studies have shown, theoretically covers over 99% of isolates causing human disease in Europe and North America and, thus, is highly effective in preventing Lyme Borreliosis.

#### **EXAMPLE 14:**

#### **A VACCINE COMPRISING THE THREE COMPONENT VACCINE (OSPA 1/2, OSPA 6/4, AND OSPA 5/3) IS REQUIRED TO OPTIMALLY COVER BORRELIA EXPRESSING OSPA TYPES 1-6**

**[00354]** The purpose of this study was to investigate and compare the immunogenicity and the cross strain coverage of functional surface binding and/or growth inhibiting antibodies induced by single and multi-component formulations of rOspA Lyme Borreliosis vaccine, again using the efficiency of anti-OspA antibodies

to bind to the surface of live *Borreliae* and to inhibit growth of *Borreliae in vitro* as correlates of protection

**[00355]** *Immunization of mice.* Ten female mice (C3H) per group were immunized with 0.1 µg of a single component vaccine comprising rOspA 1/2 antigen, rOspA 6/4 antigen, or rOspA 5/3 antigen; a two-component vaccine comprising 0.1 µg of both 1/2 + 5/3 antigens, 1/2 + 6/4 antigens, or 5/3 + 6/4 antigens; or a three-component vaccine comprising a combination 0.1 µg of all three 1/2+ 5/3+ 6/4 antigens adjuvanted with 0.2% Al(OH)<sub>3</sub> in a prime-booster regimen. Vaccination was carried out subcutaneously using a dose volume of 200 µl on days 0, 14 and 28. On day 42, individual blood samples were taken from mice to generate sera.

**[00356]** *Antibody surface binding and growth inhibition assays.* A slightly modified version of the surface binding assay was used to determine the efficiency of anti-OspA IgG to bind to the surface of live *Borreliae*. Serial dilutions of a serum pool with defined MFI titers were included in the analyses to create a standard curve from which relative titers of test sera were read off after interpolation with a non-linear regression curve. The MFI titer of standard serum for the individual strains expressing OspA types 1-6 was defined as the highest dilution at which the fluorescence intensity of the *Borreliae* was determined to be at least 3-fold over the fluorescence intensity observed with normal mouse serum. All determinations were carried out in duplicate.

**[00357]** The scatter plots presented in Figure 22 compare the MFI titers to the six strain expressing homologous OspA types observed for the immune sera of individual C3H mice after immunization with either single rOspA antigens or rOspA antigen combinations. Results showed that a formulation containing all three rOspA antigens (1/2, 5/3 and 6/4) was necessary to induce high MFI titers against all six *Borrelia strains* expressing OspA types 1-6, and that formulations composed of two rOspA antigens (i.e. covering four strains) did not fully cover the strains expressing the two OspA types not present in the formulation.

**[00358]** To determine the potency of the various vaccine combinations to induce growth inhibiting antibodies, six representative *Borreliae* strains (B31, Arcon, PBr, DK6, W, KL11), expressing OspA types 1-6 respectively, were cultured at 33 °C in the presence of heat-inactivated immune or non-immune mouse serum pools. All

sera were tested at a single dilution. The following dilutions were used: B31, PBr and KL11 1:200, Arcon, DK6 and W 1:100. PBr was cultured in the absence of 20% complement, while the other 5 strains were tested in the presence of complement. Baby rabbit complement was used for DK6, W and KL11, while guinea pig serum was used for B31 and Arcon. When the bacteria in the control cultures incubated with non-immune sera had grown sufficiently, as determined microscopically, accurate cell counts were made as described previously (see Example 10). The percentage of bacterial growth inhibition was calculated from the cell count observed with test serum relative to the normal mouse serum control. The overall growth inhibition observed for the different formulations tested was then presented (Figure 23) as the number of animals among the different groups of ten C3H mice that showed more than 50% growth inhibition. Results demonstrated that the 3-component formulation was the only formulation capable of inducing high titers of growth-inhibiting antibodies against all six representative strains expressing OspA types 1-6 (Figure 23). In all cases, the 3-component vaccine formulation provided >50% growth inhibition in >90% of the immunized animals. The 2-component vaccine formulations did not fully cover the two strains expressing the OspA types not present in the vaccine. The formulation comprising rOspA 1/2 + 6/4 did not cover the type 3 strain; the formulation comprising rOspA 1/2 + 5/3 formulation did not cover types 4 or 6; and the formulation comprising rOspA 5/3 + 6/4 did not cover type 1.

#### **EXAMPLE 15:**

#### **THE MULTIVALENT OSPA VACCINE FORMULATION COVERS *BORRELIA* EXPRESSING INTRA-TYPE VARIANTS OR SUBTYPES OF OSPA TYPES 1-6**

**[00359]** Although *Borrelia* OspA types 1-6 were selected as the basis for the design and construction of the multivalent rOspA vaccine, *Borreliae* which express OspA protein variants of types 1, 2, 3, 5, and 6 have also been isolated. These variants, while being classified as being within the same type, have slightly altered nucleotide gene sequences and amino acid protein sequences. Thus, intra-type variants or subtypes exist among OspA types 1, 2, 3, 5, and 6 (see Figure 24). No intra-type variant or subtype has yet been observed for OspA type 4.



**[00360]** The purpose of this study was to confirm that immune serum generated by immunizing mice with the 3-component multivalent rOspA vaccine contains functional antibodies which can bind to the surface of live *Borreliae* expressing these intra-type variants or subtypes.

**[00361]** For this study, a pooled mouse immune serum was generated by immunizing 70 female C3H mice three times with 0.3 µg of the 3-component multivalent rOspA vaccine on days 0, 14 and 28. On day 42, mice were bled and serum was obtained and pooled. The pooled immune serum was then used to test for binding of antibodies to the surface of live *Borreliae*. *Borrelia* cultures were incubated with the immune serum pool or control normal mouse serum at 1:100 in duplicate, and fluorescence intensities of *Borreliae* measuring binding of anti-OspA antibodies to the bacteria was monitored by FACS analyses as described herein above.

**[00362]** High levels of surface binding antibodies (defined as a fluorescence intensity of over 10 times that observed for a non-immunized mouse control serum) at a serum dilution of 1:100 were detected for most of the strains expressing OspA subtypes 1-6. In particular, high levels of antibody binding were detected with *Borreliae* strains expressing OspA sub-types 1a, 1b, 1c, 1d, 1f, 1h, 1J, 1k, and 1l; 2a, 2b, 2e, 2g, 2k, 2l, and 2n; 3a, 3c, 3d, and 3e; 5a and 5c; and 6a, 6e, 6f, 6g, and 6k (Figure 24). Weaker binding (defined as a fluorescence intensity of between 2-10 times that observed for a non-immunized mouse control serum) was observed with *Borreliae* strains expressing OspA subtypes 1g, 2j, 2m, 3b, 5d, and 6l (Figure 24), but this weaker binding was primarily due to the low expression of the OspA protein under the growth conditions used.

**[00363]** *Conclusion.* The 3-component chimeric rOspA vaccine induces functional, surface-binding antibodies against all intra-type variants or subtypes of OspA types 1, 2, 3, 5, and 6 in C3H mice.

**EXAMPLE 16:****THE MULTIVALENT OSPA VACCINE FORMULATION PROVIDES PROTECTION AGAINST OTHER TYPES OF *BORRELIA* IN ADDITION TO THOSE EXPRESSING OSPA TYPES 1-6**

**[00364]** The purpose of this study was to determine if the 3-component chimeric rOspA antigen vaccine formulation (comprising all 3 chimeric antigens – 1/2, 6/4, and 3/5) could also provide protection against *Borrelia* expressing OspA types other than the homologous OspA types 1-6. 40 C3H mice were immunized three times with 0.3 µg of the 3-component vaccine on days 0, 14 and 28. On day 42, the mice were bled, and a serum pool was made and used to evaluate the efficiency of surface binding and growth inhibition against strains expressing heterologous OspA types.

**[00365]** The results of this study showed that the 3-component chimeric rOspA vaccine does induce antibodies which bind to the surface of *Borreliae* and inhibit growth of other types of *Borreliae*, including strains of *B. spielmanii*, *B. valaisiana*, *B. lusitaniae* and *B. japonica* (see Table 9). In the case of *B. garinii* expressing OspA type 7, only weak surface binding and little or no growth inhibition was observed; however, this weak binding and small amount of growth inhibition may be due to low expression levels of OspA under the *in vitro* culture conditions used rather than to the lack of binding of immune serum antibodies.

**Table 9. Surface Binding and Growth Inhibition against other types of *Borreliae***

Genotype	B.g. OspA-7	B. spielmanii	B. valaisiana	B. lusitaniae	B. japonica
Surface Binding	(+)	+	+	+	+
Growth Inhibition	-	+	+	+	+

+: significant surface binding and / or growth inhibition

-: no significant binding / growth inhibition

(+): low intensity surface binding

**EXAMPLE 17:**  
**MULTIVALENT OSPA VACCINE FORMULATIONS INDUCES ANTIBODIES TO A**  
**COMMON EPITOPE AT THE N-TERMINUS OF THE OSPA MOLECULE WHICH**  
**CAN CONTRIBUTE TO PROTECTION AGAINST ANY OSPA EXPRESSING**  
**BORRELIA STRAIN**

**[00366]** During the course of investigating the protective efficacy of multivalent chimeric rOspA formulations, a monoclonal antibody (F237/BK2) was generated against a 2-component rOspA vaccine comprising rOspA-1/2 and rOspA-6/4. F237/BK2 was shown by anti-OspA ELISA to bind to all OspA types investigated thus far (OspA types 1-7), as well as to the 3 chimeric rOspA antigens (rOspA-1/2, rOspA-5/3 and rOspA-6/4). Such result indicate that F237/BK2 recognizes a common epitope found on all OspA molecules. Moreover, preliminary epitope mapping studies indicate that this common epitope is located on the less variable N-terminal half of the molecule (i.e. at the N-terminus of amino acid 130), where OspA sequence homologies are most commonly observed.

**[00367]** Interestingly, F237/BK2 was also shown to bind to the surface of *Borreliae* expressing homologous OspA types 1-6 and heterologous OspA types, including those expressed by *B. spielmanii*, *B. valaisiana* and *B. japonica*, albeit less efficiently than monoclonal antibodies directed against C-terminal type-specific epitopes. Using methods similar to those described in previous examples, F237/BK2 was also found to inhibit the growth of representative strains expressing OspA types 1, 2, 4, 5 and 6.

**[00368]** When F237/BK2 was tested in an *in vivo* passive protection model in mice, F237/BK2 was observed to confer protection against feral tick challenge, corresponding to a *B. afzelii* Type 2 challenge. Ticks were collected in Wundschuh (Styria, Austria), which are known to be predominantly infected with *B. afzelii*. Ten female C3H mice were injected intraperitoneally with 500 µg of affinity-purified mAb F237/BK2. Two hours later, 8 ticks were applied per animal to 10 passively immunized mice as well as to 10 sham-immunized animals. Four days later, the fed ticks were removed. On day 90, mice were sacrificed and analyzed for infection by serological testing, PCR analysis and *Borrelia* culture, as described herein above. No animal was infected in the group treated with F237/BK2, whereas 5 animals

(50%) were infected with *B. afzelii* in the control group. Thus, monoclonal antibody F237/BK2 provided statistically significant ( $p = 0.0325$ ) passive protection against a tick challenge when compared with the sham-immunized control mice. This is the first time that a monoclonal antibody which binds to a common epitope on the N-terminal half of the molecule has been reported to be involved in protection. Moreover, if a vaccine could induce antibodies recognizing this common epitope, such an antibody would certainly contribute to the vaccine's cross protective efficacy.

**[00369]** To test whether such antibodies were indeed induced by the 3-component chimeric rOspA vaccine formulation, a monoclonal antibody inhibition ELISA was carried out employing peroxidase-labeled F237/BK2. In these experiments, a GST-OspA type 3 protein was used as coating antigen, and either normal mouse serum or a serum pool from C3H mice immunized three times with the 3-component chimeric rOspA vaccine was added to the wells at a dilution of 1:100. Sixty minutes later, peroxidase-labeled F237/BK2 was added at a pre-optimized concentration to eventually give an Optical Density (OD) value of around 1 for the non-inhibiting normal mouse serum control, and incubation was continued for an additional 60 min. Finally, ELISA plates were washed and developed with TMB substrate.

**[00370]** Using this monoclonal antibody inhibition ELISA assay, it could be demonstrated that the 3-component chimeric rOspA formulation does indeed induce antibodies which bind to an epitope identical to or in close proximity to the epitope recognized by mAb F237/BK2. OD values were significantly reduced (e.g., typically by 20-30%) by the anti-OspA immune sera compared to the non-inhibiting normal mouse serum control.

**[00371]** *Conclusion.* This study shows that the 3-component chimeric rOspA vaccine is able to induce both a type-specific and a broad cross-protective immune response.

**EXAMPLE 18:**  
**ADDITIONAL SYNTHETIC OSPA NUCLEIC ACID AND POLYPEPTIDE**  
**MOLECULES**

**[00372]** The aim of the study was to design additional novel OspA antigens comprising serotypes 1 and 2, 6 and 4, and 5 and 3, respectively. Three synthetic OspA genes (SEQ ID NOS: 168 (orig sOspA 1/2), 170 (orig sOspA 6/4), and 172 (orig sOspA 5/3)) were designed to encode OspA polypeptide molecules with protective epitopes from OspA serotypes 1 and 2 (orig sOspA 1/2), OspA serotypes 6 and 4 (orig sOspA 6/4) and OspA serotypes 5 and 3 (orig sOspA 5/3) of *Borrelia*. The primary amino acid sequences of these molecules (SEQ ID NOS: 169, 171, and 173, respectively) are provided in Table 1. These sequences comprise original chimeric constructs, i.e. without mutations and without codon optimization.

**EXAMPLE 19:**  
**MULTIVALENT RECOMBINANT OSPA FORMULATION COMPRISING 3**  
**ANTIGENS (1/2, 6/4, AND 5/3) IS IMMUNOGENIC IN MICE**

**[00373]** A multivalent OspA vaccine comprising original construct formulations without codon optimization and without mutations (orig OspA 1/2, orig OspA 5/3, and orig OspA 6/4) is evaluated in a tick challenge model. Three recombinant OspA antigens containing the protective epitopes from OspA serotypes 1 and 2 (SEQ ID NO: 169), OspA serotypes 6 and 4 (SEQ ID NO: 171), and OspA serotypes 5 and 3 (SEQ ID NO: 173) are combined in a vaccine.

**[00374]** Groups of ten female C3H/HeJ mice (age at immunization: 11 weeks) are immunized subcutaneously on days 0 and 28 with a fixed dose of 0.3 µg of the multivalent vaccine (0.1 µg of each, orig OspA 1/2, orig OspA 5/3, and orig OspA 6/4). The tick challenge is done as described herein above with ticks from Budweis, Czech Republic. The ability of the feral ticks to transmit *B.burgdorferi s.l.* to mice is confirmed by challenging un-immunized control animals. The infection status of the challenged mice is determined by Western blotting, real-time PCR, and by culture.

**[00375]** Interim blood samples are taken on day 41 by orbital puncture. Final blood samples (day 70/71) are collected by heart puncture. Individual sera are

prepared from whole blood by centrifugation (10 minutes; 1000-2000xG; RT). Sera are stored at  $\leq -20^{\circ}\text{C}$  until use.

**[00376]** In this experiment unfed ticks, taken from the same batch used to challenge the mice, are characterized to determine the overall infection rate and to confirm the species of the infecting organisms.

#### **EXAMPLE 20:**

#### **A VACCINE COMPRISING A THREE-COMPONENT VACCINE (ORIG OSPA 1/2, ORIG OSPA 6/4, AND ORIG OSPA 5/3) INDUCES HIGH LEVELS OF FUNCTIONAL ANTI-OSPA ANTIBODIES WHICH BIND TO AND INHIBIT GROWTH OF *BORRELIA* STRAINS EXPRESSING OSPA TYPES 1-6**

**[00377]** The results presented in Example 13 indicate that antibody responses induced by the tri-component rOspA vaccine (lipB sOspA1/2 + lipB sOspA 5/3 + lipB sOspA 6/4), when formulated with Al(OH)<sub>3</sub>, prevent infections by strains expressing OspA types 1-6 and, therefore, are effective in preventing Lyme Borreliosis. Thus, the present study is being carried out to determine if equivalent functional immune responses are induced by the tri-component OspA vaccine comprising chimeric original (orig) OspA antigens (Orig sOspA1/2 + Orig sOspA 5/3 + Orig sOspA 6/4).

**[00378]** *Mouse immunization.* Groups of 10 female C3H/HeJ mice are immunized subcutaneously three times (day 0, day 14, day 28) with a 1:1:1 mixture of Orig sOspA1/2 + Orig sOspA 5/3 + Orig sOspA 6/4 at three different doses (1, 0.1, 0.03  $\mu\text{g}$  protein per dose) combined with 0.2% Al(OH)<sub>3</sub> as an adjuvant. Serum is generated from blood samples taken on day 40.

**[00379]** *Quantitation of OspA antibody binding to the surface of live Borreliae.* In this assay, *in vitro* grown cultures of six representative *Borrelia* strains expressing OspA types 1-6 (*B. burgdorferi sensu stricto* B31/OspA-1; *B. afzelii* Arcon/OspA-2; *B. garinii* PBr/OspA-3; *B. garinii* DK6/OspA-4; *B. garinii* W/OspA-5; and *B. garinii* KL11/OspA-6) are incubated at a fixed dilution (1:100) with pools of the peak titer mouse sera at room temperature in the presence of EDTA to prevent complement activation. The subsequent washing, labeling, detection and analysis procedures are similar to those described in Examples 10 and 13. Normal mouse serum serves as a negative control for non-specific binding of antibodies.

**[00380]** *Bacterial growth inhibition assay.* To measure the potency of the pre-challenge sera to inhibit growth of *Borreliae*, six representative strains expressing OspA types 1-6 (B31, Arcon, PBr, DK6, W, and KL11) are cultured at 33°C in the presence of serial dilutions of heat-inactivated peak titer serum pools or non-immune mouse serum (negative control). B31 is cultured in the presence of complement (guinea pig serum), while the other five strains are tested in the absence of complement. Growth inhibition assays are carried out as described in Examples 10 and 13. A standard serum preparation is used to normalize titers between different assays.

**[00381]** *Surface binding and growth inhibiting efficiency of anti-OspA antibody responses.* Fluorescence staining is measured in all six *Borrelia* strains when tested with the three serum pools derived from the different immunization dose groups (1.0, 0.1 and 0.03 µg protein per dose) of the 3-component vaccine at a dilution of 1:100.

#### **EXAMPLE 21:**

#### **A VACCINE COMPRISING THE THREE COMPONENT VACCINE (OSPA 1/2, OSPA 6/4, AND OSPA 5/3) IS REQUIRED TO OPTIMALLY COVER BORRELIA EXPRESSING OSPA TYPES 1-6**

**[00382]** The purpose of this study is to investigate and compare the immunogenicity and the cross strain coverage of functional surface binding and/or growth inhibiting antibodies induced by single and multi-component formulations of Orig sOspA Lyme Borreliosis vaccine using the efficiency of anti-OspA antibodies to bind to the surface of live *Borreliae* and to inhibit growth of *Borreliae in vitro* as correlates of protection

**[00383]** *Immunization of mice.* Ten female mice (C3H) per group are immunized with 0.1 µg of a single component vaccine comprising Orig sOspA1/2 antigen, Orig sOspA 5/3 antigen, or Orig sOspA 6/4 antigen; a two-component vaccine comprising 0.1 µg of both 1/2 + 5/3 antigens, 1/2 + 6/4 antigens, or 5/3 + 6/4 antigens; or a three-component vaccine comprising a combination 0.1 µg of all three 1/2 + 5/3 + 6/4 antigens adjuvanted with 0.2% Al(OH)<sub>3</sub> in a prime-booster regimen. Vaccination is carried out subcutaneously using a dose volume of 200 µl on days 0, 14 and 28. On day 42, individual blood samples are taken from mice to generate sera.

**[00384]** *Antibody surface binding and growth inhibition assays.* A slightly modified version of the surface binding assay described above is used to determine the efficiency of anti-OspA IgG to bind to the surface of live *Borreliae*. Serial dilutions of a serum pool with defined MFI titers are included in the analyses to create a standard curve from which relative titers of test sera are read off after interpolation with a non-linear regression curve. The MFI titer of standard serum for the individual strains expressing OspA types 1-6 is defined as the highest dilution at which the fluorescence intensity of the *Borreliae* is determined to be at least 3-fold over the fluorescence intensity observed with normal mouse serum. All determinations are carried out in duplicate.

**[00385]** To determine the potency of the various vaccine combinations to induce growth inhibiting antibodies, six representative *Borreliae* strains (B31, Arcon, PBr, DK6, W, KL11), expressing OspA types 1-6 respectively, are cultured at 33 °C in the presence of heat-inactivated immune or non-immune mouse serum pools. All sera are tested at a single dilution. The following dilutions are used: B31, PBr and KL11 1:200, Arcon, DK6 and W 1:100. PBr is cultured in the absence of 20% complement, while the other 5 strains are tested in the presence of complement. Baby rabbit complement is used for DK6, W and KL11, while guinea pig serum is used for B31 and Arcon. When the bacteria in the control cultures incubated with non-immune sera has grown sufficiently, as determined microscopically, accurate cell counts are made as described previously (see Example 10). The percentage of bacterial growth inhibition is calculated from the cell count observed with test serum relative to the normal mouse serum control. The overall growth inhibition observed for the different formulations tested is then presented as the number of animals among the different groups of ten C3H mice that showed more than 50% growth inhibition.

#### **EXAMPLE 22:**

##### **THE MULTIVALENT OSPA VACCINE FORMULATION COVERS *BORRELIA* EXPRESSING INTRA-TYPE VARIANTS OR SUBTYPES OF OSPA TYPES 1-6**

**[00386]** The purpose of this study was to confirm that immune serum generated by immunizing mice with the 3-component multivalent orig OspA vaccine (orig sOspA 1/2, orig sOspA 6/4, and orig sOspA 5/3) contains functional antibodies which



can bind to the surface of live *Borreliae* expressing these intra-type variants or subtypes.

**[00387]** For this study, a pooled mouse immune serum is generated by immunizing 70 female C3H mice three times with 0.3 µg of the 3-component multivalent orig OspA vaccine on days 0, 14 and 28. On day 42, mice are bled and serum is obtained and pooled. The pooled immune serum is then used to test for binding of antibodies to the surface of live *Borreliae*. *Borrelia* cultures are incubated with the immune serum pool or control normal mouse serum at 1:100 in duplicate, and fluorescence intensities of *Borreliae* measuring binding of anti-OspA antibodies to the bacteria are monitored by FACS analyses as described herein above.

### **EXAMPLE 23:**

#### **DOSING, SAFETY, IMMUNOGENICITY, AND FUNCTIONAL ANTIBODY RESPONSE OF THE MULTIVALENT OSP A VACCINE FORMULATION**

**[00388]** Three dose levels (30, 60, and 90µg) of trivalent (i.e., 3-component multivalent) vaccine comprising lipB sOspA 1/2<sup>251</sup> (SEQ ID NO: 2), lipB sOspA 6/4 (SEQ ID NO: 4), and lipB sOspA 5/3 (SEQ ID NO: 6), with and w/o Al(OH)<sub>3</sub> adjuvant, were tested in a dose escalation study in subjects 18-70 years of age. The vaccine formulation was tested for safety, immunogenicity, antibody persistence, and booster response in a double-blind, randomized, multicenter dose escalation study. Subjects received 3 vaccinations at monthly intervals (Day 1, Day 29, and Day 57). A booster was administered at 9-12 months to selected subjects.

#### *Safety After Primary Immunizations*

**[00389]** After the primary immunization, safety was evaluated. The adjuvanted formulations showed superior tolerability compared to non-adjuvanted formulations with respect to systemic reactions. There was no significant dose effect within adjuvanted formulations for systemic reactions. There was no significant dose or adjuvant effect for local reactions. The 90 µg non-adjuvanted formulation was excluded from the booster dose for tolerability reasons. Thus, preliminary results indicate that safety information favors adjuvanted over non-adjuvanted formulations.

*Immunogenicity After Primary Immunizations*

**[00390]** There was substantial antibody response after three-dose priming. Adjuvanted formulations showed significant lower immunogenicity against all OspA types compared to the non-adjuvanted formulations (ANCOVA analysis). There was no statistical significant dose effect within the adjuvanted formulations on Day 85 for all OspA types.

**[00391]** The 30µg and 60µg (as backup) adjuvanted formulations were selected for further study in a larger population of seronegative and seropositive subjects. Data indicate that the 30µg adjuvanted dose is immunogenic with no significant improvement at higher dose levels. Data indicate that there was a superior tolerability profile with adjuvanted formulations. The 60 µg adjuvanted dose was continued to determine if any superior response is indicated after booster vaccination or primary vaccination in seronegative/seropositive subjects.

**[00392]** Seropersistence was observed up to 9 months after the first vaccination (Day 271). In fact, antibody persistence by Day 271 was comparable for the three adjuvanted dose levels, with the 90µg adjuvanted formulation demonstrating slightly better seropersistence. Antibodies induced by the non-adjuvanted formulations persisted at somewhat higher levels.

*Immunogenicity After Booster Vaccinations*

**[00393]** There were substantial increases in antibody titers after booster vaccinations. There was a statistically significant positive effect of adjuvantation on ELISA titer. There was no influence of age on post-booster ELISA titer. Functional antibody titers correlated well with ELISA titers.

*Functional Antibody Response Data*

**[00394]** Functional antibody response was measured by a surface binding assay, a monoclonal antibody competitive inhibition (mAb CI) ELISA, and a *Borrelia* killing/growth inhibition assay. The surface binding assay is a flow cytometry-based assay that quantifies the level of antibodies within test sera that bind to the surface of live *Borrelia*. The mAb CI ELISA measures the amount of antibody within test sera which binds to known protective or Borrelicidal specific epitopes as defined by mouse anti-OspA type specific mAbs. The *Borrelia* killing/growth inhibition assay measures the killing/growth inhibition activity of test sera in the presence of

complement by quantifying the number of viable cells in a culture on the bases of ATP levels using a highly sensitive Luciferase luminescence assay.

**[00395]** In general, primary response and six-month antibody persistence levels were slightly greater with the non-adjuvanted formulations. However, post-booster functional antibody responses were equivalent, if not better, for the adjuvanted formulations. Post-booster adjuvanted functional antibody titers were (1) 10-12 fold higher than peak primary response levels for the surface binding assay; (2) 7-8 fold higher than peak primary response levels for the *Borrelia* killing/growth inhibition assay; and (3) 2-3 fold higher than primary responses for the mAb CI ELISA assay.

#### *Safety After Booster Vaccinations*

**[00396]** After the booster vaccinations, safety was evaluated. Systemic reactions occurred at a low rate both in adjuvanted and non-adjuvanted formulations. The majority of systemic reactions were mild (only two moderate reactions). Only mild reactions were reported in the 30µg dose group with or without adjuvant. No severe local reactions occurred within seven days after the booster. There were no related SAEs with any dose/formulation so far in the study

### **EXAMPLE 24:**

#### **DOSE RECOMMENDATION FOR PHASE 3 STUDY WITH THE MULTIVALENT OSPA VACCINE FORMULATION**

**[00397]** Three dose levels with and without adjuvant were tested in various subjects in Phase1/2 studies of the multivalent OspA vaccine formulation. These studies indicated that there is better tolerability and substantial antibody response of adjuvanted formulations after 3-dose priming. There were no clinically relevant differences in antibody persistence between adjuvanted formulations. There was a significant positive effect of adjuvantation on antibody titers after the booster vaccination, and optimal immune response after the booster vaccination was seen with the 30µg adjuvanted formulation with no significant improvement at higher dose levels. Functional antibody results confirmed the anti-OspA IgG ELISA results.

**[00398]** The invention has been described in terms of particular embodiments found or proposed to comprise specific modes for the practice of then invention.

Various modifications and variations of the described invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the relevant fields are intended to be within the scope of the following claims.

What is Claimed is:

1. A composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

2. A composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

3. A composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

4. A composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

5. A composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said

composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

6. A composition to induce a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

7. A composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6, said composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

8. A composition to prevent or treat *Borrelia* infection or Lyme disease in a subject comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6, said composition formulated in a unit dose of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

9. The composition according to any of claims 1-8, wherein the composition further comprises an adjuvant.

10. The composition according to claim 8, wherein the adjuvant is aluminum hydroxide.

11. The composition according to any of claims 1-8, wherein the combination of polypeptides comprises an equal amount of each polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6.

12. The composition according to any of claims 1-11, wherein the composition is an immunogenic composition or a vaccine composition.
13. The composition according to any of claims 1-12, wherein the *Borrelia* is *Borrelia sensu lato* or *Borrelia sensu stricto*.
14. The composition according to any of claims 1-12, wherein the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, *Borrelia burgdorferi sensu stricto*, *Borrelia japonica*, *Borrelia andersonii*, *Borrelia bissettii*, *Borrelia sinica*, *Borrelia turdi*, *Borrelia tanukii*, *Borrelia valaisiana*, *Borrelia lusitaniae*, *Borrelia spielmanii*, *Borrelia miyamotoi* or *Borrelia lonestar*.
15. The composition according to claim 14, wherein the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, or *Borrelia burgdorferi sensu stricto*.
16. The composition according to any of claims 1-15, wherein the composition is formulated in a unit dose effective to increase *Borrelia* antibody production in a subject to a geometric mean titer (GMT) level of about 1,000 to 10,000 at about 60 days after initial dosing.
17. The composition according to any of claims 1-15, wherein the composition is formulated in a unit dose effective to increase *Borrelia* antibody production in a subject to a geometric mean titer (GMT) level of about 2,000 to 30,000 at about 90 days after initial dosing.
18. The composition according to any of claims 1-15, wherein the composition is formulated in a unit dose effective to increase *Borrelia* antibody production in a subject to a geometric mean titer (GMT) level of about 15,000 to 50,000 after booster administration.
19. The composition according to any of claims 1-18, wherein the composition is formulated in a unit dose effective for administration in a single dose.
20. The composition according to any of claims 1-18, wherein the composition is formulated in a unit dose effective for administration in multiple doses.
21. The composition according to any of claims 1-20, wherein the unit dose is about 10 µg to about 90 µg.
22. The composition according to any of claims 1-20, wherein the unit dose is about 30 µg or about 60 µg.

23. A method of inducing a protective immune response against *Borrelia* infection or Lyme disease in a subject comprising administering to the subject an immunologically effective amount of the composition of any of claims 1-20.

24. The method of claim 23, wherein the immunologically effective amount of the composition is administered in a single unit dose.

25. The method of claim 23, wherein the immunologically effective amount of the composition is administered in multiple unit doses.

26. The method of claim 25, wherein the multiple unit doses are administered at about monthly intervals.

27. The method of claim 24 or 25, wherein a booster of the composition is further administered at about 6 to about 18 months after the initial unit dose.

28. The method of claim 24 or 25, wherein a booster of the composition is further administered at about 9 to about 12 months after the initial unit dose.

29. The method of claim 25 or 26, wherein the composition is administered at about Day 1, at about Day 29, and at about Day 57.

30. The method of claim 29, wherein a booster of the composition is further administered at about 9 months to about 12 months after the first unit dose.

31. The method according to any of claims 21-30, wherein the unit dose is about 10 µg to about 90 µg.

32. The method according to claim 31, wherein the unit dose is about 30 µg or about 60 µg.

33. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.



34. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

35. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

36. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg to about 100 µg, and a pharmaceutically acceptable carrier.

37. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

38. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to

stimulate antibody production against *Borrelia*, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

39. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises an amino acid sequence having at least 200 amino acid residues with at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent sequence identity to a polypeptide comprising an amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

40. Use of a composition comprising a combination of polypeptides, wherein each of the polypeptides in the combination comprises the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6 in the production of a medicament to prevent or treat *Borrelia* infection or Lyme disease, said composition formulated in a unit dose amount of about 10 µg, about 20 µg, about 30 µg, about 40 µg, about 50 µg, about 60 µg, about 70 µg, about 80 µg, about 90 µg, about 100 µg, and a pharmaceutically acceptable carrier.

41. The use according to any of claims 33-40, wherein the composition further comprises an adjuvant.

42. The use according to claim 41, wherein the adjuvant is aluminum hydroxide.

43. The use according to any of claims 33-42, wherein the combination of polypeptides comprises equal amounts of each of the polypeptides comprising the amino acid sequences set forth in SEQ ID NOS: 2, 4, and 6.

44. The use according to any of claims 33-43, wherein the composition is an immunogenic composition or a vaccine composition.

45. The use according to any of claims 33-44, wherein the *Borrelia* is *Borrelia sensu lato* or *Borrelia sensu stricto*.

46. The use according to any of claims 33-44, wherein the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, *Borrelia burgdorferi sensu stricto*, *Borrelia japonica*, *Borrelia andersonii*, *Borrelia bissettii*, *Borrelia sinica*, *Borrelia turdi*, *Borrelia tanukii*, *Borrelia valaisiana*, *Borrelia lusitaniae*, *Borrelia spielmanii*, *Borrelia miyamotoi* or *Borrelia lonestar*.

47. The use according to claim 46, wherein the *Borrelia* is *Borrelia afzelii*, *Borrelia garinii*, *Borrelia bavariensis*, or *Borrelia burgdorferi sensu stricto*.

48. The use according to any of claims 33-47, wherein the composition is formulated in an amount to increase *Borrelia* antibody production to a geometric mean titer (GMT) level of about 1,000 to 10,000 at about 60 days after initial dosing.

49. The use according to any of claims 33-47, wherein the composition is formulated in an amount to increase *Borrelia* antibody production to a geometric mean titer (GMT) level of about 2,000 to 30,000 at about 90 days after initial dosing.

50. The use according to any of claims 33-47, wherein the composition is formulated in an amount to increase *Borrelia* antibody production to a geometric mean titer (GMT) level of about 15,000 to 50,000 after booster administration.

51. The use according to any of claims 33-50, wherein the composition is formulated for administration in a single unit dose.

52. The use according to any of claims 33-50, wherein the composition is formulated for administration in multiple unit doses.

53. The use according to claim 52, wherein the composition is formulated for administration in multiple unit doses at about monthly intervals.

54. The use according to claim 51 or 52, wherein the composition is formulated for administration as a booster at about 6 to about 18 months after the initial unit dose.

55. The use according to claim 51 or 52, wherein the composition is formulated as a booster for administration at about 9 to about 12 months after the initial unit dose.


56. The use according to claim 52, wherein the composition is formulated for administration in multiple unit doses at about Day 1, at about Day 29, and at about Day 57.

57. The use according to claim 56, wherein the composition is formulated for administration in multiple doses followed by a booster at about 9 months to about 12 months after the first unit dose.

58. The use according to any of claims 33-57, wherein the unit dose is about 10 µg to about 90 µg.

59. The use according to any of claims 33-58, wherein the unit dose is about 30 µg or about 60 µg.

**Fig. 1**



**Fig. 2**

1	MRL	LIGF	ALA	LALIG	CAQKG	AESIGSVSVD	LPGEMKVLVS	KEKDKNGKYD			
51	LIATV	DKLEL	KGTS	DKNNGS	GVLEGVKTNK	SKVKLTISDD	LGQT	TLEVFK			
101	EDGK	TLVSKK	VTSK	DKSSTE	EKFNEKGEVS	EKIITMADGT	RLEY	TGIKSD			
151	GTGK	AKYVLK	NFT	LEGK	VAN	DKT	TLEVKEG	TVT	LSMNISK	SGEVS	VELND
201	TDSS	AATKKT	AAWN	SKTSTL	TISV	NSKKTT	QLVF	TKQDTI	TVQ	KYDS	SAGT
251	NLEGT	AVEIK	TLDEL	KNALK							

**(SEQ ID NO: 2)**

Fig. 3A

```
+1      M R L L I G F A L A L A L I G C
      NdeI
      ~~~~~~
1      CATATGCGTC TGTGATCGG CTTTGCTCTG GCGCTGGCTC TGATCGGCTG
      GTATACGCAG ACAACTAGCC GAAACGAGAC CGCGACCGAG ACTAGCCGAC

+1      A Q K G A E S I G S V S V D L P
51     CGCACAGAAA GGTGCTGAGT CTATTGGTTC CGTTTCTGTA GATCTGCCCCG
      GCGTGTCTTT CCACGACTCA GATAACCAAG GCAAAGACAT CTAGACGGGC

+1     G E M K V L V S K E K D K N G K Y
101    GTGAAATGAA GGTTCCTGGTG AGCAAAGAAA AAGACAAGAA CGGCAAGTAC
      CACTTTACTT CCAAGACCAC TCGTTTCTTT TTCTGTTCTT GCCGTTCAIG

+1     D L I A T V D K L E L K G T S D K
151    GATCTCATCG CAACCGTCGA CAAGCTGGAG CTGAAAAGTA CTTCTGATAA
      CTAGAGTAGC GTTGGCAGCT GTTCGACCTC GACTTTCCAT GAAGACTATT

+1     N N G S G V L E G V K T N K S K
201    AAACAACGGC TCTGGTGTGC TGGAGGGCGT CAAAAC TAAC AAGAGCAAAG
      TTTGTTGCCG AGACCACACG ACCTCCCGCA GTTTTGATTG TTCTCGTTTC

+1     V K L T I S D D L G Q T T L E V F
      HindIII
      ~~~~~~
251    TAAAGCTTAC GATCTCTGAC GATCTCGGTC AGACCACGCT GGAAGTTTTTC
      ATTTGCAATG CTAGAGACTG CTAGAGCCAG TCTGGTGCGA CCTTCAAAAG

+1     K E D G K T L V S K K V T S K D K
301    AAAGAGGATG GCAAGACCTT CGTGTCCAAA AAAGTAACCT CCAAAGACAA
      TTTCTCCTAC CGTTCCTGGA GCACAGGTTT TTTTATTGAA GGTTCCTGTT

+1     S S T E E K F N E K G E V S E K
351    GTCCTCTACG GAAGAAAAAT TCAACGAAAA AGGTGAGGTG TCTGAAAAGA
      CAGGAGATGC CTTCTTTTTA AGTTGCTTTT TCCACTCCAC AGACTTTTCT

+1     I I T M A D G T R L E Y T G I K S
401    TCATCACCAT GGCAGACGGC ACCCGTCTTG AATACACCGG TATTAAAAGC
      AGTAGTGGTA CCGTCTGCCG TGGGCAGAAC TTATGTGGCC ATAATTTTCG

+1     D G T G K A K Y V L K N F T L E G
      KpnI
      ~~~~~~
451    GATGGTACCG GTAAAGCGAA ATATGTTCTG AAAAACTTCA CTCTGGAAGG
      CTACCATGGC CATTTGCTTT TATACAAGAC TTTTGAAGT GAGACCTTCC

+1     K V A N D K T T L E V K E G T V
501    CAAAGTGGCT AATGATAAAA CCACCTTGGA AGTCAAGGAA GGCACCGTTA
      GTTTCACCGA TTAATAATTT GGTGGAACCT TCAGTTCCTT CCGTGGCAAT
```

Fig. 3B

```

+1  T  L  S  M    N  I  S    K  S  G    E  V  S  V    E  L  N
551  CTCTGAGCAT GAATATCTCC AAATCTGGTG AAGTTTCCGT TGAAGTGAAC
    GAGACTCGTA CTTATAGAGG TTTAGACCAC TTCAAAGGCA ACTTGACTTG

+1  D  T  D    S  S  A  A    T  K  K    T  A  A    W  N  S  K
                                EcoRI
                                ~~~~~~
601  GACACTGACA GCAGCGCTGC GACTAAAAAA ACTGCAGCGT GGAATTCCAA
    CTGTGACTGT CGTCGCGACG CTGATTTTTT TGACGTCGCA CCTTAAGGTT

+1  T  S  T    L  T  I    S  V  N  S    K  K  T    T  Q  L
651  AACTTCTACT TTAACCATTA GCGTTAACAG CAAAAAACT ACCCAGCTGG
    TTGAAGATGA AATTGGTAAT CGCAATTGTC GTTTTTTTGA TGGGTCGACC

+1  V  F  T    K  Q  D  T    I  T  V    Q  K  Y  D    S  A  G
701  TGTTCACTAA ACAAGACACG ATCACTGTGC AGAAATACGA CTCCGCAGGC
    ACAAGTGATT TGTTCGTGTC TAGTGACACG TCTTTATGCT GAGGCGTCCG

+1  T  N  L    E  G  T  A    V  E  I    K  T  L    D  E  L  K
751  ACCAACTTAG AAGGCACGGC AGTCGAAATT AAAACCCCTG ATGAACTGAA
    TGGTTGAATC TTCCGTGCCG TCAGCTTTAA TTTTGGAAC TACTTGACTT

+1  N  A  L    K  *
                                Bpu1102I  BamHI
                                ~~~~~~
801  AAACGCGCTG AAATAAGCTG AGCGGATCC
    TTTGCGCGAC TTTATTCGAC TCGCCTAGG

```

lipB sOspA 1/2<sup>251</sup> – nucleotide sequence (SEQ ID NO: 1), and amino acid sequence (SEQ ID NO: 2; complementary nucleotide sequence (SEQ ID NO: 48)



**Fig. 4**

1	MRL	LIGFALA	LALIGCAQKG	AESIGSVSVD	LPGGMTVLVS	KEKDKNGKYS
51	LEATV	DKLEL	KGTS	DKNNGS	GTLEGEKTNK	SKVKLTIADD
101	EDAKT	LVSKK	VTLKDKSSTE	EKFNEKGETS	EKTIVMANGT	RLEYTDIKSD
151	GSGKAKYVLK	DFTLE	GT	LAA	DGKTTLKVTE	GTVVLSMNIL
201	DSDTTQATKK	TGKWDSNTST	LTISVNSKKT	KNIVFTKEDT	ITVQKYDSAG	
251	TNLEGN	AVEI	KTLD	DELKNAL		

**(SEQ ID NO: 4)**

**Fig. 5A**

```

+1   M R L L I G F A L A L A L I G C
      NdeI
      ~~~~~~
1    CATATGCGTC TGTGATCGG CTTTGCTCTG GCGCTGGCTC TGATCGGCTG
      GTATACGCAG ACAACTAGCC GAAACGAGAC CGCGACCGAG ACTAGCCGAC

+1   A Q K G A E S I G S V S V D L P
51   CGCACAGAAA GGTGCTGAGT CTATTGGTTC CGTTTCTGTA GATCTGCCCC
      GCGTGTCTTT CCACGACTCA GATAACCAAG GCAAAGACAT CTAGACGGGC

+1   G G M T V L V S K E K D K N G K Y
101  GTGGCATGAC CGTTCCTGGTC AGCAAAGAAA AAGACAAAAA CGGTAAATAC
      CACCGTACTG GCAAGACCAG TCGTTTCTTT TTCGTTTTTT GCCATTTATG

+1   S L E A T V D K L E L K G T S D K
      HindIII
      ~~~~~~
151  AGCCTCGAGG CGACCGTCGA CAAGCTTGAG CTGAAAGGCA CCTCTGATAA
      TCGGAGCTCC GCTGGCAGCT GTTCGAACTC GACTTTCCTG GGAGACTATT

+1   N N G S G T L E G E K T N K S K
201  AAACAACGGT TCCGGCACCC TGGAAGGTGA AAAAACTAAC AAAAGCAAAG
      TTTGTTGCCA AGGCCGTGGG ACCTTCCACT TTTTGTATTG TTTTCGTTTC

+1   V K L T I A D D L S Q T K F E I F
251  TGAAACTGAC CATTGCTGAT GACCTCAGCC AGACCAAATT CGAAATTTTC
      ACTTTGACTG GTAACGACTA CTGGAGTCGG TCTGGTTTAA GCTTTAAAAG

+1   K E D A K T L V S K K V T L K D K
301  AAAGAAGATG CCAAACCTT AGTATCCAAA AAAGTGACCC TGAAAGACAA
      TTTCTTCTAC GGTTTTGGAA TCATAGGTTT TTTCACTGGG ACTTTCTGTT

+1   S S T E E K F N E K G E T S E K
351  GTCCTCTACC GAAGAAAAAT TCAACGAAAA GGGTGAAACC TCTGAAAAAA
      CAGGAGATGG CTTCTTTTTA AGTTGCTTTT CCCACTTTGG AGACTTTTTT

+1   T I V M A N G T R L E Y T D I K S
      KpnI
      ~~~~~~
401  CCATCGTAAT GGCAAATGGT ACCCGTCTGG AATACACCGA CATCAAAAGC
      GGTAGCATTA CCGTTTACCA TGGGCAGACC TTATGTGGCT GTAGTTTTTCG

+1   D G S G K A K Y V L K D F T L E G
451  GATGGCTCCG GCAAAGCCAA ATACGTTCTG AAAGACTTCA CCCTGGAAGG
      CTACCGAGGC CGTTTCGGTT TATGCAAGAC TTTCTGAAGT GGGACCTTCC

+1   T L A A D G K T T L K V T E G T
501  CACCCTCGCT GCCGACGGCA AAACCACCTT GAAAGTTACC GAAGGCACTG
      GTGGGAGCGA CGGCTGCCGT TTTGGTGGAA CTTTCAATGG CTTCCGTGAC

```

**Fig. 5B**

```
+1 V V L S M N I L K S G E I T V A L
551 TTGTTTTAAG CATGAACATC TTAAAATCCG GTGAAATCAC CGTTGCGCTG
AACAAAATTC G TACTTGTAG AATTTTAGGC CACTTTAGTG GCAACGCGAC

+1 D D S D T T Q A T K K T G K W D S
601 GATGACTCTG ACACCACTCA GGCCACTAAA AAAACCGGCA AATGGGATTC
CTACTGAGAC TGTGGTGAGT CCGGTGATTT TTTTGGCCGT TTACCCTAAG

+1 N T S T L T I S V N S K K T K N
EcoRI
~~~~~
651 TAACACTTCC ACTCTGACCA TCAGCGTGAA TTCCAAAAAA ACTAAAAACA
ATTGTGAAGG TGAGACTGGT AGTCGCACTT AAGGTTTTTT TGATTTTTGT

+1 I V F T K E D T I T V Q K Y D S A
701 TCGTGTTTAC CAAAGAAGAC ACCATCACCG TCCAGAAATA CGACTCTGCG
AGCACAAGTG GTTTCCTTCTG TGGTAGTGGC AGGTCTTTAT GCTGAGACGC

+1 G T N L E G N A V E I K T L D E L
751 GGCACCAACC TCGAAGGCAA CGCAGTCGAA ATCAAAACCC TGGATGAACT
CCGTGGTTGG AGCTTCCGTT GCGTCAGCTT TAGTTTTGGG ACCTACTTGA

+1 K N A L K *
Bpu1102I BamHI
~~~~~
801 GAAAAACGCT CTGAAATAAG CTGAGCGGAT CC
CTTTTTGCGA GACTTTATTC GACTCGCCTA GG
```

lipB sOspA 6/4 – nucleotide sequence (SEQ ID NO: 3), and amino acid sequence (SEQ ID NO: 4); complementary nucleotide sequence (SEQ ID NO: 49)

**Fig. 6**

1	MRL	LIG	FALA	LALIG	<u>C</u> AQKG	AESIGSVSVD	LPGGMKVLVS	KEKD	KNGKYS
51	LMAT	VEK	LEL	KGTS	DKNNGS	GTLEGEKTNK	SKVKLTIAED	LSKT	TFEIFK
101	EDGK	TLV	SKK	VTLK	DKSSTE	EKFNEKGEIS	EKTIVMANGT	RLEY	TDIKSD
151	KTGK	AKY	VLK	DFTLE	GTLAA	DGKTTLKVTE	GTVTL	SMNIS	KSGEITVALD
201	DTDSS	GNKKS	GTWD	SDTSTL		TISKNSQKTK	QLVFTKENTI	TVQN	YNRAGN
251	ALEG	SPAEIK	DLAEL	KAALK					

**(SEQ ID NO: 6)**

**Fig. 7A**

```

+1   M R L L I G F A L A L A L I G C
      NdeI
~~~~~
1   CATATGCGTC TGTTCGATCGG CTTTGCTTTG GCGCTGGCTT TAATCGGCTG
    GTATACGCAG ACAACTAGCC GAAACGAAAC CGCGACCGAA ATTAGCCGAC

+1   A Q K G A E S I G S V S V D L P
51  TGCACAGAAA GGTGCTGAGT CTATTGGTTC CGTTTCTGTA GATCTGCCCC
    ACGTGTCTTT CCACGACTCA GATAACCAAG GCAAAGACAT CTAGACGGGC

+1   G G M K V L V S K E K D K N G K Y
101 GGGGTATGAA AGTTCCTGGTA AGCAAAGAAA AAGACAAAAA CGGTAAATAC
    CCCCATACTT TCAAGACCAT TCGTTTCTTT TTCTGTTTTT GCCATTTATG

+1   S L M A T V E K L E L K G T S D K
151 AGCCTGATGG CAACCGTAGA AAAGCTGGAG CTTAAAGGCA CTTCTGATAA
    TCGGACTACC GTTGGCATCT TTTCGACCTC GAATTTCCTG GAAGACTATT

+1   N N G S G T L E G E K T N K S K
201 AAACAACGGT TCTGGCACCC TGAAGGTGA AAAAACTAAC AAAAGCAAAG
    TTTGTTGCCA AGACCGTGGG ACCTTCCACT TTTTGTATTG TTTTCGTTTC

+1   V K L T I A E D L S K T T F E I F
      HindIII
~~~~~
251 TAAAGCTTAC TATTGCTGAG GATCTGAGCA AAACCACCTT TGAAATCTTC
    ATTTGCAATG ATAACGACTC CTAGACTCGT TTTGGTGGA AACTTTAGAAG

+1   K E D G K T L V S K K V T L K D K
301 AAAGAAGATG GCAAAACTCT GGTATCTAAA AAAGTAACCC TGAAAGACAA
    TTTCTTCTAC CGTTTTGAGA CCATAGATTT TTTTATTGGG ACTTTCTGTT

+1   S S T E E K F N E K G E I S E K
351 GTCTTCTACC GAAGAAAAAT TCAACGAAAA GGGTGAAATC TCTGAAAAAA
    CAGAAGATGG CTTCTTTTTA AGTTGCTTTT CCCACTTTAG AGACTTTTTT

+1   T I V M A N G T R L E Y T D I K S
      KpnI
~~~~~
401 CTATCGTAAT GGCAATGGT ACCCGTCTGG AATACACCGA CATCAAAAGC
    GATAGCATT ACGTTTACCA TGGGCAGACC TTATGTGGCT GTAGTTTTTC

+1   D K T G K A K Y V L K D F T L E G
451 GATAAAACCG GCAAAGCTAA ATACGTTCTG AAAGACTTTA CTCTGGAAGG
    CTATTTTGGC CGTTTCGATT TATGCAAGAC TTTCTGAAAT GAGACCTTCC

+1   T L A A D G K T T L K V T E G T
501 CACTCTGGCT GCTGACGGCA AAACCACTCT GAAAGTTACC GAAGGCACTG
    GTGAGACCGA CGACTGCCGT TTGGTGAGA CTTTCAATGG CTTCCGTGAC

```

**Fig. 7B**

```

+1 V T L S M N I S K S G E I T V A L
551 TTACTCTGAG CATGAACATT TCTAAATCCG GCGAAATCAC CGTTGCACTG
    AATGAGACTC GTACTTGTAAG AGATTTAGGC CGCTTTAGTG GCAACGTGAC

+1 D D T D S S G N K K S G T W D S D
601 GATGACACTG ACTCTAGCGG CAATAAAAAA TCCGGCACCT GGGATTCTGA
    CTACTGTGAC TGAGATCGCC GTTATTTTTT AGGCCGTGGA CCCTAAGACT

+1 T S T L T I S K N S Q K T K Q L
                                PvuII
                                ~~~~~~
651 TACTTCTACT TTAACCATTA GCAAAAACAG CCAGAAAACCT AAACAGCTGG
    ATGAAGATGA AATTGGTAAT CGTTTTTGTC GGTCTTTTGA TTTGTCGACC

+1 V F T K E N T I T V Q N Y N R A G
701 TATTCACCAA AGAAAACACT ATCACC GTAC AGAACTATAA CCGTGCAGGC
    ATAAGTGGTT TCTTTTG TGA TAGTGGCATG TCTTGATATT GGCACGTCGG


+1 N A L E G S P A E I K D L A E L K
751 AATGCGCTGG AAGGCAGCCC GGCTGAAATT AAAGATCTGG CAGAGCTGAA
    TTACGCGACC TTCCGTCGGG CCGACTTTAA TTTCTAGACC GTCTCGACTT

+1 A A L K *
                                Bpu1102I BamHI
801 AGCCGCTTTG AAATAAGCTG AGCGGATCC
    TCGGCGAAAC TTTATTTCGAC TCGCCTAGG

```

lipB sOspA 5/3 – nucleotide sequence (SEQ ID NO: 5), and amino acid sequence (SEQ ID NO: 6); complementary nucleotide sequence (SEQ ID NO: 50)

Fig. 8



**Fig. 9**

5' sequence of lipidated constructs (SEQ ID NO: 31)

Amino acid sequence (SEQ ID NO: 33)

Complementary nucleotide sequence (SEQ ID NO: 51)

```
+1      M  R  L  L  I  G  F  A  L  A  L  A  L  I  G  C  A  Q  K
      NdeI
      ~~~~~
1  CATATGCGTC TGTTGATCGG CTTTGCTCTG GCGCTGGCTC TGATCGGCTG CGCACAGAAA
   GTATACGCAG ACAACTAGCC GAAACGAGAC CGCGACCGAG ACTAGCCGAC GCGTGTCTTT
```


5' sequence of non- lipidated constructs (SEQ ID NO: 32)


Amino acid sequence (SEQ ID NO: 34)

Complementary nucleotide sequence (SEQ ID NO: 52)

```
+1      M                                     A  Q  K
      NdeI
      ~~~~~
1  CATATG**** ***** ***** ***** ***** *GCAC AGAAA
   GTATAC**** ***** ***** ***** ***** *CGTG TCTTT
```



**Fig. 10**

**Fig. 11**

Lane	Construct / sample	Induced <sup>1</sup>
2	High Marker	-
3	Low Marker	-
4	WCB <sup>2</sup> lipB sOspA 1/2 <sup>251</sup>	-
5	WCB lipB sOspA 1/2 <sup>251</sup>	+
6	PC <sup>3</sup> sOspA 1/2 <sup>251</sup>	-
7	PC sOspA 1/2 <sup>251</sup>	+
8	-	-
9	WCB lipB sOspA 5/3	-
10	WCB lipB sOspA 5/3	+
11	PC sOspA 5/3	-
12	PC sOspA 5/3	+
13	-	-
14	WCB lipB sOspA 6/4	-
15	WCB lipB sOspA 6/4	+
16	PC sOspA 6/4	-
17	PC sOspA 6/4	+
18	High Marker	-
19	Low Marker	-

<sup>1</sup> Induced for 3 hours with 1mM IPTG, - implies not induced

<sup>2</sup> WCB; working cell bank

<sup>3</sup> PC; Primary cells

\* OspA






**Fig. 12**

Fig. 13



**Fig. 14**Cloning of *de Novo* synthesis productsDigestion with *Pvu* IILigation to *Kpn* I/ *Bam* H I digested vector

Required sequence in final lipB sOspA 5/3 construct (SEQ ID NO: 35); complementary nucleotide sequence (SEQ ID NO: 53)

~~~~~  
 671 PvuII 720  
 GCAAAAACAG CCAGAAACT AAACAGCTGG TATTCACCAA AGAAAACACT  
 CGTTTTTGTC GGTCTTTTGA TTTGTCGACC ATAAGTGGTT TCTTTTGTA

Oligos for 3' terminal of *Kpn* I – *EcoR* I fragment (incorporating external *EcoR* I site) (SEQ ID NO: 36); complementary nucleotide sequence (SEQ ID NO: 54)

GCAAAAACAG CCAGAAACT AAACAGCTGGG  
 CGTTTTTGTC GGTCTTTTGA TTTGTCGACCCTTAA

Oligos for 5' terminal of *EcoR* I – *Bam* H I fragment (incorporating external *EcoR* I site) (SEQ ID NO: 37); complementary nucleotide sequence (SEQ ID NO: 55)

AATTC AAACAGCTGG TATTCACCAA AGAAAACACT  
 G TTTGTCGACC ATAAGTGGTT TCTTTTGTA

**Fig. 15**

Alignment highlighting the amino acid change in lipB sOspA 1/2<sup>251</sup> (SEQ ID NO: 39) and the PCR primer sequences (SEQ ID NOs: 21 and 41) used to introduce the change.

lipB OspA 1/2 mod (SEQ ID NO: 38); consensus sequence (SEQ ID NO: 40)

```

                                     719                                     774
                                     I T V Q K Y D S A G T N L E G T A V
lipB OspA 12 mod (701) GATCACTGTGCAGAAATACGACTCCAAACGGCACCAACTTAGAAGGCACGGCAGTC
lipB sOspA 1/2 251 (700) GATCACTGTGCAGAAATACGACTCCGCAGGCACCAACTTAGAAGGCACGGCAGTC
Consensus (701) GATCACTGTGCAGAAATACGACTCC GGCACCAACTTAGAAGGCACGGCAGTC
```

Internal forward primer → AATACGACTCCGCAGGCACC (SEQ ID NO: 21)

Internal reverse primer → CGSCTCCGCAGGCACCAA (SEQ ID NO: 41)

External forward primer → bp 1 to 21 + *Nde*I site

External reverse primer → bp 808 to 828 = *Bam*H I site

Alignment of OspA sequence of Blip OspA BPBP/A1 with the modified molecule lipB sOspA 1/2<sup>251</sup>.

|     |                             |            |             |             |                       |
|-----|-----------------------------|------------|-------------|-------------|-----------------------|
|     | M R L                       | L I G F    | A L A       | L A L       | I G C A               |
| 1   | ATGAGATTAT                  | TAATAGGATT | TGCTTTAGCG  | TTAGCTTTAA  | TAGGATGTGC            |
| 1   | ATGCGTCTGT                  | TGATCGGCTT | TGCTCTGGCG  | CTGGCTCTGA  | TCGGCTGCGC            |
|     | Q K G                       | A E S      | I G S V     | S V D       | L P G                 |
| 51  | ACAAAAAGGT                  | GCTGAGTCAA | TTGGATCCGT  | TTCAGTAGAT  | TTGCCTGGTG            |
| 51  | ACAGAAAAGGT                 | GCTGAGTCTA | TTGGTTC CGT | TTCTGTAGAT  | CTGCCCGGTG            |
|     | E M K V                     | L V S      | K E K       | D K N G     | K Y D                 |
| 101 | AAATGAAAGT                  | TCTTGTAAGC | AAAGAAAAAG  | ACAAAAACGG  | CAAGTACGAT            |
| 101 | AAATGAAGGT                  | TCTGGTGAGC | AAAGAAAAAG  | ACAAGAACGG  | CAAGTACGAT            |
|     | L I A                       | T V D K    | L E L       | K G T       | S D K N               |
| 151 | CTAATTGCAA                  | CAGTAGACAA | GCTTGAGCTT  | AAAGGAACTT  | CTGATAAAAA            |
| 151 | CTCATCGCAA                  | CCGTCGACAA | GCTGGAGCTG  | AAAGGTACTT  | CTGATAAAAA            |
|     | N G S                       | G V L      | E G V K     | T N K       | S K V<br>HindIII<br>~ |
| 201 | CAATGGATCT                  | GGAGTACTTG | AAGGCGTAAA  | AACTAACAAA  | AGTAAAGTAA            |
| 201 | CAACGGCTCT                  | GGTGTGCTGG | AGGCGTCAA   | AACTAACAAAG | AGCAAAGTAA            |
|     | K L T I<br>HindIII<br>~~~~~ | S D D      | L G Q       | T T L E     | V F K                 |
| 251 | AATTAACAAT                  | TTCTGACGAT | CTAGGTCAAA  | CCACACTTGA  | AGTTTTTCAAA           |
| 251 | AGCTTACGAT                  | CTCTGACGAT | CTCGGTCAGA  | CCACGCTGGA  | AGTTTTTCAAA           |
|     | E D G                       | K T L V    | S K K       | V T S       | K D K S               |
| 301 | GAAGATGGCA                  | AAACACTAGT | ATCAAAAAAA  | GTAAC TTCCA | AAGACAAGTC            |
| 301 | GAGGATGGCA                  | AGACCCTCGT | GTCCAAAAAA  | GTAAC TTCCA | AAGACAAGTC            |
|     | S T E                       | E K F      | N E K G     | E V S       | E K I                 |
| 351 | ATCAACAGAA                  | GAAAAATTCA | ATGAAAAAGG  | TGAAGTATCT  | GAAAAAATAA            |
| 351 | CTCTACGGAA                  | GAAAAATTCA | ACGAAAAAGG  | TGAGGTGTCT  | GAAAAGATCA            |
|     | I T M A                     | D G T      | R L E       | Y T G I     | K S D                 |
| 401 | TAACAA TG GC                | AGACGGAACC | AGACTTGAAT  | ACACAGGAAT  | TAAAAGCGAT            |
| 401 | TCACCATG GC                 | AGACGGCACC | CGTCTTGAAT  | ACACCGGTAT  | TAAAAGCGAT            |
|     | G T G<br>KpnI<br>~~~~~      | K A K Y    | V L K       | N F T       | L E G K               |
| 451 | GGA ACT GGAA                | AAGCTAAATA | TGTTTTTAAA  | AATTTTACTC  | TTGAAGGAAA            |
| 451 | GGT ACC GGTA                | AAGCGAAATA | TGT TCTGAAA | AACTTCACTC  | TGGAAGGC AA           |
|     | V A N                       | D K T      | T L E V     | K E G       | T V T                 |
| 501 | AGTAGCTAAT                  | GATAAAACAA | CATTGGAAGT  | AAAAGAAGGA  | ACCGTTACTT            |
| 501 | AGTGGCTAAT                  | GATAAAACCA | CCTTGGAAGT  | CAAGGAAGGC  | ACCGTTACTC            |

**Fig. 16B**

```

      L S M N   I S K   S G E   V S V E   L N D
551  TAAGTATGAA TATTTCAAAA TCTGGGGAAG TTTCAGTTGA ACTTAATGAC
551  TGAGCATGAA TATCTCCAAA TCTGGTGAAG TTTCCGTTGA ACTGAACGAC

      T D S   S A A T   K K T   A A W   N S K T
                                   EcoRI
                                   ~~~~~~

601  ACTGACAGTA GTGCTGCTAC TAAAAAAACT GCAGCTTGA ATTCAAAAAC
601  ACTGACAGCA GCGCTGCGAC TAAAAAAACT GCAGCGTGA ATTCCAAAAC

      S T L   T I S   V N S K   K T T   Q L V
651  TTCTACTTTA ACAATTAGTG TTAACAGCAA AAAAAGTACA CAACTTGTGT
651  TTCTACTTTA ACCATTAGCG TTAACAGCAA AAAAAGTACC CAGCTGGTGT

      F T K Q   D T I   T V Q   K Y D S   A G T
701  TTAATAAACA AGACACAATA ACTGTACAAA AATACGACTC CAACGGTACC
701  TTAATAAACA AGACACGATC ACTGTGCAGA AATACGACTC CGCAGGCACC

      N L E   G T A V   E I K   T L D   E L K N
751  AATTTAGAAG GCACAGCAGT CGAAATTAAA AACTTGATG AACTTAAAAA
751  AACTTAGAAG GCACGGCAGT CGAAATTAAA ACCCTTGATG AACTGAAAAA

      A L K   *
                                   Bpu1102I  BamHI
                                   ~~~~~~

801  CGCTTTAAAA TAA
801  CGCGCTGAAA TAAGCTGAGC GGATCC

```

The top strand is the original sequence (SEQ ID NO: 42) and the bottom strand is the optimized sequence (SEQ ID NO: 43). Amino acid sequence (SEQ ID NO: 2).

Note: Three bases (CAT) at the start of the sequence are not shown, they form part of the *Nde* I site CATATG.



**Fig. 17A**

Alignment of OspA sequence of Blip OspA KT with the modified molecule  
lipB sOspA 6/4.

```

      M R L   L I G   F A L   A L A L   I G C
1  ATATGAGATT ATTAATAGGA TTTGCTTTAG CGTTAGCTTT AATAGGATGT
1  ATATGCGTCT GTTGATCGGC TTTGCTCTGG CGCTGGCTCT GATCGGCTGC

      A Q K   G A E S   I G S   V S V   D L P G
51 GCACAAAAAG GTGCTGAGTC AATTGGATCC GTTTCAGTAG ATTTACCTGG
51 GCACAGAAAG GTGCTGAGTC TATTGGTTCC GTTTCGTAG ATCTGCCCGG

      G M T   V L V   S K E K   D K N   G K Y
101 TGAATGACA GTTCTTGTA GTAAAGAAAA AGACAAAGAC GGTAAATACA
101 TGGCATGACC GTTCTGGTCA GCAAAGAAAA AGACAAAAAC GGTAAATACA

      S L E A   T V D   K L E   L K G T   S D K
      HindIII
      ~~~~~~
151 GTCTAGAGGC AACAGTAGAC AAGCTTGAGC TTAAAGGAAC TTCTGATAAA
151 GCCTCGAGGC GACCGTCGAC AAGCTTGAGC TGAAAGGCAC CTCTGATAAA

      N N G   S G T L   E G E   K T N   K S K V
201 AACACGGTT CTGGAACACT TGAAGGTGAA AAAACTGACA AAAGTAAAGT
201 AACACGGTT CCGGCACCCT GGAAGGTGAA AAAACTAACA AAAGCAAAGT

      K L T   I A D   D L S Q   T K F   E I F
251 AAAATTAACA ATTGCTGATG ACCTAAGTCA AACTAAATTT GAAATTTTC
251 GAACTGACC ATTGCTGATG ACCTCAGCCA GACCAAATTC GAAATTTTCA

      K E D   A K T L   V S K   K V T L   K D K
301 AAGAAGATGC CAAAACATTA GTATCAAAAA AAGTAACCCT TAAAGACAAG
301 AAGAAGATGC CAAAACCTTA GTATCCAAAA AAGTGACCCT GAAAGACAAG

      S S T   E E K F   N E K   G E T   S E K T
351 TCATCAACAG AAGAAAAATT CAACGAAAAG GGTGAAACAT CTGAAAAAAC
351 TCCTCTACCG AAGAAAAATT CAACGAAAAG GGTGAAACCT CTGAAAAAAC

      I V M   A N G   T R L E   Y T D   I K S
      KpnI
      ~~~~~~
401 AATAGTAAGA GCAAATGGAA CCAGACTTGA ATACACAGAC ATAAAAAGCG
401 CATCGTAATG GCAAATGGTA CCCGTCTGGA ATACACCGAC ATCAAAAGCG

+3 D G S G   K A K   Y V L   K D F T   L E G
451 ATGGATCCGG AAAAGCTAAA GAAGTTTAA AAGACTTTAC TCTTGAAGGA
451 ATGGCTCCGG CAAAGCCAAA TACGTTCTGA AAGACTTCAC CCTGGAAGGC

+3 T L A   A D G K   T T L   K V T   E G T V
501 ACTCTAGCTG CTGACGGCAA AACACATTG AAAGTTACAG AAGGCACTGT
501 ACCCTCGCTG CCGACGGCAA AACCACCTTG AAAGTTACCG AAGGCACTGT

```

**Fig. 17B**

```
+3   V   L   S   M   N   I   L   K   S   G   E   I   T   V   A   L
551  TGTTTTAAGC AAGAACATTT TAAAATCCGG AGAAATAACA GTTGCACTTG
551  TGTTTTAAGC ATGAACATCT TAAAATCCGG TGAAATCACC GTTGCGCTGG

      D   D   S   D   T   T   Q   A   T   K   K   T   G   K   W   D   S
601  ATGACTCTGA CACTACTCAG GCTACTAAAA AAAGTGGAAA ATGGGATTCA
601  ATGACTCTGA CACCACTCAG GCCACTAAAA AAACCGGCAA ATGGGATTCT

      N   T   S   T   L   T   I   S   V   N   S   K   K   T   K   N   I
                                EcoRI
                                ~~~~~~
651  AATACTTCCA CTTTAACAAT TAGTGTGAAT AGCAAAAAAA CTAAAAACAT
651  AACACTTCCA CTCTGACCAT CAGCGTGAAT TCCAAAAAAA CTAAAAACAT

      V   F   T   K   E   D   T   I   T   V   Q   K   Y   D   S   A
701  TGTATTTACA AAAGAAGACA CAATAACAGT ACAAAAAATAC GACTCAGCAG
701  CGTGTTTACC AAAGAAGACA CCATCACCGT CCAGAAATAC GACTCTGCGG

      G   T   N   L   E   G   N   A   V   E   I   K   T   L   D   E   L
751  GCACCAATCT AGAAGGCAAC GCAGTCGAAA TTAAAACACT TGATGAACTT
751  GCACCAACCT CGAAGGCAAC GCAGTCGAAA TCAAAACCCT GGATGAACTG

      K   N   A   L   K   *
                                BamHI
                                ~~~~~~
801  AAAAACGCTT TAAAATAA
801  AAAAACGCTC TGAAATAAGC TGAGCGGATC C
```

The top strand is the original sequence (SEQ ID NO: 44) and the bottom strand is the optimised sequence (SEQ ID NO: 45). The amino acid sequence (SEQ ID NO: 4).

**Note: A single base (C) at the start of the sequence is not shown, which forms part of the *Nde* I site CATATG.**

**Fig. 18A**

Alignment of OspA sequence of Blip OspA 5/3 with the modified molecule lipB sOspA 5/3.

```

      M R L L I G F A L A L A L I G C
NdeI
~~~~~
1 CATATGAGAT TATTAATAGG ATTTGCTTTA GCGTTAGCTT TAATAGGATG
1 CATATGCGTC TGTTGATCGG CTTTGCTTTG GCGCTGGCTT TAATCGGCTG

      A Q K G A E S I G S V S V D L P
51 TGCACAAAAA GGTGCTGAGT CAATTGGATC CGTTTCAGTA GATTIACCTG
51 TGCACAGAAA GGTGCTGAGT CTATTGGTTC CGTTTCTGTA GATCTGCCCG

      G G M K V L V S K E K D K N G K Y
101 GTGGAATGAA AGTTCCTTGT AGTAAAGAAA AAGACAAAGA TGGTAAATAC
101 GGGGTATGAA AGTTCCTGGT AGCAAAGAAA AAGACAAAAA CGGTAAATAC

      S L M A T V E K L E L K G T S D K
151 AGTCTAATGG CAACAGTAGA AAAGCTTGAG CTTAAAGGAA CTTCTGATAA
151 AGCCTGATGG CAACCGTAGA AAAGCTGGAG CTTAAAGGCA CTTCTGATAA

      N N G S G T L E G E K T N K S K
201 AAACAACGGT TCTGGAACAC TTGAAGGTGA AAAAAGTAC AAAAGTAAAG
201 AAACAACGGT TCTGGCACCC TGGAAGGTGA AAAAAGTAA AAAAGCAAAG

      V K L T I A E D L S K T T F E I F
HindIII
~~~~~
251 TAAATTAAC AATTGCTGAG GATCTAAGTA AAACCACATT TGAAATCTTC
251 TAAAGCTTAC TATTGCTGAG GATCTGAGCA AAACCACCTT TGAAATCTTC

      K E D G K T L V S K K V T L K D K
301 AAAGAAGATG GCAAAACATT AGTATCAAAA AAAGTAACCC TTAAAGACAA
301 AAAGAAGATG GCAAAACTCT GGTATCTAAA AAAGTAACCC TGAAAGACAA

      S S T E E K F N E K G E I S E K
351 GTCATCAACA GAAGAAAAAT TCAACGAAAA GGGTGAAATA TCTGAAAAAA
351 GTCTTCTACC GAAGAAAAAT TCAACGAAAA GGGTGAAATC TCTGAAAAAA

      T I V M A N G T R L E Y T D I K S
KpnI
~~~~~
401 CAATAGTAAG AGCAAATGGA ACCAGACTTG AATACACAGA CATAAAAAGC
401 CTATCGTAAT GGCAAATGGT ACCCGTCTGG AATACACCGA CATCAAAAAGC

      D K T G K A K Y V L K D F T L E G
451 GATAAAACCG GAAAAGCTAA AGAAGTTTAA AAAGACTTTA CTCTGAAGG
451 GATAAAACCG GCAAAGCTAA ATACGTTCTG AAAGACTTTA CTCTGAAGG

      T L A A D G K T T L K V T E G T
501 AACTCTAGCT GCTGACGGCA AAACAACATT GAAAGTTACA GAAGGCACTG
501 CACTCTGGCT GCTGACGGCA AAACCACTCT GAAAGTTACC GAAGGCACTG

```

**Fig. 18B**

```

      V T L S   M N I   S K S   G E I T   V A L
551  TTACTTTAAG CAAGAACATT TCAAAATCCG GAGAAATAAC AGTTGCACTT
551  TTACTCTGAG CATGAACATT TCTAAATCCG GCGAAATCAC CGTTGCACTG

      D D T   D S S G   N K K   S G T   W D S D
601  GATGACACTG ACTCTAGCGG CAATAAAAAA TCCGGAACAT GGGATTTCAGA
601  GATGACACTG ACTCTAGCGG CAATAAAAAA TCCGGCACCT GGGATTCTGA

      T S T   L T I   S K N S   Q K T   K Q L
                                   PvuII
                                   ~~~~~~
651  TACTTCTACT TTAACAATTA GTAAAAACAG TCAAAAAACT AAACAACCTTG
651  TACTTCTACT TTAACCATTA GCAAAAACAG CCAGAAAACT AAACAGCTGG

      V F T K   E N T   I T V   Q N Y N   R A G
701  TATTCACAAA AGAAAACACA ATAACAGTAC AAAACTATAA CAGAGCAGGC
701  TATTCACCAA AGAAAACACT ATCACCGTAC AGAACTATAA CCGTGCAGGC

      N A L   E G S P   A E I   K D L   A E L K
751  AATGCGCTTG AAGGCAGCCC AGCTGAAATT AAAGATCTTG CAGAGCTTAA
751  AATGCGCTGG AAGGCAGCCC GGCTGAAATT AAAGATCTGG CAGAGCTGAA

      A A L   K *
                                   BamHI
                                   ~~~~~~
801  AGCCGCTTTA AAATAA
801  AGCCGCTTTG AAATAAGCTG AGCGGATCC
```

The top strand is the original sequence (SEQ ID NO: 46) and the bottom strand is the optimised sequence (SEQ ID NO: 47). The amino acid sequence (SEQ ID NO: 6).

Fig. 19






Fig. 21






Fig. 22






**Fig. 23**

■ Strains homologous to the vaccine used

Fig. 24



## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2013/050058

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>INV. A61K39/02 C07K16/12 A61P31/04<br>ADD.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| According to International Patent Classification (IPC) or to both national classification and IPC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| <b>B. FIELDS SEARCHED</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| Minimum documentation searched (classification system followed by classification symbols)<br>A61K                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>EPO-Internal, BIOSIS, EMBASE, WPI Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| Category*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                      | Relevant to claim No.                                                |
| X<br><br>L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | WO 2011/143617 A1 (BAXTER INT [US]; BAXTER HEALTHCARE SA [CH]; CROWE BRIAN A [AT]; LIVEY) 17 November 2011 (2011-11-17)<br>100% identity with seq.2,4,6,8,10,12;<br>sequences 2,4,6,8,10,12<br>examples 3-5,9,15-17,22<br>-----                                                                                                                                         | 1-59                                                                 |
| X,P                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | WRESSNIGG NINA ET AL: "Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.",<br>THE LANCET INFECTIOUS DISEASES AUG 2013, vol. 13, no. 8, 10 May 2013 (2013-05-10), pages 680-689, XP002714295, ISSN: 1474-4457<br>the whole document<br>-----<br>-/- | 1-59                                                                 |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| * Special categories of cited documents :<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier application or patent but published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"&" document member of the same patent family |                                                                                                                                                                                                                                                                                                                                                                         |                                                                      |
| Date of the actual completion of the international search<br><br>10 October 2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                         | Date of mailing of the international search report<br><br>21/10/2013 |
| Name and mailing address of the ISA/<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+31-70) 340-2040,<br>Fax: (+31-70) 340-3016                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                         | Authorized officer<br><br>Covone-van Hees, M                         |

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2013/050058

| C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                                                                         |                       |
|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category*                                            | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                      | Relevant to claim No. |
| A                                                    | <p>WILSKE BETTINA ET AL: "Molecular analysis of the outer surface protein A (OspA) of <i>Borrelia burgdorferi</i> for conserved and variable antibody binding domains", MEDICAL MICROBIOLOGY AND IMMUNOLOGY, vol. 181, no. 4, 1992, pages 191-207, XP008165257, ISSN: 0300-8584<br/>the whole document</p> <p>-----</p> | 1-59                  |
| A                                                    | <p>WORMSER G P: "Lyme disease vaccine", INFECTION, SPRINGER, vol. 24, no. 2, 1 January 1996 (1996-01-01), pages 203-207, XP008139265, ISSN: 0300-8126<br/>the whole document</p> <p>-----</p>                                                                                                                           | 1-59                  |
| A                                                    | <p>WO 00/78345 A1 (MILKHAUS LAB INC [US])<br/>28 December 2000 (2000-12-28)<br/>the whole document</p> <p>-----</p>                                                                                                                                                                                                     | 1-59                  |

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/050058

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 2011143617 A1                          | 17-11-2011          | AU 2011252844 A1           | 29-11-2012          |
|                                           |                     | AU 2011252850 A1           | 29-11-2012          |
|                                           |                     | CA 2798331 A1              | 17-11-2011          |
|                                           |                     | CA 2799181 A1              | 17-11-2011          |
|                                           |                     | CN 103108652 A             | 15-05-2013          |
|                                           |                     | CN 103118701 A             | 22-05-2013          |
|                                           |                     | EP 2569008 A1              | 20-03-2013          |
|                                           |                     | EP 2569009 A1              | 20-03-2013          |
|                                           |                     | JP 2013529077 A            | 18-07-2013          |
|                                           |                     | JP 2013529078 A            | 18-07-2013          |
|                                           |                     | KR 20130062954 A           | 13-06-2013          |
|                                           |                     | US 2011293652 A1           | 01-12-2011          |
|                                           |                     | US 2012020973 A1           | 26-01-2012          |
|                                           |                     | WO 2011143617 A1           | 17-11-2011          |
|                                           |                     | WO 2011143623 A1           | 17-11-2011          |
| -----                                     |                     |                            |                     |
| WO 0078345 A1                             | 28-12-2000          | AU 4800500 A               | 09-01-2001          |
|                                           |                     | US 6592875 B1              | 15-07-2003          |
|                                           |                     | WO 0078345 A1              | 28-12-2000          |
| -----                                     |                     |                            |                     |